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 SUMMARY 
 
 
 Studies were performed to identify factors explaining the difference in the 
neurodegeneration seen in Alzheimer’s disease (AD) and in transgenic mice. A high level of 
neuronal loss is typically associated with AD, whereas in transgenic mice, this feature is only 
weakly displayed. Furthermore, the studies aimed at determining proteins occurring at altered 
levels in AD brains which could be involved in pathogenic mechanisms underlying the disease. 
The results of these investigations could help to identify Aβ variants and other proteins affecting 
the degree of neurodegeneration and would hopefully contribute to the development of 
biomarkers and new drug targets in AD. 
 Using laser dissection microscopy in combination with MALDI-TOF MS and urea-based 
Western blotting, the Aβ composition in morphologically differentiated plaque types from three 
different sources could be investigated: human brains from AD patients, pathologically aging 
(PA) individuals – i.e. individuals who form amyloid plaques, but suffer of no cognitive 
impairment - and from double-transgenic PS2APP mice. Diffuse plaques are found in human AD 
and PA, as well as in PS2APP transgenic mice and were previously suggested to be the initially 
occurring plaque type. We detected almost exclusively Aβ 42 in diffuse plaques. This Aβ variant 
was shown to be prone to aggregation. Furthermore, no differences in the Aβ species 
composition between diffuse plaques from AD and PA individuals were detected. Cored plaques, 
the main plaque type in AD, contain also predominantly Aβ 42, whereas compact plaques, which 
sporadically occur in human but are found more frequently in PS2APP mice, consist of Aβ 40. 
This has implications on the putative evolutionary path of plaque formation: Due to the Aβ 
composition of the respective plaque types, a sequential maturation of diffuse plaques over 
compact to cored plaques can be excluded. Our data support the concept that diffuse plaques are 
the initially occurring plaque type and develop independently to compact or cored plaques. The 
Aβ composition of vascular amyloid was also investigated. Here, we detected high amounts of 
Aβ 40, which is consistent with previous findings using C-terminal specific antibodies.  
 Aβ in human plaques and to a considerably lesser extent in plaques from PS2APP mice is 
N-terminally truncated. The investigation of different Braak stages revealed an increasing 
amount of N-terminally truncated Aβ variants accompanying disease progression, indicative for 
 a successive modification by exoproteases upon deposition. Consistently low levels of N-
terminally truncated Aβ forms were detected in diffuse plaques, which further support the view 
of diffuse plaques being at the beginning of the plaque maturation process. The major N-
terminally truncated Aβ variant detected by MALDI-TOF MS in human cored plaques was 
pyroglutamate 3-40 / 42. To corroborate these findings, Western blotting and immuno-
histochemistry were applied and the existence of pyroglutamate in all types of plaques in human 
AD and PS2APP transgenic mice was shown.  
The rate of aggregation of an Aβ variant is likely to be important for initial deposition of 
amyloid into plaques. To test the aggregation and toxicity properties of pyroglutamate 3-42, in 
vitro experiments were performed on PC12 and hippocampal cell lines comparing synthetic 
pyroglutamate 3-42 with Aβ 1-42. These experiments showed a considerably lower rate of 
aggregation for synthetic pyroglutamate 3-42 when compared to Aβ 1-42. Our experiments 
suggest that pyroglutamate 3-40 / 42 alone is probably not a critical seed for plaque formation. 
The cytotoxicity of Aβ peptides is correlated with the aggregation state. Synthetic pyroglutamate 
3-42 in vitro showed a significantly reduced toxicity when compared to Aβ 1-42. 
 Cross-linking of Aβ fibrils in plaques was investigated with solubility experiments. It was 
found that Aβ in human plaques is cross-linked to a higher extent than Aβ in plaques from 
PS2APP transgenic mice. A higher degree of cross-linking in human Aβ was also indicated by 
our MALDI-TOF MS analysis. The high level of cross-linking may result in a hampered 
clearance of Aβ from the brain in AD patients. Taken together, enhanced levels of post-
translational modifications in human plaques, i.e. cross-linking and N-terminal truncation of Aβ 
peptides, may lead to their reduced clearance from the brain. 
 The methodology used in our experiments allowed to discriminate between oxidized and 
reduced Aβ species. Diffuse plaques in PA were shown to contain a large proportion of oxidized 
Aβ, which could indicate a protective response in these brains and which would explain the lack 
of clinical symptoms in these individuals. 
To determine, whether the amyloid load in plaques may contribute to the high level of 
neuronal loss observed in AD as opposed to transgenic PS2APP mice, 15N-labeled Aβ 1-42 was 
used and the quantitative amyloid load in plaques from human AD and PS2APP mice was 
compared by MALDI-TOF MS. Roughly comparable amounts of Aβ in both species were found. 
 Therefore, we conclude that a dose-effect of Aβ alone can not account for the higher level of 
neurodegeneration observed in AD patients than in PS2APP mice.  
 Using LC/MS/MS the identification of additional proteins involved or affected in the 
pathogenesis of AD was aimed at. A comparison of the proteome in AD brain with control tissue 
was based on the analysis of over 2000 proteins. Proteins generally accepted to be related to AD 
like Aβ, apolipoprotein E, heat shock protein 90, glial fibrillary acidic protein (GFAP) and tau 
were detected at increased levels in AD. Numerous proteins previously tentatively implicated 
with the disease were identified at aberrant levels in AD. We found proteins indicative for an 
enhanced susceptibility to oxidative stress (e.g. decrease of peroxiredoxin 5), an impaired 
glucose metabolism (decrease of enzymes involved in citrate cycle), cytoskeletal derangement 
(e.g. decrease in alpha-internexin), synaptic dysfunction (e.g. decrease in presynaptic density 
protein-95, syntaxin-1A and synaptotagmin-1), an activation of the ubiquitin proteasome system 
(increase in ubiquitin), deficits in the neuritic network (decrease of various cell adhesion 
molecules) and membrane trafficking (e.g. decrease in AP-180), as well as altered levels of 
enzymes involved in the hyperphosphorylation of tau (e.g. decrease in phosphatase-2A). 
 Most notably, we detected 18 new proteins previously not associated with the disease, 
which occurred at altered levels in AD. These are the synaptic proteins synaptogyrin-1 and -3, 
myelin associated glycoprotein, myelin oligodendrocyte glycoprotein, contactin-1, contactin-2, 
neurexin IV and claudin-11 involved in cell adhesion, the chaperone protein Hsp 75, plectin 1, 
ankyrin, α-adducin and microtubule-associated protein RP/EB family member 3 as structural 
cytoskeletal proteins, peroxiredoxin 5 and microsomal glutathione S-transferase 3 for the 
protection against oxidative stress and programmed cell death protein 8, matrin-3 and transgelin-
3, whose functions are not known. The findings obtained by LC/MS/MS were confirmed by 
immunohistochemistry and Western blotting for selected proteins, thereby providing a first 
validation of some of the proteins found at aberrant levels in AD. Interestingly, we were able to 
authenticate decreased levels of syntaxin-1A and reticulon-1 and increased synaptogyrin-1 levels 
in AD using confocal microscopy. 
 The identification of proteins involved in the processes finally leading to 
neurodegeneration and cognitive deficits associated with AD could lead to the development of 
biological markers for the disease. Such biomarker candidates found at altered levels in AD brain 
tissue could possibly be reflected in the cerebrospinal fluid (CSF) and eventually in the periphery 
and may be explored for their value as drug targets or markers for diagnosis, disease progression 
 or even responsiveness to treatment. The results from our studies indicate pathways which 
appear promising in such a quest. 
 
INTRODUCTION 
 
 
Molecular background on Alzheimer’s Disease 
 
 Alois Alzheimer, a Bavarian psychiatrist, described at a meeting in 1906 a 
clinicopathological syndrome, which has emerged as the most common type of dementia in the 
elderly today. Alzheimer’s original patient, a woman referred to as Auguste D., exemplified 
several cardinal features of the disorder that are valid in patients nowadays: progressive memory 
impairment, disordered cognitive function, altered behavior including paranoia, delusions and 
loss of social appropriateness, as well as a progressive decline in language function. The neuro-
pathological investigation of the brain showed the cerebral cortex to be considerably shrinked 
(Figure 1).  
 
    
 
Figure 1. Cross-section of the brain from a normal individual (left) and from an AD patient (right). 
In Alzheimer's disease, there is an overall shrinkage of brain tissue. The sulci are noticeably widened and 
shrinkage of the gyri can be observed. In addition, the ventricles, or chambers within the brain that 
contain CSF, are noticeably enlarged. 
Source: http://www.ahaf.org/alzdis/about/BrainAlzheimer.htm 
 
Alzheimer noted two further abnormalities in the brain. The one being senile plaques, a structure 
previously described in the brain of elderly people. The other abnormality was neurofibrillary 
tangles (NFTs) in histological material from her cerebral cortex, a fiber structure of the nerve 
 
 cells. The nerve tangling had not been previously described, and it was mainly this abnormality 
that defined the new disease. For many decades after Alzheimer’s original description, little 
progress in defining the pathogenesis of Alzheimer’s disease (AD) occurred. With the advent of 
electron microscopy in the 1960s, the two lesions originally described by Alzheimer then became 
subject to intensive research; although considerable progress in the understanding of the disease 
has been made in recent years, these key changes are still under investigation today. 
 Senile plaques are extracellular deposits of the amyloid-β peptide (Aβ) (Glenner et al., 
1984), which is formed after a sequential cleavage of the amyloid precursor protein (APP), a 
membrane-spanning glycoprotein (Kang et al., 1987, Tanzi et al., 1987), by β- and γ-secretases. 
β-secretase is a type I transmembrane glycosylated aspartyl protease, whereas the γ-secretase 
complex consists of at least four proteins, including presenilin-1 and -2 (Nunan and Small, 2000, 
Haass, 2004). The normal functions of APP are not fully understood, but increasing evidence 
suggests that it has important roles in regulating neuronal survival, neurite outgrowth, synaptic 
plasticity and cell adhesion (Mattson, 1997). Due to heterogeneous cleavage sites of γ-secretase 
on APP, a series of Aβ peptides, including the major variants Aβ 1-40 and Aβ 1-42, are 
produced and deposited in senile plaques principally in a filamentous form as amyloid fibrils. 
The two Aβ peptides differ in their neurotoxicity, solubility and their tendency to undergo 
fibrillogenesis, with Aβ 1-42 being more toxic and more prone to aggregation (Jarrett et al., 
1993, El-Agnaf et al., 2000). Senile plaques are associated with axonal and dendritic injury and 
are generally found in large numbers in the limbic and association cortices. Several genes have 
been implicated in AD in humans, most notably those encoding APP and its processing 
proteases, which cause early-onset familial AD (FAD) when mutated (Selkoe, 2001a). In 
addition, the ε4 allele of apolipoprotein E was identified as a genetic risk factor for AD, 
increasing the risk of developing the disease considerably (Tanzi et al., 1996). An excellent 
source of current information on genetic variants associated with AD provides the AlzGene 
website (www.alzforum.org/res/com/gen/alzgene/default.asp). The identification of genes involved in 
AD ultimately allowed the development of transgenic mouse models, harboring various 
mutations in these genes. A mouse model that reflects all aspects of AD has not yet been 
produced, but some transgenic mouse lines provide highly useful phenotype(s) reproducing AD 
relevant features (McGowan et al., 2006). 
  Based upon the two diagnostic features displayed in AD brains, the amyloid cascade 
hypothesis and a model of neurodegenerative tauopathies were developed and provide a 
framework for the study of AD pathogenesis. Soon after the discovery of mutations in the APP 
gene in FAD, the amyloid cascade hypothesis was proposed (Hardy and Higgins, 1992, Selkoe, 
2001a, Hardy, 2006). Basically, this hypothesis states that altered APP expression/proteolytic 
processing or changes in Aβ stability/aggregation result in a chronic imbalance between Aβ 
production and clearance. Gradual accumulation of aggregated Aβ initiates a complex, multistep 
process that includes gliosis, inflammatory changes, neuritic/synaptic change, neurofibrillary 
tangles, reduction in neurotransmitters and finally neurodegeneration and neuronal cell death. 
Central to this hypothesis is the observation that the vast majority of mutations causing FAD 
increase the amount of fibrillogenic Aβ 42. In addition, transgenic mouse models expressing 
pathogenic mutations of APP and presenilin-1 have increased levels of Aβ and amyloid plaques 
(Hsiao et al., 1996). Furthermore, individuals with trisomy 21 have 3 copies of APP and develop 
advanced AD usually within the fourth decade of life (Mann, 1988). 
 NFTs are intraneuronal lesions primarily composed of paired helical filaments (PHFs), 
which consist of hyperphosphorylated protein tau. It is known that normal tau binds and 
stabilizes microtubules thereby maintaining the network of microtubules that are essential for 
axonal transport in neurons. Moreover, the phosphorylation of tau prevents the binding of tau to 
microtubules. Neurodegenerative tauopathies suggest that the conversion of normal tau into 
hyperphosphorylated tau results in a loss of tau function, which leads to a depolymerization of 
microtubules, thereby impairing axonal transport followed by neuronal dysfunction and 
neurodegeneration (Lee and Trojanowski, 1992, Iqbal et al., 2005, Lee et al., 2005). The 
distribution of neurofibrillary tangles spreads as the severity of Alzheimer's disease increases and 
it has been proposed that the concomitant loss of synaptic density is likely to have a more 
immediate relationship to dementia in Alzheimer's disease than does amyloid accumulation. 
However, Thal and colleagues showed that Aβ deposition in the brain follows a distinct sequence 
in which the regions are hierarchically involved and that phases of Aβ deposition are very 
predictive and correlative to disease progression of AD (Thal et al., 2002). Because brains from 
cognitively normal, pathologically aged individuals were found to display an extensive 
amyloidosis without concomitant tau pathology, it could be suggested that NFTs are ultimately 
responsible to induce the cognitive deficits. On the other hand, studies with transgenic mice 
 showed that Aβ immunotherapy reduced not only extracellular amyloid plaques, but most 
notably lead to the clearance of early tau pathology. It was shown that Aβ deposits were cleared 
first and subsequently reemerged prior to the tau pathology, indicative of a kind of hierarchical 
and direct relationship between Aβ and tau (Oddo et al., 2004). The explicit relation between Aβ 
deposition and tau pathology is not clear yet, but tau aggregation has many consequences for the 
neuron and is probably the final common cause of neurodegeneration in AD, and in the other 
tauopathies such as frontal lobe dementia and progressive supranuclear palsy. However, the 
molecular mechanism leading from Aβ accumulation with plaque deposition to tau accumulation 
and neurodegeneration with cognitive deficits are not fully elucidated at the molecular level. 
 
 A more recent hypothesis suggests that soluble oligomers are the toxic species with a 
substantial impact on synaptic function and neurodegeneration. A growing number of in vitro 
and in vivo studies suggest that soluble oligomeric peptides with high β-sheet content are toxic to 
neuronal cells and cause their dysfunction and death. According to this hypothesis, the 
sequestering of soluble Aβ into amyloid fibrils and the deposition in plaques may present a 
protective response of the brain that delays neurodegeneration (Watson et al., 2005). Recently, 
soluble Aβ-oligomers of 56 kD were detected in Tg2576 mice and were shown to contribute to 
cognitive deficits associated with AD (Lesne et al., 2006). 
 Additionally, emerging evidence indicates that intraneuronal Aβ plays a 
pathophysiological role in the progression of the disease (Tseng et al., 2004). It has been shown 
in a triple transgenic mouse model that the first pathological manifestation is the accumulation of 
intraneuronal Aβ (Billings et al., 2005) and that a progressive decrease in the intraneuronal Aβ 
pool goes along with an increase in extracellular plaque load (Oddo et al., 2006). Therefore, 
intraneuronal Aβ may serve as a source for some of the extracellular amyloid deposits. However, 
there is no doubt that extracellular Aβ accumulation in form of neuritic plaques contributes to 
AD pathology and induces a microglia-mediated chronic inflammation with devastating 
consequences. 
 The co-incidence of amyloid plaques with AD poses the question, whether plaques are 
the cause or a consequence of the disease. The fact that Aβ was shown to be toxic in vitro 
supports the view of a causative role. Therefore, the observed neuronal cell death in AD may be 
the destructive effect of plaque-related Aβ on the adjacent neuronal cell bodies or processes such 
 as dendrites or synapses. It was shown that Aβ peptides undergo extensive N- and C-terminal 
truncation, occur in oxidized forms and are subject to post-translational modifications. Enhanced 
Aβ synthesis rates coupled with decreased degradative enzyme production (Selkoe, 2001b) and 
posttranslational modifications that slow down or inhibit proteolysis like pyroglutaminated or 
cross-linked Aβ peptides, may all enhance amyloid deposit formation and subsequent 
neurodegeneration, although the degree of neuronal and synaptic losses not always correlates 
with the amyloid plaque burden (Walsh et al., 2002). Transgenic mice lack the extensive 
neurodegeneration associated with AD (King and Arendash, 2002, Higgins and Jacobsen, 2003, 
Hu et al., 2003). Considering the low level of neuron loss observed in many of the transgenic AD 
models, the question arises whether differences in the plaque amyloid load, in plaque-comprising 
Aβ variants, its oxidation state or post-translational modifications of Aβ in plaques can be 
detected in AD and may ultimately be responsible for the differing level of neurodegeneration 
observed.  
 Not much is known about the events leading to deposition and formation of senile 
plaques. Several plaque types are described and different ways of their formation were proposed 
(Armstrong, 1998). The hypothesis of a sequential evolution and time-dependent modification of 
plaques stems from the immunohistochemical evidence that fibrillogenic Aβ 1-42 is the main Aβ 
component in early diffuse plaques in AD and Down Syndrome (DS) (Iwatsubo et al., 1994, 
Iwatsubo et al., 1995). A further accumulation and aggregation of secreted Aβ may then result in 
mature amyloid plaques of various shapes, which represent different stages in the life history of 
senile plaques. Another theory suggests that different types of amyloid plaques, e.g. compact and 
cored plaques, form independently and not sequentially. The process of plaque formation and 
evolution is not solved yet, even though evidence (Armstrong, 1998) hints to an independent and 
not sequential plaque development. A specific combination of proteinous factors, like different 
Aβ variants, modifications or other plaque associated proteins, possibly influence and determine 
the evolution of diffuse plaques to the respective matured plaque types. It is known, that apart 
from Aβ, several other proteins were described to be associated with amyloid plaques. Among 
them, apolipoprotein E is the best characterized and its involvement in fibrillization and plaque 
formation was demonstrated (Wisniewski et al., 1994, Dickson et al., 1997). The elucidation of 
plaque development is important and is likely to reveal steps in the maturation process, which 
can serve as drug targets and may be influenced to slow down the disease progress. 
 Secondary to the deposition of amyloid in plaques and the formation of NFTs, various other 
biochemical processes occur during the onset and the progression of the disease. Various 
proteomic attempts have been undertaken to elucidate the pathways affected by the disease 
(Schonberger et al., 2001, Tsuji et al., 2002); several genetic approaches were also taken (Loring 
et al., 2001, Ho et al., 2005). The abnormally expressed proteins / genes that were found are in 
principle indicative for neurodegeneration and nerve cell loss, an inflammation response of the 
brain, oxidative stress and an impaired glucose metabolism. For a better understanding of the 
disease and improved therapeutic modalities it is necessary to reveal the proteins and processes 
involved, because through this knowledge reliable biomarkers and effective disease modifying 
drugs can be generated. 
 
 
Biomarkers for Alzheimer’s disease 
 
 AD is a common disease but a definitive diagnosis can still only be made by a 
postmortem assessment of brain neuropathology. Hence the necessity of a biological marker for 
AD is obvious (Lovestone, 2006). Such a marker should meet several criteria as outlined by the 
Ronald and Nancy Reagan Research Institute and the NIA Working Group report (1998). 
According to these specifications, a biomarker is “a characteristic that is objectively measured 
and evaluated as an indicator of normal biological processes, pathogenic processes, or 
pharmacological responses to a therapeutic intervention.”  
 It is difficult to follow AD progression or monitor response to treatment and to date, no 
pre-symptomatic biomarker for AD is available. By the time AD is clinically apparent, the 
disease is already well-established, limiting the possible effectiveness of any therapeutic 
intervention designed to slow progression by reducing pathological processes (see chapter 
‘Development of therapeutic agents for Alzheimer’s disease’ below). The diagnosis of AD is 
currently based on cognitive tests and behavioral analysis. Thus, the MMSE (Mini Mental State 
Examination) and the ADAS-cog (Alzheimer's Disease Assessment Scale - cognitive subscale) 
remain the most widely used measures of cognitive change and drug trial efficacy in clinical 
practice. Both MMSE and ADAS-cog, and all similar memory measures, are subject to learning 
effects and critical in utility if they are used repeatedly in a patient. Both clinical practice and 
clinical trials would be much enhanced by a quantitative biomarker usable for diagnosis or 
 disease progression. A biomarker is clearly needed also for drug development, be it in drug 
discovery and in preclinical or in early to late phase clinical development. 
 Considerable progress in the search for a biomarker has been made with markers derived 
from the well known pathological lesions using a variety of techniques to investigate 
biochemical changes in the cerebrospinal fluid (CSF), blood and other tissues and fluids. The 
most promising sources for biomarkers in AD are the CSF or blood plasma, because compared to 
brain tissue, these fluids are more easily accessible and, in case of CSF, in close contact with the 
central nervous system, where the key biochemical changes take place. Several biomarkers were 
suggested like CSF total-tau (Andreasen et al., 1998) and phospho-tau (Parnetti et al., 2001) 
levels, CSF Aβ 1-42 levels (Andreasen and Blennow, 2002) or a combination thereof (Andreasen 
et al., 2003). In addition, numerous proteins expressed at aberrant levels in AD were identified 
(Vercauteren et al., 2004). However, a considerable amount of work is required to progress any 
of these putative markers to the point where they may be useful as surrogates for diagnostics and 
monitoring disease modification trials. 
 
 
Therapeutic approaches for treatment of Alzheimer’s disease 
 
 Due to the prevalence of AD today and the prospect of a rapidly growing disease 
population due to increased life expectancy, there is an unmet medical need for therapeutic 
interventions. To date, no treatment approach has been clinically proven to modify the disease 
process in a way that significantly slows or prevents its progression. However, at the present 
time, there are some pharmacological agents that may ameliorate or temporarily suppress certain 
symptoms. Acetylcholine esterase inhibitors like tacrine, donezepil, rivastigmine and 
galanthamine may cause a delay of the decline (Doody, 2003), but a clear demonstration that 
these drugs significantly affect the disease course itself is not obtained. Currently, several 
strategies for the development of a disease modifying agent are pushed forward: 
 
 Inhibition of β-secretase – β-secretase, often referred to as BACE (beta-site APP cleaving 
enzyme) is an attractive target for therapies aiming at modifying the course of AD, as this 
enzyme initiates and is the rate limiting step in the formation of Aβ (Vassar, 2001). The 
molecular sequence and crystal structure of the key protease have been identified (Hong et al., 
 2000) and the development of specific β-secretase inhibitors is being actively pursued (John, 
2006). The observation that BACE1 knockout mice do not generate any Aβ (Roberds et al., 
2001), supports the validity of the target. Importantly, these mice appear to be healthy, with no 
obvious neurological and behavioral abnormalities. However, up to now the compounds found to 
inhibit β-secretase are either not specific enough or are too large for crossing the blood brain 
barrier after their peripheral administration. 
 
 Inhibition of γ-secretase – The screening of compound libraries revealed a substantial 
number of compounds of different structural classes that appeared to inhibit the activity of γ-
secretase (Dewachter and Van Leuven, 2002). One of the problems that emerged was the similar 
proteolytic processing of APP and the Notch receptors and the associated difficulty to reduce Aβ 
production without significantly interfering with the functions of Notch signaling in adults. 
Notch functions include a variety of cell fate decisions necessary for the proper differentiation of 
several cells. 
 A different approach to avoid amyloidogenic Aβ 1-42 is to shift the cleavage specificity 
of γ-secretase away from position 42, without altering overall Aβ levels. It was suggested that 
certain members of the non-steroidal anti-inflammatory class of drugs (NSAIDs), may induce 
such a shift if administered at appropriate doses (Townsend and Pratico, 2005). NSAIDs are also 
used to interfere with the chronic inflammatory reaction that takes place in AD. The best-
characterized action of NSAIDs is the inhibition of cyclooxygenase (COX) (Hoozemans et al., 
2003). However, the doses of NSAIDs used to date are very high and more work is needed to 
determine whether chronic NSAID administration could have true therapeutic benefit. 
 
 Immunological approach – The immunological strategy involves either a classical 
vaccination with Aβ in order for the host immune system to generate anti-Aβ antibodies or 
providing antibodies passively. In both cases, the primary function of the antibodies is binding to 
its target, i.e. Aβ, thereby enhancing the clearance and/or preventing the deposition of Aβ in 
plaques. Active immunization with Aβ 1-42 was initially shown to be able in clearing pre-
existing Aβ deposits and also in preventing the development of new Aβ plaques and associated 
neuropathology in transgenic mouse models of AD (Schenk et al., 1999). Furthermore, the 
reduction in Aβ burden is accompanied by improved cognitive performance. 
  Several hypotheses how anti-Aβ antibodies may work therapeutically are discussed. It 
was suggested, that the antibody could enter the brain and bind to Aβ plaques (Bard et al., 2000) 
and/or shifts the CNS - plasma Aβ equilibrium by acting as peripheral sink (DeMattos et al., 
2001). 
 
 The approaches currently undertaken for drug discovery in AD follow predominantly the 
concept of the amyloid cascade hypothesis. The overall aim of the attempts is to lower the 
amyloid brain burden, either by modifying APP processing enzymes or by directly targeting 
amyloid plaques in the brain. For this reason, a deeper understanding of Aβ variants deposited in 
plaques – one topic of this thesis – is of considerable interest and is fundamental for the 
development of amyloid targeting drugs. Since preclinical drug development relies on animal 
models, the knowledge of the comparative Aβ plaque composition in AD and the investigated 
PS2APP transgenic mice is of special importance. Substantial differences in the nature and 
amount of Aβ peptides could affect the translation of preclinical data into the clinics. This is 
especially relevant for immunotherapeutic approaches which utilize the binding of antibodies to 
amyloid plaques and a detailed knowledge of occurring Aβ variants is essential. The observed 
difference in the degree of neuronal cell loss between AD patients and transgenic animal models, 
which is extensive in AD, but limited in transgenic mice, offers to study Aβ plaque composition 
and identify Aβ modifications, which might impact on neurodegeneration in AD. Identification 
of proteins other than Aβ involved in biochemical processes affected by AD, might further 
enrich this knowledge and could reveal biological markers and drug targets unrelated to Aβ. 
 
 
 
 AIMS OF THE INVESTIGATION 
 
 
 The key aims of this thesis were to determine proteomic factors involved in 
neurodegeneration. Aβ variants including post-translational modifications were determined in 
AD and double-transgenic PS2APP mice, in order to possibly explain the observed differences in 
neuronal cell loss in human patients and the transgenic animals. By investigation of proteins 
beyond Aβ it was expected to get insight into additional pathways involved in disease 
progression in AD brains opening the possibility to identify biomarkers and new drug targets. 
 
Four specific steps were taken; each step is described in a stand-alone manuscript (one published 
[I], two submitted [II, IV] and one prepared for submission [III]): 
 
 
- Quantification of the amyloid load in plaques from AD and PS2APP mice and a detailed 
 physico-chemical analysis of Aβ in deposited amyloid plaques [I] 
 
 
- Identification of early, disease-relevant Aβ species in AD with impact on 
 neurodegeneration and comparison to PS2APP mice and pathological aging 
 individuals [II] 
 
 
- Identification of pyroglutamate as a component of senile plaques in AD and 
 PS2APP mice, and in vitro aggregation and toxicity studies with synthetic N3pE-42 [III] 
 
 
- Proteomic comparison of AD and control brain tissue: Determination of affected 
 biochemical pathways and identification of potential biomarkers [IV] 
 
 
 METHODOLOGY AND TOOLS 
 
 
 Detailed information concerning patients, animals, material and methods is given in the 
individual papers. In the following an overview spanning across all four approaches of the 
experimental work is presented. 
 
 
Human brain tissue and transgenic mice 
 
 Human brain tissue from eight different individuals was used [I-IV]. The brain tissue was 
collected approximately two hours postmortem and was immediately frozen at -80°C. Brains 
were neuropathologically staged according to Braak (Braak and Braak, 1991). The age of the 
patients ranged from 77 to 89 years, five female and three male patients were used for 
investigation. The available brain tissue bank allowed to investigate AD brains with different 
Braak stages from IV to VI and to compare with controls and pathological aging (PA) 
individuals. Individuals with Braak stages V and VI showed heavy, with Braak stages IV and PA 
cases moderate plaque load. Individuals with Braak stage II were used as controls and did not 
exhibit amyloid plaque pathology. Differences in the amyloid composition of plaques from 
different Braak stages could hence be correlated to disease progression. 
 Additionally, brain tissue from six PS2APP double-transgenic mice (Richards et al., 
2003) at an age of 8 and 20 months was employed [I-III]. PS2APP mice overexpress mutant 
forms of human presenilin 2 (N141I) and human APP (K670N, M671L). The animals develop an 
age-related cognitive decline associated with severe cerebral amyloidosis. Additionally, an 
inflammation response in discrete brain regions, and behavioral changes, evaluated by the Morris 
water maze and active avoidance tests, were observed. Neuronal cell loss in transgenic mice in 
general is observed only to a small extent, but the employed transgenic PS2APP mouse model 
exhibits many of the features typical for AD and was therefore considered as a suitable tool to 
investigate the role of amyloid and plaques in AD. 
 Histochemistry 
 
 Frozen brain tissue was used and sections of 10 - 30 μm from AD and PA individuals, as 
well as from PS2APP mice were cut with a cryostat microtome. Subsequently, the brain sections 
were stained with different antibodies at a concentration of 1 – 10 μg/ml. 
 Using anti-Aβ antibody and thioflavine S, vascular amyloid, diffuse plaques, compact 
plaques and cored plaques could be distinguished according to their morphology and staining 
properties [I-II]. These different plaque types were isolated using laser dissection microscopy 
and the Aβ composition thereof was determined using MALDI-TOF MS and urea-based Western 
blotting. In addition, using a pyroglutamate specific antibody, the localization of pyroglutamate 
in plaques from human AD brains and PS2APP mice was traced [III]. 
 Antibodies against proteins other than Aβ and identified at aberrant levels by LC/MS/MS 
were used to reveal co-localization of the respective proteins with amyloid-plaques and reactive 
astrocytes or to determine an abundance difference between AD and control tissue [IV]. 
 
 
Laser dissection microscopy  
 
 Laser dissection microscopy (LDM) is the non-contact laser microdissection of 
membrane-mounted native tissue (MOMeNT). The method allows the isolation of a microscopic 
area with high precision (Simone et al., 1998), whereas the surrounding tissue remains intact and 
the excised area retains its morphological structure. LDM can be used to obtain a highly 
homogenous sample set, e.g. the accumulation of specific cell or plaque types, and enhances the 
opportunities for the molecular analysis of pathological processes significantly. The usefulness 
of LDM in AD was shown for the isolation of thousands of plaques and subsequent analysis by 
mass spectrometry (Liao et al., 2004, Miravalle et al., 2005). Within this thesis, LDM was 
employed to isolate specifically different types of amyloid plaques or vascular amyloid after 
(immuno-) histological differentiation [I-III] for subsequent analysis by MALDI-TOF MS or 
urea-based Western blotting. The methods of analysis were refined to maximize sensitivity. 
Highest possible sensitivity was aimed in order to allow characterization of minute amounts of 
homogeneous plaque types, rather than averaging the senile plaque load by the analysis of brain 
 homogenates. Depending on the isolated plaque type, the species and the method of further 
analysis, different numbers of amyloid plaques were required: required plaque numbers ranged 
from as little as one single PS2APP compact plaque to 10-20 human cored and diffuse plaques 
for analysis by urea-based Western blotting, whereas 30 PS2APP compact plaques, 50 cored 
plaques and 100 diffuse plaques from human AD were needed to surpass the detection limit of 
the MALDI-TOF mass spectrometer. 
 
 
Western blotting 
 
 Conventional SDS-PAGE and Western blotting was modified according to Ida and 
colleagues (Ida et al., 1996) to enhance sensitivity. The method was used to determine solubility 
differences between human and PS2APP mouse plaques [I], quantify plaque derived Aβ in 
human and PS2APP mice [I], in the sample preparation procedure for LC/MS/MS to separate 
brain proteins [IV], as well as to compare protein levels between AD and control tissue [IV]. 
 High sensitivity urea-based Western blotting allowed the separation of full length Aβ 
peptides, e.g. Aβ 1-40 and Aβ 1-42, at a detection limit of 1-2 fmol (Klafki et al., 1996, Wiltfang 
et al., 1997) [II-III]. Additionally, it enabled to discriminate between the oxidized and reduced 
forms of Aβ 40 and 42. 
 
 
MALDI-TOF MS 
 
 MALDI-TOF MS measurements [I-III] were performed on a Bruker UltraFlex TOF / 
TOF mass spectrometer in reflector mode using standard operating parameters. Peptide 
sequencing by tandem mass spectrometry [I] was performed on the same instrument operated in 
the LIFT mode according to the manufacturer’s standard operating parameters.  
 Analysis of plaque constituting Aβ variants was done using a protocol that includes 
endoproteinase Lys-C digestion of Aβ peptides. The cleavage of Aβ by Lys-C generates three 
fragments, whereas the C-terminal fragment could not be detected probably due to its 
hydrophobicity. For detection of the C-terminal Aβ fragment, an ionization modifier, 6-
 guanidohexanoic acid – N-hydroxysuccinimide (6-GuHe), was developed. 6-GuHe enabled 
identification of the C-terminal fragments and discriminating of oxidized and reduced forms [II]. 
The digestion with Lys-C was performed for enhanced sensitivity and the resulting peptides 
could be detected with a sensitivity of ~ 200 - 300 fmol. 
 The use of 15N-labeled Aβ 1-42 allowed quantification of plaque derived Aβ in human 
and PS2APP mice in a highly accurate manner [I]. 
 
 
LC/MS/MS 
 
 Liquid chromatography combined with tandem mass spectrometry is a technique that 
couples solute separation by HPLC, with detection of column effluent by mass spectrometry. 
This allows the analysis of thousands of proteins from a complex protein mixture even at 
concentrations in the femto- or sub-femtomolar range. The LC/MS/MS technique was 
demonstrated to be suitable for proteomic characterization in various fields, like cancer research 
(Baker et al., 2005, Gagne et al., 2005), glycoproteomic analysis (Hashii et al., 2005, Wuhrer et 
al., 2005) or AD (Liao et al., 2004). In our studies, LC/MS/MS was used for the comparison of 
protein levels in grey matter from severe AD and control tissue [IV]. More than 2000 proteins 
from less than 1 mg brain tissue were identified and compared in a semi-quantitative manner. 
Numerous proteins with significantly altered levels in AD were detected and identified using the 
HumanGP protein library. Among known AD-related proteins like Aβ, tau, GFAP, ubiquitin and 
apolipoprotein E, a total of 18 new proteins were detected which previously had not been 
associated with the disease. 
 
 
SELDI-TOF MS 
 
 This technology is suitable to perform mass spectrometric analysis of protein mixtures 
retained on chromatographic chip surfaces. Preactivated surfaces allow coupling of antibodies to 
the spot surfaces, generating user-defined arrays. The skills of handling the chips were acquired 
in the laboratory of Prof. Dr. med. Jens Wiltfang in Erlangen, Germany and aimed to specifically 
analyzing full-length Aβ isolated from laser dissected plaques. The analysis of synthetic Aβ and 
PS2APP mouse brain homogenates of 20 month old mice was done for setting up the 
methodology. Brain homogenates contain large amounts of Aβ and several C-terminal truncated 
Aβ forms were detected (Figure 2). However, even though we were able to detect the main Aβ 
species in vascular amyloid and cored amyloid plaques, namely Aβ 1-40 and Aβ 1-42, it was not 
possible to identify N-terminally and other C-terminally truncated Aβ species due to sensitivity 
limitations. It is likely, that the sample preparation procedure, which included formic acid 
treatment, interfered with the binding of Aβ to its antibody on the chip surface. 
 
 
Figure 2. SELDI-TOF MS analysis of PS2APP transgenic mouse brain homogenates. 
Using an Aβ specific antibody, a series of Aβ peptides were detected, including Aβ 1-37 (m/z 4072.5), 
Aβ 1-38 (m/z 4129.4), Aβ 1-39 (m/z 4228.8), Aβ 1-40 (m/z 4327.6) and Aβ 1-42 (m/z 4511.7). The 
successful analysis of brain homogenates indicates the potential of the method. However, the analysis of 
laser dissected plaques did not reveal N-terminal and C-terminal truncated Aβ variants due to sensitivity 
limitations. 
 
 
 OVERALL RESULTS AND DISCUSSION 
 
 
 The present set of studies clarified two complementary aspects of protein 
characterization, providing insight into various processes that contribute to neurodegeneration 
and loss of cognitive functions observed in AD. On the one hand, an amyloid-based approach 
was undertaken to determine Aβ variants and post-translational modifications of Aβ and to 
characterize and quantify the amyloid load of plaques in AD and in PS2APP transgenic mice. 
The aim was to identify Aβ species responsible for the high level of neuron loss observed in AD 
contrasting to the low level of neurodegeneration observed transgenic models in general. A 
characterization of plaques observed in pathological aging was additionally made, as individuals 
with these changes do exhibit amyloid plaques, but show no cognitive deficits. 
 As an alternative approach on the other hand, we identified proteins other than Aβ that 
occur at altered levels in AD and which might impact additionally on neurodegeneration. Such 
proteins could present potential biomarkers in AD and might be useful in the diagnosis or 
monitoring the progression of the disease or help in increasing the efficiency of developing new 
pharmacological treatment modalities for AD. 
 
 
Aβ variants, posttranslational modifications of Aβ and amyloid load in plaques from human 
AD brains, PA individuals and transgenic PS2APP mice [I-III] 
 
 The investigation of the amount and nature of Aβ variants in plaques of PS2APP mice 
and AD / PA revealed substantial differences in the Aβ composition and degree of 
posttranslational modification in plaques of human AD patients and the transgenic PS2APP 
mouse model. 
 The main plaque types occurring in human AD patients are cored and diffuse plaques, 
whereas a large number of compact plaques was found in PS2APP mice. Vascular amyloid was 
frequently detected in human AD, but only sporadically in the PS2APP transgenic mouse model. 
The Aβ composition in the various plaque types is different: Cored plaques consist mainly of Aβ 
42, whereas compact plaques, which can sporadically be found also in human, and vascular 
 amyloid contain mostly Aβ 40. Aβ 42 was shown previously to be prone to more extensive 
aggregation than Aβ 40 (Jarrett et al., 1993). We detected Aβ 1-42 as the main Aβ component in 
diffuse plaques. 
 Diffuse plaques are commonly accepted to be the initial plaque type occurring in AD 
(Selkoe, 2001a); they are also found in PS2APP mice, although here they show already at this 
maturation stage structural differences when investigated by immuno-electron microscopy. 
Diffuse plaques can also be found in brains of cognitively normal PA cases (Thal et al., 2004). A 
characterization of diffuse deposits using MALDI-TOF MS and urea-based Western blotting 
revealed no difference in the main Aβ component in PA and AD subjects. However, diffuse 
plaques in PA individuals showed a higher degree of oxidized methionine 35 than cored plaques 
in AD. It was demonstrated that oxidized Aβ shows a reduced toxicity (Clementi et al., 2004). 
This could indicate a protective response of the brain and would explain the absence of clinical 
symptoms typical for AD in PA individuals, although they carry considerable diffuse plaque load 
in the neocortex. 
 The evolution of different plaque types is subject to speculations (Armstrong, 1998); the 
present study provides important information for clarification. Considering the short life span of 
mice contrasting with the progression of the disease in humans over several decades, it might be 
suggested that compact plaques represent an intermediate plaque type, which develop over time 
to cored plaques. However, taking our data into account, this is very unlikely to be the case since 
compact plaques consist of Aβ 40 and cored plaques mainly of Aβ 42; hence transformation of 
compact to cored plaques would require a posttranslational attachment of amino acids. Our data 
support the following evolutionary sequence: plaque maturation starts with diffuse plaques, 
which then independently evolve either to typical cored or compact plaques. Various factors, like 
plaque associated proteins, kinetics of Aβ deposition and clearance or posttranslational 
modifications then would lead to divergent processes resulting in the species dependent 
frequency of different plaque types observed in AD and PS2APP mice. An overview of the 
different plaque types detected can be seen in Figure 3.  
 
 
Figure 3. Histology of human and PS2APP transgenic mouse brain sections. 
Brain sections from PS2APP mice (A, E) and from human AD (B-D, F-H) specimen were doublestained 
with thioflavine S and Aβ antibody in order to differentiate between the different plaque types. 
Arrowheads indicate diffuse plaques, arrows highlight compact plaques. A typical example of a cored 
plaque is given in C and G. Human vascular amyloid can be seen in D and H. 
 
 Aβ peptides in plaques undergo extensive N-terminal truncation in AD (Mori et al., 1992, 
Miller et al., 1993, Sergeant et al., 2003, Miravalle et al., 2005), a process which is reported to a 
considerably smaller extent in some transgenic mouse models (Kuo et al., 2001). This likely 
impacts on the evolution of plaques and might contribute to the level of neurotoxicity of Aβ. It 
was therefore of interest to investigate and compare N-terminal truncated Aβ forms of plaques 
from AD and PS2APP mice with our method, using MALDI-TOF MS in combination with laser 
dissection microscopy (Rüfenacht et al., 2005). Because brains from patients at various Braak 
stages were available, a correlation of N-terminal truncation with disease severity could be 
evaluated. We detected a progressive increase in N-terminally truncated Aβ species in human 
cored plaques correlating with disease progression in AD, indicative for a successive truncation 
of Aβ by an exoprotease upon deposition. Accordingly, lower levels of N-terminally truncated 
Aβ variants were detected in plaques from PS2APP mice, reflective for the shorter time of 
disease course. We identified pyroglutamate 3-40 /42 (N3pE-40 / 42) as the major N-terminal 
truncated Aβ species in human cored plaques by MALDI-TOF MS (Figure 4) and were able to 
confirm its abundance by immunohistochemistry and urea-based Western blotting using an 
N3pE-42 specific antibody. Although diffuse plaques in AD show only low levels of N-terminal 
truncation, N3pE-40 / 42 could also be identified by mass spectrometry. It was described earlier, 
that N3pE-40 / 42 could be a likely seed for plaque deposition (Saido et al., 1995, Saido, 2000). 
This is not supported by our data. We detected only small amounts of N3pE-40 / 42 in diffuse 
 
plaques (i.e. the precursor stage of cored plaques) and the aggregation and toxicity properties of 
synthetic pyroglutamate 3-40 / 42 studied in vitro do not support the idea of an involvement of 
pyroglutamate in initial disease stages. Pyroglutamate, however, contributes to the amyloid load 
in the brain through its resistance to most of the aminopeptidases and hence the amount of N3pE-
40/ 42 present in the brain is indicative for disease progression. 
 
 
Figure 4. N-terminal truncation of Aβ derived from 30 human cored plaques and detected by 
MALDI-TOF MS. 
Typically, N-terminal Aβ peaks corresponding to Aβ 1-16 (1954.9), 2-16 (1839.9), 3-16 (1768.8), N3pE-
16 (1750.8), 4-16 (1639.8) and 5-16 (1492.7) were observed. Pyroglutamate 3-16 was detected as the 
major N-terminal truncated Aβ variant. m/z 1325.7 corresponds to the Aβ fragment 17-28. i.s., internal 
standard. 
 
 
 As was described earlier, Aβ present in homogenized senile plaques are crosslinked to a 
higher extent in AD than in transgenic mice (Kuo et al., 2001). We found, that human plaques 
require strong hydrolyzation conditions, namely formic acid for solubilization, whereas PS2APP 
mouse plaques could be solubilized in SDS-containing buffer already. Furthermore, our mass 
spectrometric data support the hypothesis of a high level of crosslinking in human plaques. 
 
 Enhanced stability of Aβ deposits through crosslinkage in AD is likely to contribute to a 
hampered clearance of Aβ from the brain and therefore has consequences for 
immunotherapeutical approaches used for the treatment of AD. 
 The Aβ peptide was described to be neurotoxic and a difference in the amyloid load in 
plaques from AD and PS2APP mice consequently would explain different degrees of neuronal 
cell death in AD and PS2APP transgenic animals. The quantification of the amyloid load, 
however, revealed a roughly comparable amount of Aβ present in human and PS2APP mouse 
plaques by mass spectrometry. A dose-effect of Aβ alone therefore can not explain the observed 
difference of neurodegeneration in transgenic PS2APP mice and man.  
 In summary, the different levels of neuronal cell death observed in AD and PS2APP 
mouse models is probably an interplay of various factors. Beside genetic and kinetic differences 
that most likely play a role, we focused on the analysis of Aβ and detected enhanced N-terminal 
truncation of Aβ, indications for a higher degree of crosslinking of Aβ fibrils and the occurrence 
of different main plaque types with dissimilar constituting Aβ variants in AD, which might 
contribute to the different levels of neuronal cell loss observed in PS2APP mice and AD. 
Furthermore, our results suggest that oxidation events on the Aβ peptide in the brain may 
significantly influence the degree of nerve cell loss and cognitive symptoms. The amyloid load in 
plaques per se cannot account for neurodegenerative differences.  
 
 
Identification of proteins involved in pathogenic processes of AD and potential biomarkers 
[IV] 
 
 Apart from the above mentioned Aβ-related factors likely to influence neurodegeneration 
in AD, the proteomic background of human AD patients can provide more insight. Therefore, we 
compared protein levels from human AD and control tissue to detect and quantify altered protein 
levels and possibly to thereby identify proteins hitherto not implicated in mechanisms leading 
from the deposition of Aβ and tau to nerve cell loss and cognitive failure. We found that various 
processes are affected by the disease. Our method using LC/MS/MS allowed to detect more than 
2000 proteins in AD brain tissue and we identified altered levels of numerous proteins. These are 
proteins which are known to be involved in the deposition of Aβ and the hyperphosphorylation 
 of tau, or are indicative of an aberrant energy metabolism, an enhanced susceptibility to 
oxidative damage, an inflammatory response, cytoskeletal impairment, disease related deficits in 
cell adhesion molecules, impaired membrane trafficking and a synaptic impairment in AD. 
Beyond that, 18 proteins previously not implicated with the disease were detected at aberrant 
levels in AD and selected proteins were confirmed by immunohistochemistry and Western 
blotting.  
 The diversity of involved pathways reflects many of currently discussed mechanisms 
contributing to the development of nerve cell loss and synaptic failure in AD. Several proteins 
identified at altered levels in this study could be causatively linked or be a stand-alone 
phenomenological observation – but all are indicators of a malfunction of various processes in 
AD. A direct connection between different pathways is difficult to establish and many questions 
are still open; however, the following thoughts are an attempt to combine several puzzle stones 
to a more coherent picture. 
 It can be suggested, that an inflammatory response with the activation of microglia and 
astrocytes is induced upon deposition of Aβ into plaques. In AD, activated microglia congregate 
around amyloid plaques and degenerating neurons, and may produce toxins and inflammatory 
cytokines that contribute to the neurodegenerative process. In addition to activation of microglia, 
the innate immune response includes engagement of the classical complement cascade and 
induction of chemokines and pentraxins. These inflammatory changes may be an important 
mediator, together with the neurotoxic Aβ aggregates, of subsequent neuronal injury and 
synaptic dysfunction seen in the brains of AD patients. The effects of Aβ accumulation and the 
concomitant inflammatory response may give rise to oxidative stress with an excessive 
generation of free radicals and peroxidative injury to proteins, lipids and other macromolecules. 
Mitochondria are the primary source of cellular oxidants and therefore a prime target of 
cumulative oxidative damage. A damage of mitochondrial proteins and DNA is likely to 
decrease their functionality and activity and contributes to the observed aberrant energy 
metabolism by decreased levels of metabolic enzymes. Removal of reactive oxygen species 
(ROS) eventually requires their chemical reduction; a functional deficiency in the tricarboxylic 
acid (TCA) cycle is likely to lead to reduced production of the electrons (NADH equivalents), 
which are needed for the chemical reduction of ROS. Oxidative stress can damage the 
pyruvatedehydrogenase (PDH) complex, which in turn leads to an accumulation of pyruvate or 
lactate. Most importantly, a decreased activity of the PDH complex results in a shortage of the 
 neurotransmitter acetylcholine, another characteristic of AD, by an inadequate supply of acetyl-
CoA. A shortage of energy caused by an impaired TCA cycle in turn has widespread 
consequences, since synaptic vesicle exocytosis and axonal transport is dependent on the 
hydrolysis of ATP. An additional effect of Aβ induced oxidative stress is the disturbance of the 
ionic homeostasis in surrounding neuronal cells by an impairment of pump activities. This could 
lead to an excessive calcium accumulation, which might affect the activity of calcium-regulated 
relevant kinases and phosphatases that could subsequently contribute to the 
hyperphosphorylation of tau. The loss of tau function upon hyperphosphorylation in principle 
can be compensated by the other two neuronal microtubule-associated proteins MAP 1A / 1B 
and MAP 2, which have similar functions. A decrease in MAP levels - as observed in our study -
indicates an impairment of this compensation mechanism. The breakdown of the microtubule 
network in the affected neurons contributes to general cytoskeletal impairment and compromises 
axonal transport, leading to retrograde degeneration which, in turn, results in neuronal 
dysfunction and dementia. Impaired membrane trafficking was reflected by reduced levels of 
several proteins with a known function in clathrin-mediated synaptic vesicle recycling. Reduced 
levels of such proteins could affect the control of synaptic vesicle endocytosis and the synaptic 
terminals of these neurons would become incapable of supplying adequate synaptic vesicles. 
These defects could lead to functional disruption of synapses, resulting in impaired 
communications between neurons – an essential determinant of learning and memory. 
Neurotrophic factors, like nerve growth factor or brain-derived neurotrophic factor, are secreted 
by cells in a neuron's target field, and act by protecting the neuron from apoptosis. Altered 
clathrin-mediated endocytosis could also play a role in impaired neurotrophic factor uptake and 
consequently in impaired signaling cascades, which may contribute to the pathogenesis of 
Alzheimer’s disease. The interplay of various pathways finally results in the high level of 
neurodegeneration seen in AD and to the observed clinical symptoms like cognitive failure and 
behavioral alterations. 
 
 A group of proteins not included in the above mentioned framework of AD are the cell 
adhesion molecules (CAMs). Various proteins in AD, involved either in neurite outgrowth or cell 
adhesion, were detected at decreased levels in this study, indicative for an impaired neuritic 
network. Synapses are highly specialized structures designed to guarantee precise and efficient 
communication between neurons and their target cells, and numerous proteins are involved in the  
 Table 1 
Protein Ratio AD / control tissue Reference 
Reported 
(De-)regulation 
    
cell adhesion / neurite outgrowth    
    
Thy-1 membrane glycoprotein  0.65 Leifer et al. 1992 ↓ 
Myelin-associated glycoprotein 0.59 -  
Claudin-11 0.45 -  
Neurexin IV 0.41 -  
Myelin oligodendrocyte glycoprotein 0.38 -  
Contactin 1  0.7 -  
Contactin 2  0.28 -  
    
chaperones    
    
Hsp 27 1.59 Renkawek et al., 1993 ↑ 
Hsp 75 1.48 -  
Hsp 90 1.43 Anthony et al., 2003 ↑ 
Hsp 60 0.68 Yoo et al., 2001 ↓ 
T-complex protein 1 0.46 Schuller et al., 2000 ↓ 
    
cytoskeleton    
    
Microtubule-associated protein tau 2.36 Mandelkow et al., 1994 ↑ 
Plectin 1 1.3 -  
Ankyrin 2 0.69 -  
Alpha-internexin 0.64 Dickson et al., 2005 n.d. 
Alpha adducin 0.59 -  
Microtubule-associated protein 1B 0.51 Hasegawa et al., 1990 n.d. 
Microtubule-associated protein 
RP/EB family member 3 0.19 -  
    
inflammation    
    
GFAP 4.45 Styren et al., 1998 ↑ 
Vimentin 1.44 Porchet et al., 2003 ↑ 
Complement C3  only AD McGeer et al., 1989 ↑ 
Complement C4 only AD McGeer et al., 1989 ↑ 
    
glucose metabolism    
    
Isocitrate dehydrogenase 0.7 Hoyer, 1991 ↓ 
Succinyl-CoA ligase 0.65 Hoyer, 1991 ↓ 
Malate dehydrogenase, cytoplasmic 0.55 Hoyer, 1991 ↓ 
Malate dehydrogenase, mitochondrial 0.51 Hoyer, 1991 ↓ 
Succinate dehydrogenase 0.51 Hoyer, 1991 ↓ 
Phosphofructokinase 1 0.49 Hoyer, 1991 ↓ 
    
 
  
Table 1 (continued) 
hyperphosphorylation of tau    
    
Mitogen-activated protein kinase 3 (ERK 1) only AD Pei et al., 2002 ↑ 
Mitogen-activated protein kinase 1 (ERK 2) 0.86 Pei et al., 2002 ↑ 
Serine/threonine protein phosphatase 2A 0.45 Gong et al., 1995 n.d. 
    
citrullination of proteins    
    
Protein-arginine deiminase type II 1.45 Ishigami et al., 2005 ↑ 
    
oxidative stress    
    
Peroxiredoxin 5 0.61 -  
Microsomal glutathione S-transferase 3 0.47 -  
Superoxide dismutase [Mn] decreased Krapfenbauer et al., 2003 ↔ 
    
synaptic proteins   
    
Synaptogyrin-1 1.73 -  
Synaptogyrin-3 increased -  
Synaptotagmin-1 0.62 Yoo et al., 2001 ↓ 
Nogo protein 0.54 Strittmatter et al., 2002 n.d. 
Reticulon-1 0.53 Yan et al., 2004 n.d. 
Syntaxin-1A (HPC-1) 0.32 Minger et al., 2001 ↓ 
Presynaptic density protein 95 (PSD-95) 0.3 Gylys et al., 2004 ↓ 
    
membrane trafficking   
    
Clathrin coat assembly protein AP180  0.58 Yao et al., 1999 ↓ 
    
proteolysis    
    
Ubiquitin 1.92 Iqbal et al. 1997 ↑ 
    
others    
    
Amyloid Beta only AD Glenner & Wong, 1984 ↑ 
Apolipoprotein E  2.33 Strittmatter et al., 1993 ↑ 
Alpha-1-antichymotrypsin  (ACT) only AD Abraham et al., 1988 ↑ 
Matrin-3 0.49 -  
Major prion protein  0.43 Lantos et al., 2005 ↓ 
Transgelin-3 (Neuronal protein NP25) 0.4 -  
Programmed cell death protein 8 0.34 -  
        
 
Table 1. Proteins detected at altered levels in AD. 
The ratio is indicative for the protein abundance in AD compared to control tissue. Proteins only present 
in AD are indicated. 'Increased' refers to protein level for proteins detected in only one of the control 
samples; 'decreased' indicates the protein level for proteins detected in only one of the AD cases. Arrows 
indicate change in protein levels found in AD in the respective references. The complete table and 
references can be seen in [IV]. n.d., not determined 
 formation of synaptic connections (Ruegg, 2001). CAMs play a prominent role at all stages of 
synapse assembly, from contact initiation to stabilization (Gerrow and El-Husseini, 2006). A 
breakdown in the organization of CAMs and activation of their signal transduction mechanisms 
is likely to contribute to neuronal dysfunction and failure as seen in AD. In addition, a decrease 
in protein levels of molecules involved in axonal guidance may further negatively influence the 
process of synapse formation in AD. 
 
 Table 1, excerpted from a more complete compilation in [IV], lists some of the proteins 
detected at altered levels in the brain of AD cases. 
 
 The identification of the proteins involved in the molecular pathogenesis of AD is a 
requirement for a better understanding of the disease and for the eventual development of a 
biological marker, be it for diagnosis, for monitoring the progression of the disease or for 
assessing the effects of putative new pharmacological agents developed for AD. In our study, we 
identified numerous proteins with altered levels in AD. Proteins with changed levels in 
postmortem AD brains may present potential biomarkers, but are only useful if the protein or 
fragments thereof are measurable in the CSF and most preferentially also in the periphery. The 
brain clearly resembles the adequate target and a suitable starting point in the search for novel 
biomarkers of AD. However, biomarker candidates need further investigation and confirmation, 
but most importantly the brain pathology needs to be reflected in easier accessible tissues or 
fluids, like CSF or blood. 
 Discovery of a biomarker from altered brain protein levels needs to be rationalized in 
relation to AD and the molecular pathways involved. As an example, we detected decreased 
levels of six enzymes involved in the citrate cycle. A decreased glucose breakdown may possibly 
lead to the accumulation of intermediate products like pyruvate or α-ketoglutarate, which may be 
secreted and eventually be detected in urine or blood more sensitively than the responsible 
enzymes alone. Oxidative stress resulting in ROS might be another event triggering the 
occurrence of a therapeutic or diagnostic useful biomarker. Even though we might not be able to 
measure differences in the single oxidative stress related proteins, we eventually might be able to 
detect an accumulation of lipid peroxidation products or a secretion of damaged mitochondrial 
proteins upon oxidative stress induced nerve cell death into peripheral fluids. Schwemmer and 
colleagues have suggested earlier, that urinary nitrotyrosine levels may serve as a biomarker to 
 detect changes in oxidant stress (Schwemmer et al., 2000). Nitrotyrosine is formed by nitration 
of tyrosine residues via peroxynitrite (van der Vliet et al., 1995), a reactive oxygen species 
previously described to occur in AD and to interfere with key enzymes of the TCA cycle 
(Bolanos et al., 1997). Nitrotyrosine may therefore also serve as a biological marker for AD 
related oxidative stress.  
 However, the difficulty in using proteins or intermediate products from the glycolytic 
pathway as well as oxidative-stress related enzymes and products is their limited specificity. A 
decrease in the degradation of glucose and increased oxidative stress are processes that can occur 
under a variety of (patho-) physiological conditions unrelated to AD. The incidence of for 
example nitrotyrosine in urine is thus not necessarily related to AD-related oxidative stress. For 
this reason, proteins involved in such ubiquitous pathways could only be important as biological 
markers in an overall quantitative manner. Since the brain is relatively small compared to the rest 
of the body and separated by the blood brain barrier, significant changes in the brain levels of 
such a non-specific putative biomarker are possibly attenuated and cannot be detected easily in 
peripheral fluids. A biomarker in AD needs to have a high specificity for the discrimination from 
other diseases. Optimally suited for such a surrogate marker would be an AD-specific protein or 
metabolite, or a modification, which is uniquely related to the pathogenesis of AD, is not part of 
another biochemical pathway and does not occur in the periphery and also in other types of 
dementia. In our studies, we identified several synaptic proteins, e.g. syntaxin-1A and 
synaptotagmin-1, occurring at decreased levels in AD brain compared to healthy control tissue. 
This could on one hand be indicative for AD triggered neuronal loss and on the other hand could 
reflect a synaptic impairment associated with AD. In contrast to these observations, we detected 
increased levels of synaptogyrin-1 and -3 in AD, a protein which is known to be associated with 
presynaptic vesicles in neuronal cells. Many synaptic proteins, including synaptogyrin-1 and -3, 
are brain specific. Altered synaptic brain protein levels as detected in our study might be 
reflected in CSF and eventually be detected in the periphery and would thus present ideal 
biomarkers for AD.  
 We detected elevated levels of protein-arginine deiminase 2 (PAD 2) in AD, catalyzing 
the citrullination of proteins. Citrullination refers to the process of deimination, which changes 
the basic character of arginine to a neutral peptidyl citrulline (Gyorgy et al., 2006). This process 
could change the structure of a protein to a more open configuration (Tarcsa et al., 1996). The 
abnormal accumulation of citrullinated proteins, especially GFAP and vimentin, was observed in 
 AD (Ishigami et al., 2005) and it was suggested, that citrullination promotes the disassembly 
process of these intermediate filament proteins (Gyorgy et al., 2006). The degradation of 
citrullinated proteins is possibly impaired, as the action of specific proteases is disturbed, which 
may explain in turn the observed accumulation. Because citrulline is not a natural amino acid, it 
is possible that the accumulation of proteins harboring a citrulline triggers an innate immune 
response of the brain in AD. Formed auto-antibodies may then eventually be detectable in the 
serum of AD patients and might serve as useful marker for AD. This is exactly what has been 
found in rheumatic arthritis, where auto-antibodies against citrullinated proteins are built and 
serve as specific and predictive markers for the disease (Aho et al., 1994). 
 Proteomic information obtained from the investigation of brain tissue is important and 
useful in the discovery of a biomarker for this devastating disease. The characterization of 
postmortem brains can reveal altered levels of a multitude of proteins implicated in various 
pathogenic pathways of AD. A consideration of formation and clearance pathway(s) of such 
proteins or of the formed (intermediate) products, significantly increases the probability of 
identifying a specific and useful marker in more easily accessible fluids. A modified approach to 
translate the findings from postmortem brain to a useful biomarker is to look for metabolic 
peptide fragments of the identified proteins. It can be speculated, that early events leading to 
neurodegeneration and apoptotic or senescent cells in AD would lead to the degradation of 
numerous proteins. For example, neuron specific cytoskeletal proteins occur abundantly in the 
brain; neurodegeneration and cell loss would likely result in the release of degraded portions of 
such structural proteins, which may eventually be detected in the CSF or in the periphery. 
 In summary, studies, such as the ones performed in the present thesis, giving insight into 
the nature of affected pathways or processes in AD are an indispensable pre-condition for the 
successful identification and development of biomarker candidates, which can be found in 
peripheral fluids. 
 
 
 CONCLUDING REMARKS AND FUTURE PERSPECTIVES 
 
 
 The present investigation on a detailed analysis of the amyloid-β protein in plaques 
regarding the nature and extent of N-terminal truncation, plaque comprising Aβ variants, 
amyloid plaque load, main plaque types and cross-linking of fibrils cannot answer all questions 
regarding the role of Aβ in the neurodegenerative process of AD. However, they give insight into 
the molecular composition of specific amyloid plaque types and help to more clearly outline the 
missing links. A comparison of plaque constituting Aβ variants in AD and PS2APP transgenic 
mice is essential in preclinical drug development (e.g. immunization approach), where PS2APP 
mouse models are used in evaluating drug efficiency. Our methodology enabled to investigate 
specific plaque types, thus presenting an advantage over the analysis of brain homogenates, 
which average the senile plaque load. This allowed getting more insight into the course of plaque 
evolution and the process of N-terminal truncation.  
 Even though our study indicates a high level of oxidized Aβ in diffuse plaques, especially 
in PA cases, the mechanism of protection by met-35 oxidation on the pathogenesis of AD is still 
an unresolved mystery. Since oxidation of met-35 was described to influence toxicity and 
aggregation properties of Aβ, the correlation of oxidation status in plaques from different Braak 
stages or brain regions with the degree of neurodegeneration, might present an essential step in 
the elucidation of plaque-specific impact on neurodegeneration in AD. A clarification of the role 
of oxidized Aβ in AD might further complement the understanding of the disease.  
 To further gain clarity on the process of neurodegeneration, the specific analysis of 
neuritic plaques is likely to reveal important additional information. Neuritic plaques are amyloid 
depositions associated with dystrophic neurites containing tau. In the present studies, we 
analyzed morphologically differentiated plaque types, i.e. cored, compact or diffuse plaques. 
Only a subset of plaques from the different types is neuritic and a further differentiation and 
investigation revealing their Aβ composition, extent of N-terminal truncation and oxidation 
status may further contribute to determine the role of plaques in AD. The approach used in our 
studies could potentially be very valuable also for the analysis of amyloid plaques in specific 
brain regions. Thal and colleagues described a hierarchical involvement of distinct areas of the 
brain in Aβ deposition (Thal et al., 2002, Thal et al., 2006). An analysis of amyloid plaques in 
 different brain regions, e.g. plaques from areas affected early in the disease process is a further 
step in identifying disease relevant Aβ variants. Additionally, an analysis of plaques from 
different FAD mutations could be aimed at. It is not known to date how different mutations in 
the APP, PS1 or PS2 genes affect the nature of deposited Aβ species. It was reported, that the 
arctic mutation facilitates senile plaque formation in transgenic mice (Lord et al., 2006). A 
detailed analysis of plaque constituting Aβ variants would therefore be highly informative and 
might reveal Aβ variants affecting the plaque deposition process. Other FAD mutations exhibit 
different features and a characterization of the deposited Aβ variants holds promise to give 
important insight into the impact of Aβ species to the pathogenesis of AD.  
 Another field of application includes transgenic mouse models. Numerous transgenic 
mouse models with different genetic backgrounds were described (McGowan et al., 2006). A 
comparative analysis and characterization of Aβ deposited either intraneuronally or in amyloid 
plaques is important in the definition of the relevance of any transgenic mouse model used as 
preclinical tool to evaluate drug efficiency. 
 Our studies also provided insight into alteration of levels of proteins other than Aβ in AD 
and allow for overview of various processes involved in the pathogenesis of the disease. 
Although this work can be regarded as exploratory, because the number of patients investigated 
was limited, the results are promising new and contribute to a more thorough understanding of 
the disease. The identification of new proteins involved in AD triggered a follow-up study. The 
results will be evaluated with a larger number of patients in an approach currently performed at 
Roche. Inclusion of different Braak stages for analysis is expected to substantiate findings, 
because this would allow for the detection of proteins changing their levels as a function of 
severity of disease. Since we detected various proteins previously unknown to be related to AD, 
their specific function and role in the pathogenesis of AD needs to be determined for the 
derivation of biological markers or new drug targets. Knockout mice are used in a variety of 
ways. They allow to test the specific functions of particular gene products and to observe the 
processes that these particular genes could regulate. A knock-out of genes identified in this 
approach alone or in combination with the already available transgenic AD mouse models might 
reveal more information of how a protein occurring at altered levels in AD contributes to the 
etiopathology of the disease. As mentioned above, the translation of the findings of proteins 
detected at altered levels in AD to biological markers measurable in the periphery can happen in 
 various ways. Future approaches could include a closer investigation of the proteome of CSF or 
peripheral fluids with respect to the candidates detected during this study. Can these proteins, 
metabolic fragments thereof or auto-antibodies generated against abnormal protein 
accumulations be detected? Are they specific for AD and do their changes correlate with disease 
progression? The technologies to answer these questions are SELDI-TOF MS, MALDI-TOF 
MS, LC/MS/MS and 2D-gel electrophoresis, i.e. those technologies successfully applied, at least 
in part, already in the present studies. 
 A project build upon the present work and to identify biomarkers in AD would 
preferentially be divided into two phases. During the first phase the identification of biological 
markers that correlate with cognitive decline could be aimed at. Using human plasma samples 
collected over a period of time, would allow for a longitudinal study, monitoring specific 
changes in protein composition as a function of disease progression. Plasma samples of two 
patient groups could be analyzed using 2D-gel electrophoresis: cases with slow or no cognitive 
decline could be compared to individuals with a more rapidly progressing disease 
phenomenology, determined by MMSE scores. Changes in protein expression levels might then 
be measured and followed over time. With the help of bioinformatics, the data could be 
evaluated and a set of putative biomarkers for disease progression from these subject sample sets 
could be established. 
 In a second phase, the markers identified in the first phase should be validated with 
complementary methods, e.g. Western blot or ELISA. For this reason, a second plasma sample 
set is analyzed to determine if these markers might serve as surrogates of symptomatic change. 
Hopefully, such investigations might complement therapeutic assessment in clinical trials and 
could speed up the development of new drugs. 
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The accumulation and aggregation of the beta-amyloid peptide (Ab) in the brain represents a key
factor in the pathogenesis of Alzheimer’s disease (AD). Many of the transgenic mouse models for AD
exhibit an amyloid pathology with neuritic plaques but they typically vary by the type and abundance
of plaques identified in their brains and by the onset and severity of cognitive impairment. Thus, an
important consideration in the characterization of AD transgenic mouse models should be the quantitative
evaluation of the amyloid load in the brain together with a detailed physico-chemical analysis of Ab from
the deposited plaques. Here we present an analytical procedure to collect single amyloid plaques from
anatomically defined brain regions by laser dissection microscopy that can be quantitatively assessed
in their Ab isoforms composition by matrix-assisted laser desorption/ionization time-of-flight mass
spectrometry. Quantification was achieved by stable isotope dilution using calibrated 15N-labeled Ab
standards that were spiked in the sample immediately after laser dissection. Using this method, we found
that the amyloid loads in brain plaques isolated from the transgenic AD mouse model PS2APP or from
human were similar. Total Ab composition was estimated at ∼50–100 fmol per excised plaque disc, as
confirmed by immunoblot analysis. N-Terminal truncated Ab isoforms were identified in both transgene
and human amyloid plaques but with significantly elevated levels in human samples. Copyright  2005
John Wiley & Sons, Ltd.
KEYWORDS: Alzheimer’s disease; Aˇ peptide; laser dissection microscopy; matrix-assisted laser desorption/ionization
time-of-flight mass spectrometry
INTRODUCTION
Alzheimer’s disease (AD),1 the most common form of
dementia in humans, is histopathologically characterized
by the intracellular aggregation of hyperphosphorylated tau
protein in neurofibrillary tangles and by the extracellular
accumulation of Aˇ peptides in neuritic amyloid plaques,
in particular in limbic and association cortices.1 Cleavage
of the amyloid precursor protein (APP) by the ˇ- and -
secretases releases both the Aˇ1 – 40 and Aˇ1 – 42 peptides,
the latter being far more prone to aggregation, leading to
Aˇ deposition in the brain in the form of insoluble fibrils
that can be visualized in situ by congo red and thioflavin
S stains or by immunohistochemistry.2,3 Plaque formation
is thought to represent a dynamic process and the relative
frequency of morphologically different plaque depositions
changes during the progression of AD. Diffuse plaques are
mostly prevalent in the preclinical stages whereas compact
plaques are increasingly observed as the disease progresses
ŁCorrespondence to: Heinz Do¨beli, Pharma Research Basel,
F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, CH-4070 Basel,
Switzerland. E-mail: heinz.doebeli@roche.com
†These authors contributed equally to this work.
to clinical dementia.3,4 The apparent causal neurotoxicity of
the amyloid plaques and the observation that early-onset
familial forms of AD are characterized by the enhanced
production of the secreted Aˇ peptides have led to the
amyloid hypothesis, which postulates that the Aˇ peptide
is a key factor in the pathogenesis of AD.5 However, a
molecular mechanism linking the accumulation of plaques
with the memory loss characteristic for this disease has yet
to be established.
Numerous transgenic mouse models, overexpressing the
mutated human APP either alone or together with mutations
of human presenilins known to affect the processing of
APP, have been reported to mimic amyloidosis and plaque
deposition with neuronal damage.6 – 8 Recently, a triple
transgenic mouse has been developed that exhibits tau
pathological features and thereby displays most of the
critical aspects of AD pathology.9 In the frame of the
amyloid hypothesis, Aˇ appears to be causally involved
in the aetiology of AD. Thus, an important consideration
in the characterization of AD transgenic mouse models is
the quantitative evaluation of the amyloid load in the brain
together with a detailed physico-chemical analysis of Aˇ
from the deposited plaques. Plaque quality is currently best
Copyright  2005 John Wiley & Sons, Ltd.
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investigated in situ by immunochemistry10 or fluorescence
staining11 and by the propensity of amyloid plaques to be
dissolved in conventional urea-containing sodium dodecyl
sulfate (SDS) buffers.12 Aˇ composition has typically been
relying on the availability of well-characterized antibodies
directed against various epitopes of Aˇ or by the use of
urea-based SDS polyacrylamide gel electrophoresis (PAGE)
analysis, for separation of the multiple Aˇ isoforms, followed
by immunodetection.13 In addition, Stoeckli et al.14 recently
presented a new analytical method that allows the direct
mass spectrometric evaluation of plaques from mouse brain
thin sections. However, most of aforementioned techniques
do not provide accurate quantification data as losses that
occurred at the sample preparation levels are typically not
considered.
In this paper, we present an alternative analytical
approach based on the sectioning of the amyloid plaques
by laser microdissection, the addition of a stable isotope-
labeled Aˇ internal standard and the detailed, quantitative
analysis of the amyloid content of plaques by matrix-assisted
laser desorption/ionization time-of-flight mass spectrome-
try (MALDI-TOFMS). The method was first cross-validated
using the transgenic AD mouse PS2APP,15 comparing the
mass spectrometric method with a sensitive western blot
analysis. Its usefulness was then demonstrated in show-
ing significant quantitative differences in Aˇ composition
between amyloid plaques isolated from the transgenic AD
mouse and from human. In particular, we believe that the
ability to detect quantitative and qualitative differences from
plaques collected according to their distinct staining proper-
ties within the same brain section represents an important
asset to understand better the molecular basis of amyloid
plaque formation.
EXPERIMENTAL
Amyloid peptide standards
15N-Aˇ1 – 42 (M35Mox) peptide was produced by recombinant
DNA technology using E. coli fed with [15N]ammonium
chloride.16,17 Synthetic Aˇ1 – 42 and Aˇp3 – 42 (Glu at position 3
converted to pyroglutamic acid) peptides were purchased
from Bachem. The integrity of each Aˇ species was
checked by electrospray mass spectrometry and the exact
concentration of the Aˇ peptides’ stock solutions, dissolved
in 50% formic acid and used for spiking, were determined by
amino acid analysis (Dr P. Hunziker, Protein Analysis Unit,
University of Zu¨rich, Switzerland).
Collection and preparation of brain slices
All animal experiments were performed in full accordance
with the guidelines issued by the Swiss Veterinary Office.
Twenty-month-old double-transgenic PS2APP mice15 were
obtained from Dr H. Bluethmann (F. Hoffmann-La Roche).
Mice were killed either by cervical dislocation or by
decapitation after anaesthesia with halothane. The skull pan
was opened with scissors and the brain was removed and
divided into hemispheres before freezing in dry-ice.
Human cortical brain tissue (kindly provided by Profes-
sor R. Fall, New Zealand) was collected from a single patient.
The tissue was collected 2 h after death and immediately
frozen at 80 °C.
Brain tissue sections of 10 µm thickness were excised from
cortical areas using a Model CM3050 S cryostat microtome
(Leica Microsystems). These slices were placed on a glass
cover-slip and stored until staining at 20 °C. Cover-slips
used for laser dissection microscopy were coated with a
1.35 µm thick polyethylene foil (LPC-MOMenT-Object slides,
8150, PALM Robot Microbeam).
Staining of brain thin sections
Prior to the staining procedures, brain tissue slices were
rehydrated for 5 min with phosphate-buffered saline (PBS;
6 mM phosphate buffer, pH 7.4, 85 mM NaCl) and fixed on a
glass slide by applying ice-cold 70% acetone for ¾1 min.
Sections visualized by immunostaining were washed
twice for 2 min with 1 ml of PBS containing protease
inhibitors (one protease inhibitor cocktail tablet (Catalog
No. 1 836 145) per 50 ml; Roche Diagnostics) and unspecific
binding sites were blocked for 15 min with 500 µl of PBS
containing 1% BSA (bovine serum albumin fraction 5;
Roche) and 1% ovalbumin (ovalbumin from hen egg white;
Fluka). The slices were then incubated for 30 min at room
temperature with 200 µl of a 3 µg ml1 primary antibody
BAP-2 solution (specific for the Aˇ peptide epitope amino
acids 2–8, kindly provided by Dr M Brockhaus, F. Hoffmann-
La Roche). The samples were then washed three times for
5 min with 500 µl of PBS containing 1% BSA. Detection was
performed using an Alexa Fluor 488-conjugated secondary
antibody (goat anti-mouse antibody diluted 1 : 200 in PBS
containing 1% BSA; Molecular Probes) applied for 30 min at
room temperature. The preparations were then washed once
for 5 min with 1 ml of PBS and once for 2 min with doubly
distilled water before being air-dried and stored at 20 °C
until further usage.
Congo red staining was performed using the diagnostic
amyloid stain kit HT60 (Accustain Amyloid Stain, Congo
Red, Sigma Diagnostics).
Thioflavin S was applied as a 1% solution for 3–5 min
followed by a wash step with 70% ethanol for 3–5 min.
Plaque excision by laser dissection and 15N-Ab
peptide spiking
Laser dissection microscopy was performed according to
Schu¨tze and Lahr.18 An inverse fluorescence microscope
(Axiovert 135; Carl Zeiss) was attached to a pulsed nitrogen
laser (337 nm, PALM Robot MicroBeam) with beamsplitters
to allow simultaneous visualization of the sample and
laser dissection. Laser dissection was performed in a two-
step process comprising cold ablation, an excision process
based on a restricted photodecomposition process without
heating19 and laser pressure catapulting for contamination-
free harvesting. Samples were visualized using the 10- or
20-fold objectives. Settings for laser focus and energy were
re-optimized for each slide.
Immunostained mouse or human cortex sections were
first air-dried for ¾30 min before individual amyloid plaques
were excised by laser ablation. A single laser pulse of
increased energy, with its focal plane slightly below the
Copyright  2005 John Wiley & Sons, Ltd. J. Mass Spectrom. 2005; 40: 193–201
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sample, induced the transport of the excised material directly
into the cap of a 500 µl Eppendorf tube held above the line
of laser fire. By repeating this procedure several times, the
excised material could be accumulated in a single cap filled
with ¾25 µl of liquid (either NuPAGE SDS Sample Buffer
(Invitrogen) containing 8 M urea for SDS–PAGE or 70%
formic acid or water for MALDI-TOFMS) for better adhesion
of the material. After collection, the liquid was spun down
at 15 500 g into the tube. The cap containing the plaques
was then additionally rinsed twice with 30 µl of buffer, spun
down and all fractions were pooled.
Amyloid plaque preparations analyzed by mass spec-
trometry were typically spiked with the 15N-Aˇ peptide
internal standard immediately after laser dissection. Based
on iterative cycles of experiments, 45 or 60 fmol of [15N]Aˇ
peptide per dissected human or mouse plaque, respectively,
were added to the samples to generate mass spectra pro-
files exhibiting the preferred 1 : 1 Aˇ peak ratio between
endogenous material and internal standard.
SDS–PAGE and western blots
The dried samples obtained after dissolution of the plaques
in formic acid were neutralized with 50 µl of 1% (v/v) pyri-
dine–water solution, dried again and then taken up in 25 µl
of SDS sample buffer containing 8 M urea. Samples were ana-
lyzed on a 12% Bis-Tris NuPage SDS-PAGE system according
to the manufacturer’s recommendations (Invitrogen). West-
ern blotting was performed according to Ida et al.20 using
Hybond-C extra, RPN303E nitrocellulose membrane (Amer-
sham). Binding of Aˇ to the membrane was enhanced by
heating the blotted membrane for 3 min in a microwave
oven (900 W) in PBS. Enhanced chemiluminescence detec-
tion of Aˇ was performed with the monoclonal WO-2 as
primary antibody (kindly provided by Dr K. Beyreuther,
Heidelberg, Germany) and a horseradish peroxidase-labeled
secondary antibody (Amersham).
Dissolution, endoproteinase Lys-C digestion and
ZipTip desalting
Samples were incubated in 90 µl of 70% (v/v) formic
acid–water solution overnight at room temperature, after
which they were subjected to sonication (3 ð 3 min in a
water-bath at room temperature with intermediate vortex
mixing). Dissolution of plaques with 1,1,1,3,3,3-hexafluoroi-
2-propanol was not as effective as with formic acid. The
formic acid was then evaporated in an evacuated centrifuge
and the residue was dissolved in 10 µl of unbuffered
10 mM NH4HCO3 solution and digested with 15 ng of
endoproteinase Lys-C (Wako) for 2 h at 20 °C. The resulting
peptide fragments were adsorbed on a 0.6 µl RP-18 matrix
ZipTip pipette tip (Millipore), desalted with 5% (v/v)
methanol–water containing 0.1% (v/v) trifluoroacetic acid
and eluted with 2.5 µl of 60% (v/v) acetonitrile–water
containing 0.1% (v/v) trifluoroacetic acid.
Mass spectrometry
Mass spectrometric analysis of amyloid plaques was per-
fomed in triplicate using three consecutive dilutions to
circumvent possible signal suppression due to salt contami-
nation and poor crystallization conditions. The 2.5 µl of eluate
was mixed with 2.5 µl of a ˛-cyano-4-hydroxycinnamic acid
solution (Sigma; 5 mg ml1 in 50% (v/v) acetonitrile–water)
containing bradikynin and adrenocorticotropic hormone
(ACTH 18–39) as internal standards and 1 µl thereof was
spotted on a standard stainless-steel Bruker MALDI 384-
target plate (Bruker Daltonics). The remaining solution (4 µl)
was diluted with 6 µl of the matrix solution and 6 µl of the
60% (v/v) acetonitrile–water containing 0.1% (v/v) triflu-
oroacetic acid solution (generating a 1 : 4 dilution) and 1 µl
thereof was spotted on the MALDI target. The resulting solu-
tion (15 µl) was then further diluted with 30 µl of the matrix
solution and 30 µl of the 60% (v/v) acetonitrile–water con-
taining 0.1% (v/v) trifluoroacetic acid solution (generating
a 1 : 12 dilution) and 1 µl thereof was also spotted on the
MALDI target.
All measurements were performed on a Bruker UltraFlex
Tof/Tof mass spectrometer in reflector mode using standard
operating parameters. To reduce signal variability due to
sample preparation heterogeneity, spectra were acquired in
the automatic acquisition mode in 10 cycles of 20 shots each
using a different spot location after a maximum of four cycles.
A 20-shot spectrum was accepted for averaging by Bruker’s
fuzzy logic evaluation software if the signal-to-noise ratio of
the highest peak between m/z 1200 and 2100 was >4 and its
resolution >3000.
Peptide sequencing by tandem mass spectrometry was
performed on the same instrument operated in the LIFT
mode according to the manufacturer’s standard operating
parameters. Tandem mass spectra were analyzed using the
Mascot search algorithm (http://www.matrixscience.com/).
Mass spectrometric quantification of Ab
Quantification of the Aˇ content in amyloid plaques was
achieved by directly measuring the most intense peaks-
height ratios Aˇ1 – 16/15N-Aˇ1 – 16 and Aˇ17 – 28/15N-Aˇ17 – 28,
assuming 98% labeling of the 15N-peptides as judged from
the isotopic envelope (Fig. 1(a)). The concentration range for
which a linear relationship could be validated was tested
using various amounts of 14N-Aˇ and 15N-Aˇ synthetic
peptides mixed in various ratios and analyzed by mass
spectrometry as described above (Fig. 1(b)). Spectra were
accepted for quantification if the following analytical criteria
were met: the signals for Aˇ1 – 16, 15N-Aˇ1 – 16, Aˇ17 – 28 and
15N-Aˇ17 – 28 had to exceed a signal-to-noise ratio of 4
and the ratio Aˇ17 – 28/15N-Aˇ17 – 28 had to be within the
range 3 : 7 to 7 : 3. In addition, mass spectra that were
obviously contaminated with foreign peaks (e.g. keratins)
were excluded from the quantification process.
For simplification, the three mass spectra obtained from
one amyloid preparation (undiluted and 1 : 4 and 1 : 12
dilution, see above) were considered as three independent
measurements, that is, every valid mass spectrum generated
from experiments performed with a given number of plaques
was equally weighted for quantification purposes.
Quantification was performed by using the intensity
of the highest peak of the corresponding peak pattern.
Compared with the integration of the area of the entire
peak pattern, the amount of Aˇ1 – 16 is underestimated by
1.9% and that of Aˇ17 – 28 by 4.6%.
Copyright  2005 John Wiley & Sons, Ltd. J. Mass Spectrom. 2005; 40: 193–201
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Figure 1. Quantification by mass spectrometry. (A) Observed (upper panels) and calculated (lower panels) isotopic ratio for two
amyloid peptides, Aˇ17–28 (m/z 1325.7 and 1339.7) and Aˇ1–16 (m/z 1954.8 and 1981.8) for 14N- and 15N-labeled peptides,
respectively. The calculation is based on a 15N labeling degree of 98%. For quantification, the intensities of the highest peaks were
measured and put into relation to the height of the standard. (B) Linearity of signal. Known amounts of 14N-Aˇ and 15N-Aˇ were
mixed and processed according to the protocol. The data given in this figure represent the mixtures of synthetic Aˇ1–42, which was
compared with two different 15N-Aˇ1–42 lots. One of the standards was predominantly monomeric; the second one, which derived
from the first lot, was allowed for aggregation.
RESULTS
Assay principle
Quantitative Aˇ peptide analysis from Alzheimer plaques
was achieved by combining laser dissection microscopy
with mass spectrometry using an internal standard (Fig. 2).
Selected amyloid plaques were dissected from brain cryosec-
tions by laser dissection and were transferred into a test-tube
by laser catapulting. The plaques were treated overnight in
70% formic acid to solubilize the amyloid fibrils and, after
removal of the acid by evaporation, the dissolved Aˇ pep-
tides were subjected to proteolysis using the endoproteinase
LysC. The generated fragments, in particular the N-terminal
peptide Aˇ1 – 16 and the middle fragment Aˇ17 – 29, have been
demonstrated to be detected with a 100-fold higher sensi-
tivity than the full-length Aˇ1 – 40 or Aˇ1 – 42 peptides.21 The
preparations were then concentrated and desalted using
ZipTips before being spotted on the MALDI target. This
last step was important to enhance sensitivity and to pre-
vent spectral overlap of the main sodium adduct with the
internal standards, which would have made an accurate
quantification difficult. Quantification of the endogenous Aˇ
peptide was performed using a known amount of 15N-Aˇ
peptide16 directly added to the dissected plaque samples.
Since endogenous and 15N-Aˇ peptides do not differ chem-
ically from each other, except for the presence of the 15N
heavy isotope in the standard, all experimental losses were
assumed to be equally reflected on both Aˇ species, thus
allowing absolute quantification by comparing peak ratios.
Identification of endogenous Ab
The MALDI-TOFMS profiles obtained from amyloid plaques
were virtually free from non-Aˇ components (Fig. 3). The
most dominant peaks were accounted by the two N-terminal
fragments, Aˇ1 – 16 and Aˇ17 – 28 (m/z 1954.8 and 1325.7, respec-
tively), accompanied by their respective internal standards
(m/z 1981.8 and 1339.7, respectively). The identity of each
of those fragments was further substantiated by sequencing
using tandem mass spectrometry (Fig. 4). The C-terminal
fragments Aˇ29 – 40 or Aˇ29 – 42 were not detected using these
Copyright  2005 John Wiley & Sons, Ltd. J. Mass Spectrom. 2005; 40: 193–201
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Figure 2. Analytical procedure. The procedure’s starting
material was a thin section of a brain slice containing the
structures of interest. Plaques were selected, excised under
the microscope by a laser beam and transferred into a
test-tube. The preparations obtained were spiked with an
appropriate amount of 15N-Aˇ internal standard and the
plaques were dissolved in formic acid. The Aˇ peptides were
then subjected to endoproteinase Lys-C digestion and the
generated fragments were concentrated and desalted using a
ZipTip pipette tip before mass spectrometric analysis.
Quantification was achieved by comparing the peak-height
ratio for each observed Aˇ fragment with the added 15N-Aˇ
internal standard.
conditions. These hydrophobic peptides were poorly ion-
ized during the MALDI process and they may have been
only partially recovered from the ZipTip desalting step.
Further, we identified several additional peaks that corre-
sponded by mass to the additional N-terminal fragments
Aˇ2 – 16 (m/z 1839.9), Aˇ3 – 16 (m/z 1768.8), Aˇp3 – 16 (Glu3 con-
verted to pyroglutamic acid;m/z 1750.8), Aˇ4 – 16 (m/z 1639.8)
and Aˇ5 – 16 (m/z 1492.7). The identity of Aˇp3 – 16 was also
confirmed by tandem mass spectrometric analysis (Fig. 4).
The corresponding 15N-labeled fragments were not observed
even if the spiked Aˇ internal standard was applied to the
brain slice before laser microdissection. This finding strongly
suggests that the observed N-terminal Aˇ peptide hetero-
geneities were already present in the amyloid plaque at the
sampling time and that they were not generated, among
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Figure 3. Mass spectrometric profiles from mouse and human
amyloid plaques. The profiles were generated with 30 mouse
plaques spiked with 1.8 pmol of 15N-Aˇ (upper panel) and 30
human plaques spiked with 1.35 pmol of 15N-Aˇ (lower panel).
Typical for human plaques is the deficit of the N-terminal
fragment Aˇ1–16, reflected by the inversed peak proportions
(see also Table 1), which is indicative of the higher degree of
N-terminal truncations. Occasionally, in the mouse specimen
the endogenous Aˇ1–16 fragment bearing mutations at three
positions could be observed. i.s., internal standard; asterisks,
formylation products.
others, during laser ablation, dissolution with formic acid or
mass spectrometric analysis. Finally, in the analysis of amy-
loid plaques dissected from mouse brain tissue, a tiny peak
at mass m/z 1858.9 potentially corresponding to the endoge-
nous rodent Aˇ1 – 16 fragment was also detected (Fig. 3), in
agreement with the findings of Pype et al.22
Sensitivity and quantification
Quantification of the human Aˇ peptide was achieved by
comparing the peak height of the two Aˇ 14N-labeled frag-
ments’ most intense peaks generated from the endogenous
material (atm/z 1325.7 and 1955.9) with the peak height of the
corresponding Aˇ fragments’ 15N monoisotopic peak gener-
ated from the added internal standard (at m/z 1339.7 and
1981.8; Fig. 2). These measurements were repeated numerous
times over a wide range of conditions to ensure accurate
statistics (Table 1). The mass spectral profiles from which
these measurements were derived had to fulfil the following
criteria to be accepted for this purpose. The signal-to-noise
ratio of the four peaks of interest had to exceed four and the
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Figure 4. Tandem mass spectrometric analysis of three Aˇ fragments. Aˇ17–28 (upper panel), Aˇ1–16 (middle panel) and Aˇp3–16
(lower panel) were derived either from standards (left panels) or from amyloid plaques (right panels). The most abundant fragments
are labeled.
14N-Aˇ17 – 28/15N-Aˇ17 – 28 peak-height ratio had to be within
the range 3 : 7 to 7 : 3. Not surprisingly, the likelihood of
obtaining a suitable mass spectral profile decreased as a
decreasing number of plaques were analyzed. Using these
criteria, we found roughly equivalent amounts of Aˇ amy-
loid peptide per excised plaque in both brain specimens
(87 š 29 fmol in mouse tissue and 61 š 26 fmol in human
tissue, calculated from the Aˇ17 – 28 fragment).
Differences between human and mouse amyloid
plaques
Interestingly, in both tissues, the measured amount of
the Aˇ1 – 16 peptide was reproducibly lower than that
of the corresponding Aˇ17 – 28 fragment. In mouse, the
Aˇ1 – 16/Aˇ17 – 28 ratio was 77% whereas in human it was
only 51%. In the latter, this deficit could clearly be correlated
with the increased presence of truncated N-terminal Aˇ
peptides.23 Their relative distribution in mouse and human
is shown in Fig. 5. Whereas most of the N-terminal peptide’s
truncations appeared to be limited to the first two amino
acids in mouse, additional species in higher abundance
were present in human, including Aˇ4 – 16, Aˇ5 – 16 and
Aˇp3 – 16. Their increased presence in human can be observed
as a ‘right-shifted’ distribution compared with what was
observed in the mouse (Fig. 5). It is noteworthy that none
of those derivatives could be detected with the 15N-labeled
internal standard, strongly indicating that these N-terminal
truncated Aˇ peptides were not artefactual.
The sensitivity and the dynamic range of the method
were compared with a high-sensitivity western blot.20 A
selected number of plaques were excised by laser dissection,
dissolved with formic acid, dried down in a Speed-Vac
and neutralized with pyridine, before being resuspended
in an SDS-PAGE sample buffer containing 8 M urea. After
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Table 1. Quantitation of Aˇ peptide in mouse and human amyloid plaquesa
Origin of Plaques
Plaques per
experiment
Number of
experiments
Number of
MS profiles
Number of
quantifiable
MS profiles
Aˇ17 – 28
fmol/plaque
Aˇ1 – 16
fmol/plaque
Ratio
Aˇ1 – 16/Aˇ17 – 28
mouse 1 15 42 16 (38%) 59 54 0.92
mouse 2 8 22 1 (4%) 104 23 0.22
mouse 5 2 6 4 (67%) 60 55 0.92
mouse 10 4 12 11 (92%) 72 61 0.85
mouse 15 1 3 1 (33%) 73 45 0.62
mouse 16 2 6 5 (83%) 50 34 0.68
mouse 25 2 6 6 (100%) 131 107 0.82
mouse 30 2 6 6 (100%) 136 126 0.93
mouse 36 2 6 6 (100%) 112 96 0.86
mouse 49 2 6 6 (100%) 75 68 0.91
Average over all experiments 40 62 87 C/ 29 67 C/ 31 0.77
human 1 6 15 0 — — —
human 2 2 5 0 — — —
human 3 10 29 7 (24%) 75 40 0.53
human 5 5 15 5 (33%) 71 41 0.57
human 9 6 18 5 (28%) 76 62 0.82
human 10 2 6 4 (67%) 111 52 0.47
human 15 2 6 1 (17%) 73 23 0.31
human 25 2 6 3 (50%) 36 22 0.60
human 30 10 30 13 (43%) 21 10 0.49
human 36 2 6 5 (83%) 35 18 0.51
human 49 3 9 5 (56%) 52 15 0.29
Average over all experiments 50 48 61 C/ 26 31 C/ 17 0.51
a The Aˇ peptide contents in human cortex (from one case) and mouse amyloid plaques (from three different mouse brains all with
an age of 20 months) were calculated as described in the Experimental section. The column ‘Quantifiable MS profiles’ represents
those mass spectral profiles fulfilling the quantification criteria defined in the section ‘Mass spectrometric quantification of Aˇ’. The
fmol/plaque values indicated here represent only the fraction of the excised plaque that was enclosed in the analyzed 10 µm thin
section. The true Aˇ content could be extrapolated if amyloid plaques were assumed to have a spherical character. Depending on the
plaque’s true diameter, the amounts indicated in the table should be multiplied several fold.
electrophoresis, samples were blotted on to a nitrocellulose
membrane and probed with an Aˇ peptide-specific antibody
(data not shown). The plaques’ amyloid content was
estimated by applying known amounts of a calibrated
amyloid solution to the same gel. The average amount of
Aˇ peptide found per plaque and the limit of detection
were of the same order of magnitude for both methods.
However, quantification by the mass spectrometric method
was considerably more accurate owing to the presence of
an internal standard compensating for the experimental
losses.
DISCUSSION
To our knowledge, this is the first published report describ-
ing a procedure to quantify directly the Aˇ content from
individual plaques by mass spectrometry. This method, by
maintaining the sample’s topological information, also differ-
entiates itself from other mass spectrometry-based analyses
requiring brain tissue homogenization23,26 or pooling of cell
supernatants24,25 An alternative approach allowing the direct
investigation of Aˇ peptide by imaging mass spectrometry
has been presented by Stoeckli et al.14 Using brain tissue sec-
tions from the APP23 transgenic AD mouse, they were able
to demonstrate the presence of several C-terminal variants
such as Aˇ1 – 37, Aˇ1 – 38, Aˇ1 – 39, Aˇ1 – 40, Aˇ1 – 42 and Aˇ1 – 42ox.
However, in the absence of a suitable internal standard, the
plaques’ Aˇ peptide content was only measured in a relative
fashion.
Since reasonable mass spectral profiles can be obtained
from a few hundred picograms of Aˇ peptide, it is
now possible to compare plaques selected according to
morphological or topological criteria. In this respect, it has
become evident to us that human and humanized mouse
plaques differ in several aspects. Under the microscope,
amyloid plaques from mouse tissue showed a virtually
identical staining with Congo red, thioflavin or anti-Aˇ
antibodies whereas most plaques from human tissue were
reliably detected only by immunostaining. Mouse plaques
were readily dissolved in an 8 M urea-containing SDS buffer
whereas the dissolution of human plaques required the
harsher formic acid treatment. Finally, the mouse and
the human plaques clearly differ in their levels of N-
terminal heterogeneity, both in amount and in complexity.
These findings all independently suggest that experimental
Copyright  2005 John Wiley & Sons, Ltd. J. Mass Spectrom. 2005; 40: 193–201
57
200 P. Ru¨fenacht et al.
Figure 5. Distribution of truncated N-terminal Aˇ peptides in human and mouse amyloid plaques. The histograms show an
evaluation of mass spectrometric profiles derived from 48 human plaque samples (from one brain specimen) and 62 mouse plaque
samples (from three different mice). The height of the hatched bars in the histogram indicates the percentage of mass spectrometric
experiments in which an Aˇ species was detected at the indicated ratio. The empty bars represent the fraction of those profiles,
where no truncated Aˇ versions could be observed. The larger number of N-terminal truncated peptides found in human is observed
as a right-hand shift compared with what is observed in the mouse.
evidences derived from humanized mouse plaques may not
necessarily directly apply to human plaques.
The abundance and integrity of two main N-terminal
peptides were effectively assessed by the analytical pro-
cedure, in agreement with the identification of N-terminal
Aˇ variants reported for brain extracts of the insoluble Aˇ
compartment of AD patients25 and transgenic mice carrying
the London APP mutant.22 However, the small fragment
Aˇ11 – 1622 and the main C-terminal fragments Aˇ29 – 40 and
Aˇ29 – 42 were not detected using the described instrumen-
tal set-up. We were nevertheless able, using a procedure
omitting the digestion and the desalting steps but otherwise
similar to the one described above, to detect the full-length
Aˇ1 – 40 and Aˇ1 – 42 amyloid peptides, albeit at a much lower
sensitivity than the individual digested peptides (data not
shown). We were surprised that only a few non-Aˇ-derived
peaks were detected in the mass spectral profiles. While the
Aˇ peptide represents the main component of senile plaques,
many more proteins have been detected by immunological
methods and the list of these proteins is still growing.27 This
may be due to the vast excess of Aˇ in the plaques, the
fixation procedure of the sample on the glass slide prior to
laser dissection, the tailoring of the fragmentation of Aˇ to
optimize ionization and/or ionization suppression resulting
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in the quenching of signals from minor components. A pre-
liminary attempt to analyze digested plaques components
by liquid chromatography/electrospray mass spectrometry
revealed two additional proteins, cystatin A and ubiquitin,
thus indicating that the presented method, per se, is suit-
able for characterizing further plaque proteins. (During the
review process, we became aware of an on-line publication
which contains a list of 488 proteins identified in amyloid
plaques by mass spectrometry.28)
Acknowledgements
We thank Daniela Matscheko for performing some initial experi-
ments, Nicole Soder for producing 15N-Aˇ, Franc¸oise Gerber for
help in tissue staining and thin sectioning, Arno Friedlein for verify-
ing the Aˇ fragments by tandem mass spectrometry and Christian
Czech for critical help in establishing the high-sensitivity western
blot assays.
REFERENCES
1. Selkoe DJ. Alzheimer’s disease: genes, proteins, and therapy.
Physiol. Rev. 2001; 81: 741.
2. Dickson TC, Vickers JC. The morphological phenotype of beta-
amyloid plaques and associated neuritic changes in Alzheimer’s
disease. Neuroscience 2001; 105: 99.
3. Yamaguchi H, Hirai S, Morimatsu M, Shoji M, Ihara Y. A variety
of cerebral amyloid deposits in the brains of the Alzheimer-type
dementia demonstrated by beta protein immunostaining. Acta
Neuropathol. 1988; 76: 541.
4. Thal DR, Ru¨b U, Schultz C, Sassin I, Ghebremedhin E, Del
Tredici K, Braak E, Braak H. Sequence of A beta-protein
deposition in the human medial temporal lobe. J. Neuropathol.
Exp. Neurol. 2000; 59: 733.
5. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s
disease: progress and problems on the road to therapeutics.
Science 2002; 297: 353.
6. Price DL, Sisodia SS. Mutant genes in familial Alzheimer’s
disease and transgenic models. Annu. Rev. Neurosci. 1998; 21:
479.
7. Higgins GA, Jacobsen H. Transgenic mouse models of
Alzheimer’s disease: phenotype and application. Behav.
Pharmacol. 2003; 14: 419.
8. Morgan D. Learning and memory deficits in APP transgenic
mouse models of amyloid deposition. Neurochem. Res. 2003; 28:
1029.
9. Oddo S, Caccamo A, Kitazawa M, Tseng BP, LaFerla FM.
Amyloid deposition precedes tangle formation in a triple
transgenic model of Alzheimer’s disease. Neurobiol. Aging 2003;
24: 1063.
10. Hanzel DK, Trojanowski JQ, Johnston RF, Loring JF. High-
throughput quantitative histological analysis of Alzheimer’s
disease pathology using a confocal digital microscanner. Nat.
Biotechol. 1999; 17: 53.
11. Styren SD, Hamilton RL, Styren GC, Klunk WE. X-34, a
fluorescent derivative of congo red: a novel histochemical stain
for Alzheimer’s disease pathology. J. Histochem. Cytochem. 2000;
48: 1223.
12. Kuo YM, Kokjohn TA, Beach TG, Sue LI, Brune D, Lopez JC,
Kalback WM, Abramowski D, Sturchler-Pierrat C, Staufen-
biel M, Roher AE. Comparative analysis of amyloid-ˇ chemical
structure and amyloid plaque morphology of transgenic mouse
and Alzheimer’s disease brains. J. Biol. Chem. 2001; 276: 12 991.
13. Wiltfang J, Smirnov A, Schnierstein B, Kelemen G, Matthies U,
Klafki HW, Staufenbiel M, Hu¨ther G, Ru¨ther E, Kornhuber J.
Improved electrophoretic separation and immunoblotting of
beta-amyloid (Ab) peptides 1–40, 1–42 and 1–43. Electrophoresis
1997; 18: 527.
14. Stoeckli M, Staab D, Staufenbiel M, Wiederhold KH, Signor L.
Molecular imaging of amyloid ˇ peptides in mouse brain sections
using mass spectrometry. Anal. Biochem. 2002; 311: 33.
15. Richards JG, Higgins GA, Ouagazzal AM, Ozmen L, Kew JNC,
Bohrmann B,Malherbe P, Brockhaus M, Loetscher H, Czech C,
Huber G, Bluethmann H, acobsen H, Kemp JA. PS2APP
transgenic mice, coexpressing hAPPswe andhPS2mut,
show age-related discrete brain amyloid deposition and
inflammationassociated with cognitive deficits. J. Neurosci. 2003;
23: 8989.
16. Riek R, Gu¨ntert P, Do¨beli H, Wipf B, Wu¨thrich K. NMR studies
in aqueous solution fail to identify significant conformational
differences between the monomeric forms of two Alzheimer
peptides with widely different plaque- competence, Aˇ(1–40)ox
and Aˇ (1–42)ox. Eur. J. Biochem. 2001; 268: 5930.
17. Do¨beli H, Draeger N, Huber G, Jakob P, Schmidt D, Seil-
heimer B, Stu¨ber D, Wipf B, Zulauf M. A biotechnolocal
method provides accesss to aggregation competent monomeric
Alzheimer’s 1–42 residue amyloid peptide. Biotechnology 1995;
13: 988.
18. Schu¨tze K, Lahr G. Identification of expressed genes by laser-
mediated manipulation of single cells. Nat. Biotechnol. 1998; 16:
737.
19. Srinivasan R. Ablation of polymers and biological tissue by
ultraviolet lasers. Science 1986; 234: 559.
20. Ida N, Hartmann T, Pantel J, Schroder J, Zerfass R, Forstl H,
Sandbrink R, Masters CL, Beyreuther K. Analysis of
Heterogenous ˇA4 peptides in human cerebrospinal fluid and
blood by a newly developed sensitive western blot assay. J. Biol.
Chem. 1996; 271: 22 908.
21. Gru¨ninger-Leitch F, Berndt P, Langen H, Nelboeck P, Do¨beli H.
Identification of ˇ-secretase-like activity using a mass
spectrometry-based assay system. Nat. Biotechnol. 2000; 18: 66.
22. Pype S, Moechars D, Dillen L, Mercken M. Characterization of
amyloid beta peptides from brain extracts of transgenic mice
overexpressing the London mutant of human amyloid precursor
protein. J. Neurochem. 2003; 84: 602.
23. Naslund J, Schierhorn A, Hellman U, Lannfelt L, Roses AD,
Tjernberg LO, Silberring J, Gandy SE, Winblad B, Greengard P,
Nordstedt C, Terenius L. Relative abundance of Alzheimer A
beta amyloid peptide variants in Alzheimer disease and normal
aging. Proc. Natl. Acad. Sci. USA 1994; 91: 8378.
24. Wang R, Sweeney D, Gandy SE, Sisodia SS. The profile of soluble
amyloid ˇ protein in cultured cell media. J. Biol. Chem. 1996; 271:
31 894.
25. Huse JT, Liu K, Pijak DS, Carlin D, Lee VM, Doms RW. Secretase
processing in the trans-Golgi network preferentially generates
truncated amyloid species that accumulate in Alzheimer’s
disease brain. J. Biol. Chem. 2002; 277: 16 278.
26. Sergeant N, Bombois S, Ghestem A, Drobecq H, Kostan-
jevecki V, Missiaen C, Wattez A, David JP, Vanmechelen E,
Sergheraert C, Delacourte A. Truncated beta-amyloid peptide
species in pre-clinical Alzheimer’s disease as new targets for the
vaccination approach. J. Neurochem. 2003; 85: 1581.
27. Hashimoto T, Wakabayashi T, Watanabe A, Kowa H, Hosoda R,
Nakamura A, Kanazawa I, Arai T, Takio K, Mann DM,
Iwatsubo T. CLAC: a novel Alzheimer amyloid plaque
component derived from transmembrane precursor, CLAC-
P/collagen type XXV. EMBO J. 2002; 21: 1524.
28. Liao L, Cheng D, Wang J, Duong DM, Losik TG, Gearing M,
Rees HD, Lah JJ, Levey AI, and Peng J. Proteomic
characterization of postmortem amyloid plaques isolated by
laser capture microdissection. JBC Papers in Press 25: June 2004;
Manuscript M403672200.
Copyright  2005 John Wiley & Sons, Ltd. J. Mass Spectrom. 2005; 40: 193–201
59
 
APPENDIX II 
 
 
 
 
 
 
High Sensitivity Analysis of Aβ Composition in Amyloid Deposits 
from Human and PS2APP Mouse Brain 
 
 
 
by 
 
 
 
Andreas Güntert, Heinz Döbeli and Bernd Bohrman 
 
 
 
 
 
Neuroscience, in press 
 
 
High Sensitivity Analysis of Aβ Composition in Amyloid Deposits from 
Human and PS2APP Mouse Brain 
 
Andreas Günterta, Heinz Döbelia and Bernd Bohrmanna* 
 
aPharma Research Basel, F. Hoffmann - La Roche Ltd, Grenzacherstrasse 124, CH-4070 
Basel, Switzerland 
 
*corresponding author: Tel: +41-61-688-8369; Fax.: +41-61-688-1720. 
E-mail address: bernd.bohrmann@roche.com
 
 
Key words: mass spectrometry, pathological aging, pyroglutamate, ultrastructure, laser dissection microscopy, 
Alzheimer’s disease  
 
Cortical amyloid-beta (Aβ) deposition is considered essential in Alzheimer’s disease (AD) and is also detectable 
in nondemented individuals with pathologic aging (PA). The present work presents a detailed analysis of the Aβ 
composition in various plaque types from human AD and PA cases, compared to plaque Aβ isolated from 
PS2APP mice. To determine minute amounts of Aβ from 30 to 50 laser dissected amyloid deposits, we used a 
highly sensitive mass spectrometry procedure after restriction protease Lys-C digestion. This approach allowed 
the analysis of the amino-terminus and, including a novel ionization modifier, for the first time the carboxy-
terminus of Aβ at a detection limit of ~200 fmoles. In addition, full length Aβ 40/42 and pyroglutamate 3-42 was 
analyzed using a highly sensitive urea-based Western blot procedure. Generally, Aβ fragments were less 
accessible in human deposits, indicative for more posttranslational modifications. Thioflavine S positive cored 
plaques in AD were found to contain predominantly Aβ  42, whereas thioflavine S positive compact plaques and 
vascular amyloid consist mostly of Aβ 40. Diffuse plaques from AD and PA, as well as from PS2APP mice are 
composed predominantly of Aβ 1-42. Despite biochemical similarities in human and PS2APP mice, immuno-
electron microscopy revealed an extensive extracellular matrix associated to Aβ fibrils in AD, specifically in 
diffuse plaques. Amino-terminal truncations of Aβ, especially pyroglutamate 3-40/42, are more frequently found 
in human plaques. In cored plaques we measured an increase of N-terminal truncations of ~20% between Braak 
stage IV to VI. In contrast, diffuse plaques of AD and PA cases, show consistently only low levels of amino-
terminal truncations. Our data support the concept that diffuse plaques represent initial Aβ deposits but indicate a 
structural difference for Aβ depositions in human AD compared to PS2APP mice already at the stage of diffuse 
plaque formation. 
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INTRODUCTION 
 
Alzheimer’s disease (AD) is characterized by a wide array of neuropsychiatric alterations, the most dominant 
being memory loss. Pathologically, AD brains show extracellular protein deposits of amyloid-β (Aβ) in different 
types of senile plaques and intraneuronal bundles of paired helical filaments (PHF) of phosphorylated tau 
protein, referred to as neurofibrillary tangles. 
 Aβ peptides are the main protein component of plaques (Glenner et al., 1984) and derive from a 
proteolytic cleavage of the amyloid precursor protein (APP), a membrane-spanning glycoprotein (Kang et al., 
1987, Tanzi et al., 1987). Aβ peptides are secreted upon sequential cleavage of APP by β-secretase, a type I 
transmembrane glycosylated aspartyl protease, and γ-secretase, a large protein complex that includes at least four 
proteins (Nunan and Small, 2002, Haass, 2004). Due to heterogeneous γ-secretase cleavage sites, a series of Aβ 
peptides, including the major species Aβ 1-40 and Aβ 1-42, are produced. 
 AD occurs predominantly as a sporadic, age-dependent disease, but several inherited variants were also 
identified. Gene mutations which cause an early onset familial AD (FAD) are known and all these mutations 
lead to an increased secretion of Aβ, especially Aβ 42. Therefore, it is tempting to assume that the pathogenesis 
in AD is strongly related to an accumulation of Aβ (Selkoe, 1991, Hardy and Higgins, 1992). Aβ 1-42 is 
considered crucial in β-amyloidogenesis (Jarrett et al., 1993) being the initially deposited Aβ variant (Iwatsubo 
et al., 1994, Iwatsubo et al., 1995). In addition to the C-terminal heterogeneity of Aβ peptides, a variety of N-
terminal truncated Aβ 40/42 species are reported (Miller et al., 1993, Sergeant et al., 2003, Miravalle et al., 2005, 
Rufenacht et al., 2005). 
 Aβ deposits can also be found in a remarkable number of cognitively normal PA individuals. These 
deposits primarily occur as diffuse amyloid depositions, with a different distribution (predominantly in cortical 
regions) compared to AD patients brains (Thal et al., 2004). 
 To investigate the role of Aβ in AD, a variety of transgenic mouse strains have been developed that 
utilize mutant human APP and presenilin 1 and 2 mutations. Several transgene mouse models that exhibit AD-
like phenotypes, especially amyloid deposits, astroglial activation, synaptic loss and dysfunction, memory 
deficits and finally neurodegeneration are described (McGowan et al., 2006). However, the available AD mouse 
models only partially display the human pathophysiology and the morphological appearance of plaques from 
human brain are different from those observed in some transgenic mice (Masliah et al., 1996, Kuo et al., 2001). 
Recently, triple transgenic mice harbouring three mutant genes, i.e. APP, presenilin 1 and tau, have been 
developed (Oddo et al., 2003).  
 Considering the low level of neuron loss observed in many of the transgenic AD models (King and 
Arendash, 2002, Hu et al., 2003), other factors beside full length Aβ 40 and Aβ 42 may account for the massive 
neurodegeneration observed in AD patients. We have previously quantified by mass spectrometry the Aβ content 
in plaques from AD patients and PS2APP double transgenic mice (Richards et al., 2003) using 15N-labeled 
amyloid peptide as a reference (Rufenacht et al., 2005). As the amount of Aβ in plaques from PS2APP mice 
exceeds the Aβ amount in human, we could exclude a simple dose-effect for the low degree of 
neurodegeneration. 
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 So far, the composition and Aβ content of human senile plaques was examined either by the use of C-
terminal end-specific antibodies (Harigaya et al., 2005) and by the analysis of brain homogenates (Mori et al., 
1992, Miller et al., 1993, Sergeant et al., 2003), . Here, we used a method which allows the isolation of single 
plaques from brain thin sections using laser dissection microscopy (Schutze and Lahr, 1998). This enabled to 
collect small numbers of morphologically defined plaque types and vascular amyloid of vessels with cerebral 
amyloid angiopathy (CAA) and analyze their Aβ composition by mass spectrometry and urea-based Western 
blot assay. We compared different types of senile plaques isolated from human AD and PA cases as well as from 
PS2APP mice in order to investigate plaque-dependent differences in Aβ composition and discuss the impact on 
neurodegeneration. Through the use of a modified MS protocol, we intended to get more detailed knowledge 
about disease relevant Aβ peptides. 
 Human AD patients and PS2APP mice show differences in the occurrence of plaque types which are 
correlated to specific differences in comprising Aβ variants. This suggests that amyloid plaque deposition 
proceeds elsewise in human AD patients and in PS2APP mice, which likely impacts differentially on 
concomitant neurodegeneration. 
 The approach enables the isolation and accumulation of microscopic structures like plaques or single 
cells. In combination with MALDI-TOF MS and Western blotting even the breakdown of oxidized and reduced 
Aβ species is possible. The accuracy and sensitivity of the method therefore harbors future potential for the 
investigation of various processes in Alzheimer’s disease and other neurodegenerative disorders. 
 
 
EXPERIMENTAL PROCEDURES 
 
Human tissues and transgenic mice 
 
Human brains from AD patients were obtained from the Sun Health Research Institute through Dr. Thomas G. 
Beach (Sun City, AZ, USA). The brain tissue was collected approximately two hours after death and was 
immediately frozen at -80°C. Brains were neuropathologically staged according to Braak (Braak and Braak, 
1991). Plaques were isolated from the temporal, frontal and occipital association gyrus and hippocampus of 5 
different AD patients (89, 84, 80, 78 and 77 years old) with Braak stages IV (n=1), V (n=2) and VI (n=2). 
Vascular amyloid was isolated from the superior parietal gyrus of an 84 year old patient with high incidence of 
CAA. Patients with Braak stage V and VI show heavy, with Braak stage IV moderate plaque load. 
 In addition, plaques were isolated from the temporal cortex of two PA individuals (87 and 88 years old) 
obtained from Dr. C. Wischik (Cambridge, UK). 
 The PS2APP transgenic mice develop an age-related cognitive decline associated with severe cerebral 
amyloidosis and reactive gliosis as described previously (Richards et al., 2003). Three twenty-month old mice 
were used. Mice were killed by decapitation after anesthesia with fluothane. The skull pan was opened with 
scissors and the brain was removed and divided into hemispheres before freezing in dry-ice and preparing 
sagittal sections.  
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Preparation of brain slices 
 
Frozen brain tissue was used and sections of 10 μm thickness were cut with a cryostat microtome (Leica 
Microsystems, CM3050 S). The slices were directly mounted onto glass cover slip coated with a 1.35 μm thin 
polyethylene foil (PALM Robot Microbeam, LPC-MOMeNT-Object slides, 8150) and stored until staining at -
20°C.  
 
Staining of brain thin sections 
 
Brain tissue slices were rehydrated for 5 min with phosphate buffered saline (PBS, Gibco, 14200-067) 
containing protease inhibitors (Roche Diagnostics GmbH, 1836145, 1 tablet per 50 ml) and fixed on the 
polyethylene foil covered glass slide by applying 70% acetone (0°C) for approximately 1 min. Sections were 
washed twice for 2 min with 1 ml PBS and thioflavine S was applied as a 1% aqueous solution for 3–5 min 
followed by a differentiation step with 70% ethanol for 3–5 min. By incubation of the sections with 500 μl PBS 
containing 1% bovine serum albumin (BSA, fraction V, Roche Applied Science) and 1% Ovalbumin (Sigma, St. 
Louis, MO, USA) for 15 min, unspecific binding sites were blocked. The slices were then incubated for 1 h at 
room temperature with 200 μl of 10 μg/ml of BAP-2 (mouse anti-Aβ antibody, amino-terminal specific; kindly 
provided by Dr. M. Brockhaus, F. Hoffmann-La Roche) or AT8 (mouse anti-PHF tau antibody; Pierce 
Biotechnology Inc, Rockford, IL, USA). Subsequently, the samples were washed three times for 5 min with 500 
μl of PBS containing 1% BSA. Detection was performed using an Alexa Fluor 555- or 488-conjugated 
secondary antibody (goat anti-mouse antibody diluted 1:200 in PBS containing 1% BSA; Invitrogen AG, 
Molecular Probes, Basel, Switzerland) applied for 1 h at room temperature. The preparations were then washed 
once for 5 min with 1 ml PBS and once for 2 min with distilled H2O before being air-dried and stored until 
submitted to laser dissection at -20°C. 
 
Immuno-electron microscopy 
 
Perfusion-fixation of 8 month old PS2APP mouse brains and subsequent immersion of brain tissue was done 
with 4% formaldehyde and 0.05% glutaraldehyde in PBS for two hours before cutting into approximately 100 
μm thick sections using a vibratome and cryoprotected by immersion in increasing concentrations of glycerol 
(10 – 20 – 30% v/v) in 10 mM phosphate buffer, pH 7.4 for 30 min each concentration. Vibratome sections were 
carefully picked up by forceps and plunged into liquid ethane cooled by liquid nitrogen. Frozen tissue slices 
were stored in liquid nitrogen before being transferred to the pre-cooled chamber (-90°C) of an automated 
freeze-substitution apparatus (AFS, Reichert, Austria). The tissue was immersed overnight in anhydrous 
methanol at -90°C, containing 0.5% (w/v) uranyl acetate. The temperature was allowed to rise to -45°C, at a rate 
of 6.7˚C/h. Samples were washed three times with anhydrous methanol for 30 min each to remove residual water 
and excess uranyl acetate before infiltration with Lowicryl HM20 resin (Chemische Werke Lowi, Waldkraiburg, 
Germany). Infiltration with resin was done in mixtures of HM20 and methanol at volumes 1:1 and 2:1, each for 2 
h, and pure HM20 for 2 h, 16 h and 20 h. Samples were processed in the flow through system of the Reichert 
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AFS apparatus and polymerized by indirect UV irradiation (360 nm) for 24 h at -45°C, followed by UV-
irradiation for 1 day at room temperature to achieve complete resin polymerization. 
Ultrathin sections were prepared  on a Reichert Ultracut S using a diamond knife (Diatome) and collected onto 
formvar / carbon - coated 200-mesh nickel grids. The sections were floated on 0.05 mol/L glycine in PBS for 15 
minutes to inactivate free aldehyde groups and then on 2.5% (w/v) hen egg white albumin (Fluka) with 2.5% 
(w/v) bovine serum albumin (Roche Applied Science) in PBS for 15 minutes to block nonspecific binding sites. 
Sections were incubated with 10 µg/ml mAb BAP-2 in 2% BSA/PBS for 1 hour. After 6 washes in BSA/PBS, 
the sections were incubated with a secondary goat anti-mouse IgG (Amersham, Arlington Heights, IL, USA), 
conjugated to 10 nm gold at 1:20 dilution in 2% BSA with 0.1% Tween 20 in PBS for 1 hour, and washed in 
BSA/PBS. For  controls, we used sections treated with normal mouse serum, which resulted in a negligible 
background of not more than 10 gold particles in an area of 10 µm2. The sections were postfixed in 2% 
glutaraldehyde in PBS for 5 minutes, washed, and stained with 4% aqueous uranyl acetate for 10 min, followed 
by lead citrate for 90 seconds. Electron micrographs were taken with a JEOL 1210 at 100 kV. 
 
Laser dissection and sample preparation 
 
Laser dissection microscopy was performed as previously reported (Schutze and Lahr, 1998). An inverse 
fluorescence microscope (Axiovert 135, Carl Zeiss AG, Oberkochen, Germany) attached to a pulsed nitrogen 
laser (PALM Robot MicroBeam, 337 nm, P.A.L.M. Microlaser Technologies GmbH, Bernried, Germany) with 
beam splitters, to allow for immunofluroescence inspection during laser dissection, was used. Laser dissection 
was performed in a two-step process comprising cold ablation, an excision process based on a restricted 
photodecomposition process without heating (Srinivasan, 1986), and laser pressure catapulting for 
contamination-free harvesting. The laser microbeam was focused through a 10x or 20x objective lens. Settings 
for laser focus and energy were re-optimized for each slide. 
 Immunostained mouse or human brain sections were first air-dried for 30 min before individual amyloid 
plaques were excised by laser ablation. A single laser pulse of increased energy with its focal plane slightly 
below the sample provoked the transport of the excised material directly into the cap of a 500 μl Eppendorf tube 
placed above the focused laser beam. By repeating this procedure several times, the excised material was 
accumulated in a single cap filled with 50 μl of distilled water for better adhesion of the material. After 
collection, the liquid was spun down at 15’500 x g into the tube. The cap containing the plaques was then 
additionally rinsed twice with 58.5 μl of concentrated formic acid, spun down, and all fractions were pooled. 
After a dissolution period of 18 h, the samples were subjected to sonication  
(3 x 3 min in a water-bath at room temperature with intermediate vortex mixing) and were dried in an evacuated 
centrifuge to dryness for further processing of the amyloid peptides.  
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Amyloid peptides, quality control and quantification 
 
The 15N-labeled Aβ 1-42 ox (methionine at position 35 oxidized to methionine sulfoxide) peptide was produced 
by recombinant DNA technology using E. coli fed with 15N–ammonium chloride (Dobeli et al., 1995, Riek et al., 
2001). 15N-labeled Aβ 1-40 red was obtained from rPeptide (rPeptide, Athens, Georgia, USA). Synthetic Aβ 1-
42, Aβ 1-40, Aβ 1-38, and N3pE-42 (glutamate at position 3 converted to pyroglutamic acid) peptides were 
purchased from Bachem (Bachem Holding AG, Bubendorf, Switzerland) or Nova Biochem (Nova Biochem, 
Läufelfingen, Switzerland). The integrity of each Aβ species was checked by electrospray mass spectrometry 
and the exact concentration of the Aβ peptide stock solutions used for spiking was determined by amino acid 
analysis (Dr. P. Hunziker, Protein Analysis Unit, University of Zürich, Switzerland). 
 
Synthesis of the ionization modifier 
 
Conversion of 6-guanidohexanoic acid into its HBF4 salt: 6-guanidohexanoic acid has a poor solubility in 
organic solvents, but when converted into its HBF4 salt, it is soluble in methanol. A 346 mg quantity of 6-
guanidohexanoic acid (2 mmol) was dissolved in 8 ml H2O and then neutralized with ca 250 μl 8 M 
tetrafluoroboric acid. After lyophilization, 514 mg of a white powder was obtained; theoretical yield: 526 mg. 
Synthesis of the 6-guanidohexanoic acid N-hydroxy-succinimide adduct: 250 μl volume of a 200 mM solution of 
6-guanidohexanoic acid HBF4 salt (50 μmol) in methanol and 250 μl of a 200 mM solution of N-
hydroxysuccinimide (50 μmol) dissolved in dimethylformamide were added to 77 mg N-cyclohexylcarbodiimide 
N’-methyl polystyrene beads (ca. 100 μmol reactive immobilized groups). The slurry was gently agitated on a 
rotary shaker at 20 °C and the reaction was monitored by electron spray mass spectrometry (positive ion mode, 
m/z = 271). After approximately 8 hours the reaction was completed and the 6-guanidohexanoic acid–N-
hydroxysuccinimide (6-GuHe, Fig. 4A) reagent could then be introduced into the desired assay for up to 48 
hours. 
 
Endoproteinase Lys-C digestion, modification, desalting by ZipTip, mass spectrometry 
 
As previously described (Rufenacht et al., 2005), the dried samples were digested with 10 μl of 10 mM NaHCO3 
solution, containing 15 ng of endoproteinase Lys-C (Wako Chemicals GmbH, 125-05061, Reuss, Germany) for 
2 h at room temperature. For detection of the C-terminal part, the peptides were modified by adding 5 μl of 6-
guanidohexanoic acid–N-hydroxysuccinimide reagent (ca. 500 nmoles, reaction conditions: 1 h at 20 °C). Prior 
to mass spectrometry, the samples were desalted using ZipTip pipette tips (Millipore, Billerica, MA, USA). 
Adsorption of the peptides was performed according to the suppliers recommendations using 0.6 μl RP-18 
matrix ZipTip pipette tips, for desalting a 5% (v/v) methanol-water containing 0.1% (v/v) trifluoroacetic acid 
solution was used. In order to increase the sensitivity, the eluted peptides were divided into three pools using 
acetonitrile concentrations of 30%, 60% and 90% (v/v). The elution volume contained 2 x ca. 2.5 μl.  
 The eluate was mixed with an equal volume of a α-cyano-4-hydroxycinnamic acid solution (Sigma-
Aldrich Chemie GmbH, C2020; 5 mg/ml in 50% (v/v) acetonitrile-water). One μl thereof was spotted onto a 
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standard stainless-steel Bruker MALDI 384-target plate (Bruker Daltonics GmbH, Bremen, Germany). The 
measurements were performed on a Bruker UltraFlex time of flight mass spectrometer in reflector mode using 
standard operating parameters. Spectra were acquired manually at 4 different shot locations and a total of 400 
shots were added per spectrum. 
 
Determination of the proportion of Aβ x-16, Aβ 17-28 and Aβ 29-40/42 
 
In mass spectrometry profiles without ionization modifier, peak height ratios were determined by measuring the 
relative peak heights in a given peak pattern as described previously (Rufenacht et al., 2005). For comparison 
with Aβ isolated from plaques, we analyzed synthetic Aβ peptides and detected a ratio of Aβ 1-16 (m/z 1954.8) 
to Aβ 17-28 (m/z 1325.4) of ~3:2. 
Spectra with ionization modifier show a more complex peak pattern. Aβ 1-16 and Aβ 17-28 may yield three 
peak signals: one representing the unmodified peptide, one with one 6-GuHe and one with two 6-GuHe attached. 
All Aβ-related peaks were measured and N-terminal, middle fragment and C-terminal related peaks were put 
into relation to the sum of all Aβ-related peaks heights. Since some of our plaque samples revealed mass spectra 
which were close to the detection limit, we performed control experiments to verify that the changed ratio of the 
Aβ fragments was not caused by dilution. Synthetic or biosynthetic Aβ 1-40 or Aβ 1-42 was titrated towards the 
detection limit. The proportions of Aβ 17-28 to Aβ 29-40/42 remained unchanged (A. Güntert, unpublished 
observations).  
 Quantification of the Aβ content was performed as described previously (Rufenacht et al., 2005) using 
15N labeled biosynthetic Aβ 1-42 ox or synthetic Aβ 1-40 red (rPeptide). By spiking the plaque samples with 15N 
labelled Aβ, overall losses, both for 14N and 15N Aβ, induced by the sample preparation procedure could be 
controlled. Since endogenous and 15N-Aβ peptides do not differ chemically from each other, except for the 
presence of the 15N heavy isotope in the standard, all experimental losses can be assumed to be equally reflected 
on both Aβ species, thus allowing absolute quantification by comparing peak ratios. However, the carboxy-
terminus is heterogeneous first due to the different endings (40 and 42) and second by the varying proportion of 
reduced or oxidized methionine at position 35. This leads to an overlap of the peak patterns, e.g. of the 14N-Aβ 1-
40 ox with 15N-Aβ 1-40 red. In order to keep the option to detect all potential Aβ carboxy-terminal fragments we 
did not spike routinely. 
 
SDS-PAGE / Western blot 
 
For the separation of Aβ peptides, we applied the urea version of the N,N'-bis-(2-hydroxyethyl)-glycine / bis - 
Tris/Tris/ sulfate SDS-PAGE (Wiltfang et al., 1991). Due to urea-induced differential shifts in conformation, Aβ 
peptides that differ in only one amino acid can be separated (Klafki et al., 1996, Wiltfang et al., 1997). The 
composition of the separation gel initially applied for the analysis of Aβ peptides was modified from 
15%T/5%C/8 M urea to 12%T/5%C/8 M urea (%T = percentage (w/v) of total acrylamide monomer; %C = 
percentage (w/w) of bisacrylamide / total acrylamide monomer), and gel thickness was reduced to 0.5 mm. Gels 
were run at room temperature for 2.15 h at a constant current of 12 mA/gel, using the MiniProtean II 
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electrophoresis unit (Bio-Rad Laboratories, Hercules, CA, USA). In an experiment, a known number of laser 
dissected plaques were compared to 100 pg synthetic Aβ 1-38 / 40 / 42 in 10 µl sample buffer. 
Western blotting and immunostaining were performed as previously described (Wiltfang et al., 1997). Aβ 
peptides were transferred for 30 min at 1 mA/cm2 and room temperature under semi-dry conditions onto 
Immobilon-P PVDF membranes (Millipore, IPVH08100, Billerica, MA, USA). For immunostaining, PVDF 
membranes were washed for 30 seconds in distilled H2O and boiled for 3 min in PBS using a microwave oven 
(Ida et al., 1996, Wiltfang et al., 1997). Blocking was performed for 1 hour at room temperature in the presence 
of 5% nonfat dry milk in PBS-T (PBS containing 0.5% Tween-20). Incubation with the primary mouse antibody 
WO-2 (The Genetics Company, Zuerich, Switzerland) recognizing the N-terminal amino acids 4-10 of the Aβ 
peptide at a concentration of 2 μg/ml was done overnight at 4°C. Membranes were then washed for 30 min, 15 
min, and 2 × 10 min in PBS-T. After the washing steps, the membranes were incubated with a horseradish 
peroxidase linked anti-mouse antibody (Amersham Biosciences, Piscataway, NJ, USA) for 1 h. After a 
wash for 3 × 10 min at room temperature, the membranes were developed for 5 min at room temperature with 
ECLPlusTM (Amersham) solution according to the protocol of the manufacturer. Visualization was done with 
conventional X-Ray films (Amersham). 
The migration properties of the peptides were analyzed using the following synthetic amyloid peptide standards: 
1-38, 1-40, 1-42 (M35M red, all with a reduced methionine at position 35) as well as with 1-40 and 1-42 (M35M 
ox, both with a sulfoxide at position 35). 
 
 
RESULTS 
 
Selection of plaque types 
 
Using a doublestaining procedure with thioflavine S and BAP-2 antibody against Aβ, we could discern three 
morphologically different plaque types and vascular amyloid in human and PS2APP brains (Fig. 1). The 
discrimination of different plaque types essentially followed a morphological classification used to characterize 
the amyloid pathology in AD (Thal et al., 2006). Accordingly, we distinguished between thioflavine S positive 
and thioflavine S negative amyloid depositions. Thioflavine S negative plaques are commonly known as diffuse 
plaques. Thioflavine S positive depositions, which contain densely packed Aβ fibrils were further differentiated 
into cored and compact plaques. Compact plaques were positive for thioflavine S and BAP-2 antibody, while 
diffuse plaques were stained only by BAP-2 antibody (Fig. 1A, B, E, F). In cored plaques only the central core 
was stained by thioflavine S, while the peripheral Aβ was stained solely by BAP-2, comparable to the 
morphology of diffuse deposits (Fig. 1C, G). Vascular deposits were visible by both thioflavine S and 
immunostaining (Fig. 1D, H). Staining properties allowed to differentiate unambiguously cored, compact and 
diffuse plaques, enabling the specific isolation by subsequent laser dissection microscopy.  
 Although compact plaques occur in human as well as in PS2APP mice, their occurrences in the two 
species are different. In 20 month old PS2APP mice (Fig. 1A, E) compact plaques of different sizes represent the 
majority, whereas in the cortex and the hippocampus of AD patients (Fig. 1B, F) this plaque type occurs at only 
~10%. Cored plaques predominate (~90%) in the AD patients investigated (Fig. 1C, G). Diffuse plaques (arrow 
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heads in Fig. 1 A, B, E, F) are detectable at high frequency in AD and PA, but occurred less often in PS2APP 
mice. 
 In PA individuals, primarily diffuse amyloid deposits were detected but only sporadically some cored 
plaques could be found, especially in the transition to the white matter. Compact plaques were not identified in 
these brains. A tau-specific staining with AT8 showed that neuritic plaques and tau pathology occured only 
occasionally as rare events in PA, whereas in AD brains a substantially higher number of neuritic plaques and 
very pronounced tau pathology was detectable as expected (A. Güntert, unpublished observations). 
 
Ultrastructural morphology of amyloid-β plaques 
 
Immuno-electron microscopy was carried out on low temperature-embedded brain tissue. The method combines 
the advantage of superior preservation of ultrastructure and antigenicity for efficient immunocytochemical 
staining. 
Immunogold labeling, using a monoclonal antibody against the N-terminal portion of the Aβ peptide  (BAP-2), 
revealed Aβ deposits which occur as fibrillar structures in diffuse plaques of PS2APP mice and human AD 
patients (Fig. 2). Remarkably, the Aβ fibrils of mouse diffuse plaques are intermingled as single or few fibrils in 
the extracellular space in the neuropil and thus can contact directly the cell membrane of neurites (Fig. 2A). In 
contrast, human diffuse plaques contain few Aβ fibrils that are surrounded by a considerable amorphous 
extracellular matrix (Fig. 2B). It was demonstrated by immuno-histochemistry, that human amyloid plaques are 
associated with a number of proteoglycans like decorin and laminin (van Horssen et al., 2002, Mok et al., 2006). 
Compact mouse plaques contain a very high number of homogenously and densely packed Aβ fibrils 
(Supplementary data, Fig. 1A). Dystrophic neurites were found at the periphery of mouse plaques, especially 
mature compact plaques. Also, microglia cells were frequently observed in close contact with fibrillar plaques, 
forming an interdigitating complex of fibrils and the microglial cytoplasm.  
Cored human plaques which resemble a more mature plaque stage are built up by numerous clusters of Aβ 
fibrils, which can occur as densely packed large bundles (Supplementary data, Fig. 1B). Immunogold labelling 
confirms that almost all detectable Aβ is present in its polymerized fibrillar state, although the local density of 
Aβ fibrils can vary considerably and domains of extracellular matrix are also visible. The fibrillar bundles are 
often in spatial contact to the surrounding neuropil, although the subcellular details are less evident, because of 
the used sample preparation that cannot avoid influences of the post-mortem time on ultrastructural preservation. 
Vascular human amyloid is characterized by a type of dense packing of Aβ fibrils comparable to Aβ fibrils in 
compact plaques from PS2APP mice (Supplementary data, Fig. 2). 
 
MALDI - TOF MS 
 
The cleavage of the Aβ peptide by the restriction protease Lys-C generates three fragments. The amino-terminal 
and the middle fragments were detected with high sensitivity (Tab. 1) and could be used to quantify the amyloid 
content in the excised plaques. However, the C-terminal part could not be observed. A possible explanation 
would be the hydrophobicity of this Aβ fragment which interferes with adequate ionization, necessary for MS 
analysis. In order to overcome this limitation, we developed an ionization modifier (Fig. 4A) which allowed us 
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to detect for the first time the carboxy-terminal fragments as well, specifically Aβ 29-40 and Aβ 29-42. We are 
the first group to analyze, from minute amounts of plaque Aβ isolated by laser dissection microscopy, the C-
terminal Aβ fragments. Notably, this method allowed the discrimination between the oxidized and the reduced 
form of Met-35.  
 We observed almost exclusively Aβ fragments when we used endoproteinase Lys-C for fragmentation, 
although very many more proteins have been reported to be present in plaques. Apparently, the Aβ 1-16 and 
Aβ 17-28 or the 6-GuHe derivatized Aβ 17-28 and Aβ 29-40/42 fragments dominate during the ionization 
procedure. As the number of plaques required to reach the detection limit of our mass spectrometric procedure 
was different depending on the plaque type and specimen, we typically collected and pooled 30 compact plaques 
from PS2APP mouse specimen, 50 cored plaques, 200 diffuse deposits and 70 compact plaques or 15 human 
vessels with CAA from human AD brain per sample. Mouse plaques contain a ~1.5 fold higher amount of 
detectable Aβ than human plaques, according to Rufenacht et al., 2005. Thioflavine S positive compact plaques 
represent a rare species in humans and thus needed to be gathered from five consecutive brain sections, whereas 
the abundant cored in human AD and the mouse compact plaques could be collected from one single brain 
section.  
 
Detection of the amino-terminal Aβ peptides and Aβ fragment 17-28 
 
Cored plaques were isolated from 5 different patients and 4 different brain regions thereof; diffuse 
plaques were dissected from hippocampal and temporal brain regions. In a previous study with one AD case, we 
found Aβ 1-16, 2-16, 3-16, pyroglutamate 3-16, 4-16 and 5-16 (Rufenacht et al., 2005). Findings are confirmed 
in the current study and extended by the analysis of five AD cases at different disease stages (Fig. 3 and Tab. 2). 
Arg-5 is likely most prone for ionization and truncations beyond that position are probably not detected due to 
poor ionization. Additionally, Aβ 11-16 or pyroglutamate 11-16 are likely to escape the detection range in our 
mass spectrometry procedure, due to their low mass.  
 To evaluate the ionization and Lys-C digestion properties of N-terminal truncated Aβ variants, 
commercially available synthetic pyroglutamate 3-42 was compared to biosynthetic 15N-labelled Aβ 1-42. 
Defined amounts of Aβ 1-42 and pyroglutamate 3-42 were mixed in the ratios 3/7, 1/1, and 7/3, subsequently 
Lys-C digested and analyzed by MALDI-TOF-MS. The obtained standard curve revealed a linear relationship 
between the different ratios of Aβ peptides and showed comparable ionization properties of full length Aβ 1-16 
and pyroglutamate 3-16 (Supplementary data, Fig. 3). Other N-terminally truncated Aβ peptides were not 
available and could therefore not be compared to full length Aβ. However, they can be assumed to have 
comparable ionization properties since only N-terminal truncations beyond Arg-5 are likely to exhibit different 
ionization properties in the MALDI-TOF MS. 
 The detected amounts and ratios of the various Aβ species did not vary markedly between investigated 
brain regions (Tab. 2)., Beside Aβ 1-16, which was found as the predominant type in all samples, pyroglutamate 
3-16 represented the major detectable N-terminal truncated Aβ fragment and, according to peak heights, 
accounted for ~20-25% of total Aβ found in the analyzed samples. With increasing Braak stage a decreasing 
amount of Aβ 1-16 was found, while N-terminal truncations increase gradually with disease progression. This 
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was evident for cored plaques, showing an increase of approximately 20% from Braak stage IV, V to VI. The 
largest proportion of Aβ 1-16 could consistently be detected in diffuse plaques from AD cases at all Braak stages 
and in PA cases. Diffuse plaques from both PA cases did not show any differences to diffuse plaques isolated 
from AD patients’ brains, regarding the pattern and relative peak heights of N-terminal truncated Aβ forms. 
To exclude artifacts from the preparation procedure, we included every time samples with synthetic Aβ 
1-40 / 42. Furthermore, to ensure that the pyroglutamate detected in amyloid isolated from senile plaques was 
not induced artificially, five synthetic peptides starting with a glutamate or glutamine were treated with 
concentrated formic acid and analyzed by mass spectrometry. Only minor amounts of glutamine were converted 
to pyroglutamate, whereas the glutamate-starting peptides did not show cyclisation (A. Güntert, unpublished 
observations).  
 
Detection of the carboxy-terminal Aβ peptide and Aβ fragment 17-28 
 
We used the 6-GuHe (Fig. 4A) to derivatize the peptides generated by the Lys-C digestion. The addition of the 
guanido group changes the detection limits of the three expected peptides in favour of the carboxy-terminus and 
at the expense of the amino-terminal peptide (Tab. 1). Derivatization with 6-GuHe leads to a poor detection of 
the amino-terminal peptides, probably because multiple guanido groups are deleterious. Since the middle 
fragment Aβ 17-28 is detected with both protocols, there is the possibility to compare the relative proportions of 
all three peptides. 
The total data set was derived from spectra of 10 PS2APP mouse compact plaque samples , 2 human compact, 9 
human cored and 3 human diffuse plaque samples (2 from a PA case, 1 from an AD case) as well as from 7 
samples of human vascular amyloid and from 8 synthetic Aβ 1-40 and 15 Aβ 1-42 samples. Individual plaques 
or vessels were excised, pooled and analyzed by MALDI-TOF MS after chemical modification with ionization 
modifier 6-GuHe. To increase sensitivity, a pre-wash with 30% ACN was introduced and cleaner eluates with 
60% ACN were obtained for analysis (Fig. 4). A third step with 90% ACN was performed to check for complete 
elution. For comparison of the relative quantities, we used only the 60% fraction. 
 Using this procedure, we were able to determine the relative proportions of the C-terminal Aβ 
fragments 29-40 and 29-42 in cored and diffuse plaques, as well as in vascular amyloid from human AD and in 
compact plaques from PS2APP mice. Carboxy-terminal fragments ending at residues other than Val-40 or Ala-
42 were not detected. 
 Fig. 4B and C show spectra derived from the analysis of 50 human cored plaques, spiked with 0.6 pmol 
15N-Aβ 1-42 ox. The spectra show that the method allows discrimination between the reduced (m/z 1425.1) and 
the oxidized (m/z 1441.1) form of the methionine at position 35 of the Aβ fragment 29-42.  
In all samples, the ratio of oxidized and reduced forms of Aβ 29-40 was comparable to the ratio of oxidized and 
reduced forms of Aβ 29-42. In the data set of Fig. 5, the amount of oxidized species increased in the following 
order: human vascular amyloid (47 ± 21%), human compact plaques (49 ± 20%), human cored (64 ± 14%), 
PS2APP compact plaques (72 ± 16%) and human diffuse plaques from from AD (91%) and PA (92 ± 2%). Since 
we did not work under an N2 atmosphere during the plaque collection and sample preparation procedure, 
artificial oxidation cannot be excluded. Therefore, conclusions from the observed proportions between the 
oxidized and the reduced forms should be taken with caution. 
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 Aβ fragments 17-28 and Aβ 29-40/42 are clearly detectable when synthetic Aβ is analyzed after 6-
GuHe modification. In contrast, Aβ derived from human cored and diffuse plaques were consistently different 
from those of the synthetic or biosynthetic Aβ peptides with significantly decreased levels of Aβ 17-28. 
Compact plaques from PS2APP mice show intermediate proportions. 
 We found that in human plaques the Lys-C fragment Aβ 17-28 is detectable in a substantial excess over 
the full-length amino-terminal part without 6-GuHe modification (Fig. 5A). After the modification with 6-GuHe, 
the carboxy-terminus is detectable in human plaques in a twofold excess over Aβ 17-28 (example in Fig. 4C). 
This means that the relative proportions are Aβ 29-40/42 > Aβ 17-28 ≥ Aβ x-16. This relationship found in 
human brain specimen could be explained with the presence of inter-chain cross-links between Aβ peptides and 
N-terminal truncations thereof (Kuo et al., 2001, Sergeant et al., 2003). In comparison, human vascular amyloid 
and especially PS2APP mouse compact plaques show different peak proportions with higher detectable amounts 
of Aβ 17-28. This hints to less extensive cross-linking in PS2APP mouse compact plaques and vascular amyloid 
compared to human senile plaques. 
 Fig. 5B shows the peak ratios between the carboxy-terminal peptides Aβ 29-40 and Aβ 29-42 in the 
analyzed types of Aβ deposits. Vascular amyloid and compact plaques showed an excess of Aβ 29-40, whereas 
human cored plaques and diffuse plaques contained predominantly Aβ 29-42. As samples from different brains 
or Braak stages reveal identical spectra, all data were analyzed collectively. The findings fit well with the 
analysis by Western blotting as outlined below. 
 
Western blot analysis 
 
 In order to study the major full length Aβ types that occur in vascular amyloid as well as in compact 
and cored plaques, they were isolated by laser dissection and analyzed by urea-based Western blots (Fig. 6A). 
Complementary to the results obtained by mass spectrometry we found mainly Aβ 1-40 in human compact 
plaques and vascular amyloid. In contrast, mainly Aβ 1-42 was detected in human cored plaques. The high 
sensitivity of the Western blot assay enabled us to study the composition of diffuse plaques from human and 
from PS2APP mice. Fig. 6B shows that diffuse plaques from PA as well as from AD cases and PS2APP mice 
contain, like human cored plaques, predominantly Aβ 1-42. 
 In addition to that, the employed laser dissection microscopy with subsequent Western blot analysis 
allowed the discrimination between oxidized and reduced Aβ species. To our knowledge, we are the first group 
able to show the oxidation state of Aβ peptides isolated from senile plaques by Western blotting. To compare 
migration distances, synthetic or biosynthetic Aβ 1-40/42 ox and red were used as reference peptides. 
Incidentally, Aβ 1-42 ox and Aβ 1-38 red migrate to almost identical positions, but because we did not detect 
any Aβ 1-38 in plaques by MALDI-TOF MS and because of a slight shift of the migration distance, we 
considered the appearing bands to be indicative for Aβ 1-42 ox. Again we observed differences in the 
proportions of oxidized to reduced Met-35 Aβ forms between different samples, these differences were more 
pronounced in the Western blot analysis as in the 6-GuHe MALDI-TOF MS analysis. The larger heterogeneity 
with respect to the oxidation state of Aβ detected by Western blotting can likely be explained by the smaller 
number of sampled plaques. However, Fig. 6 shows representative results. 
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 By using an N-terminal specific Aβ antibody, extensive N-terminal truncated Aβ forms are less 
efficiently detected by Western blotting. Antibodies specific for N-terminal truncated Aβ species allow the 
detection of these peptides. With an Aβ N3pE-42 specific antibody we detected substantial amounts of 
pyroglutamate 3-42 in human cored plaques (Fig. 6C). Immunohistochemistry with this antibody was positive 
for all cored plaques (A. Güntert, unpublished observations). These findings confirm the data obtained by mass 
spectrometry. 
 
 
DISCUSSION 
 
 The present study provides a detailed analysis of the Aβ composition in different amyloid plaque types 
from AD patients, PA individuals and PS2APP mice. Our method allowed to dissect morphologically different 
plaque types and to analyse them by three independent methods: 1) Western blotting, 2) mass-spectrometry 
using endoproteinase Lys-C and 3) mass-spectrometry using endoproteinase Lys-C in combination with the 
newly developed ionization modifier 6-GuHe for detection of the C-terminal Aβ fragments. Endoproteinase Lys-
C generates Aβ fragments, which are detected by MALDI-TOF MS with a much higher sensitivity as would be 
the case for full-length Aβ. The addition of the ionization modifier 6-GuHe allows detection of the hydrophobic 
C-terminal Aβ fragment. The modification of α- and ε-amino groups with a guanido-group containing tag 
renders the C-terminal fragments accessible to mass spectrometric analysis. Without 6-GuHe modification, the 
carboxy-terminus of Aβ cannot be detected, while with 6-GuHe modification, the carboxy-terminus becomes 
detectable although at the expense of the amino-terminus. Likely, the amino-terminus after 6-GuHe modification 
could not be detected because of too many ionisable groups. In summary, both methods are complementary and 
enable the investigation of the entire Aβ peptide.  
 The used methodology has shown to be suitable for the analysis of minute amounts of Aβ obtained from 
distinct plaque types. This allowed to investigate Aβ deposits from well-defined regions. Aβ-related effects, 
especially with regard to down-stream neurodegeneration can be addressed at a cellular level. We have analysed 
the Aβ composition in diffuse, compact and cored plaques and also of vascular amyloid from different human 
AD brains at Braak stages IV, V and VI. Additionally, diffuse amyloid depositions were isolated and analyzed 
from cognitively normal, aged PA cases. In PS2APP mice we examined diffuse and compact plaques; cored 
plaques and vascular amyloid were only occasionally visible in the 20 month old mice. 
 Analysis by Western blotting and MALDI-TOF MS of vascular amyloid and compact plaques revealed 
mainly Aβ 1-40 and only minor amounts of Aβ 1-42. This is consistent with data from earlier studies using end-
specific antibodies (Joachim et al., 1988, Suzuki et al., 1994). In contrast, the most abundant human plaque 
types, i.e., diffuse and cored plaques from cortical and hippocampal brain regions, revealed primarily Aβ 1-42, 
so did the analysis of diffuse plaques from PS2APP mice. This is in agreement with immunocytochemical 
studies which reported that diffuse plaques found in different anatomical brain regions of AD patients are Aβ 1-
42 positive, but Aβ 1-40 negative (Iwatsubo et al., 1994). Accordingly, the data confirm the concept that the 
initially deposited Aβ variant in AD is Aβ 1-42 and that Aβ 1-40 is deposited at a later stage of plaque 
maturation (Selkoe, 2001). Therefore, it can be assumed that there is a similar process of initial plaque 
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deposition, both in human AD and PS2APP mice.  Concerning the time course of plaque maturation, our data 
suggest that compact plaques with their high quantity of Aβ 40 cannot be precursors of cored plaques which 
contain mainly Aβ 42. More likely, plaque maturation starting with diffuse plaques can proceed towards typical 
cored plaques, resembling neuritic plaques with associated dystrophic neurites and reactive gliosis or towards 
compact plaques with a dense packing of Aβ fibrils (Fig. 7). Additional factor(s) like a plaque associated protein, 
kinetics of Aβ deposition / clearance or different ratio of Aβ variants present in brains of human AD patients 
compared to PS2APP mice, might lead to a divergent process resulting in mainly cored plaques in human and 
predominantly compact plaques in PS2APP mice. Ultrastructural differences were revealed, especially for 
diffuse plaques by immuno-electron microscopy. Diffuse plaques of AD patients develop with considerable 
involvement of extracellular matrix proteins even at an early stage of fibril formation indicative for 
compensatory processes to inactivate the extracellular deposits. 
 We aimed to get more information on factors that might impact directly or indirectly on synaptic 
plasticity and finally on neurodegeneration. Candidates could be an Aβ variant leading to increased cytotoxicity 
and/or a less degradable Aβ species that accumulates and serves as template for increased Aβ aggregation. It was 
reported, that oxidation of Met-35 reduces toxic effects of Aβ in vitro (Clementi et al., 2004). It was additionally 
demonstrated, that oxidation reduces fibril assembly and prevents the formation of protofibrils (Hou et al., 2002). 
We were able to discriminate between oxidized and reduced Aβ variants with MALDI-TOF MS, as well as with 
Western blot analysis. The encountered substantial heterogeneity of samples analyzed by Western blotting can 
be explained by the biological heterogeneity in sporadic AD and smaller sample sizes compared to MS analysis. 
However, we consistently detected only low levels of reduced and high levels of oxidized Aβ 42 by MS and by 
Western blotting in diffuse plaques from PA cases. Extensive oxidation of Aβ might be regarded as beneficial to 
attenuate toxic amyloid deposits; the absence of tau pathology and clinical symptoms in PA supports this view.  
Another putative factor likely having impact on neurodegeneration in AD patients, which is less 
frequent or absent in transgenic animals is N3pE-40/42. This pyroglutamate variant is a major component of 
human plaques and less accessible to Aβ degrading enzymes (Saido et al., 1995, Tekirian et al., 1999, Harigaya 
et al., 2000). The occurence of N-terminally truncated Aβ species was demonstrated to be decreased in APP23 
and PS2APP mice compared to human plaques (Kuo et al., 2001, Rufenacht et al., 2005). Other reports showed, 
that amino-truncated Aβ species represent more than 60% of all Aβ species in AD brains (Miller et al., 1993, 
Sergeant et al., 2003). However, the amyloid analyzed in these reports derived from brain homogenates 
averaging the senile plaque load. Laser dissection microscopy allowed the isolation of specific plaque types at 
microscopical precision. Small numbers of dissected plaques were then accessible for a detailed analysis. We 
could show that N-terminal truncation is minor in diffuse but substantial in cored plaques. Although considerable 
amounts of N-terminal truncated Aβ forms were found in cored human plaques, a substantial amount of full 
length Aβ 1-40/42 was also detectable. This fact is important regarding Aβ immunotherapies, where often 
amino-terminal specific antibodies are used. The fact that both, full length and N-terminal truncated, Aβ species 
are found in amyloid plaques indicates that the full-length species are sufficient to trigger a potential plaque 
clearance mechanism involving microglia, which finally removes all kinds of Aβ species.  
The high level of amino-terminal truncations of Aβ, especially N3pE-40/42, in mature human plaques 
observed in this and other reports (Saido et al., 1996, Harigaya et al., 2005, Rufenacht et al., 2005) is likely 
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related to proteolytic processes taking place over prolonged time by a number of proteases (Iwata et al., 2005). 
The results given in Tab. 2 are in agreement with this explanation. The percentage of degraded amino-terminus 
in cored plaques increases at the expense of full length Aβ 1-16 and is directly correlated with AD progression. 
A recent report indicates, that full length Aβ is a minor component in cotton wool and diffuse plaques from an 
FAD patient (Miravalle et al., 2005). Laser dissection of 10’000 plaques and analysis by MALDI-TOF detected 
extensive N-terminal truncation, indicating a role in early-onset FAD. Our approach only requiring a small 
number of diffuse plaques detected high levels of full length Aβ in AD and PA. This adds further support to the 
concept that diffuse plaques resemble early amyloid assemblies and cored plaques mature depositions. 
In AD mice, the abundance and extent of N-terminal truncated Aβ forms were reported, although at 
lower levels (Kuo et al., 2001, Rufenacht et al., 2005). 
Since the extent of N-terminal truncation is likely to influence aggregation properties and also increase 
cell toxicity of Aβ (Pike et al., 1995, Saido, 2000), an accession of N-terminally truncated Aβ variants with 
certain FAD mutations or with disease progression in sporadic AD as we determined in cored plaques, might 
induce excessive neurodegeneration in advanced AD. 
Beyond N-terminal truncated Aβ variants, the influence of other factors should be considered. 
Differences in the concentration of soluble Aβ 1-40 and Aβ 1-42 and the presence or absence of associated 
proteins that are known to impact on fibril and plaque formation, like apolipoprotein E and serum amyloid P 
(SAP) (Pepys et al., 1994, Thal et al., 2005), may account for species differences. Also, the dynamics of 
amyloidosis is accelerated in many AD models, but the extent of neuron loss variable and often less pronounced. 
Therefore AD models are limited for equivalent prediction of time course and degree of neurodegeneration 
encountered in human AD patients.  
 Additional differences between human plaques and PS2APP mice plaques compared to synthetic Aβ are 
found in the proportions between endoproteolytic Lys-C fragments. In human plaques, we observed that the 
amount of Aβ 29-40/42 exceeds the amount of Aβ 17-28. On the other hand, the proportions in PS2APP mouse 
plaques were comparable to synthetic Aβ, where Aβ 17-28 was the major detectable fragment. Previously, we 
demonstrated that the level of Aβ 17-28 exceeds the level of Aβ x-16 (Rufenacht et al., 2005), which could be 
explained by the existence of additional N-terminal truncated Aβ forms, that are not detected by the employed 
mass spectrometry procedure. More important, solubility experiments were performed with laser dissected 
plaques and we identified species dependent and solvent dependent differences for Aβ extraction. Formic acid 
was shown by us and others to be most efficient for Aβ solubilization. A considerable larger Aβ signal on 
Western blots could be detected from human plaques when incubated with formic acid than with SDS containing 
8M urea. Contrary, no differences in Aβ amounts for PS2APP mouse plaques when extracted with SDS 
containing 8M urea compared to 70% formic acid were identified (A. Güntert, unpublished observations). 
Previous reports from APP23 and Tg2576 transgenic mice are consistent with these experiments (Kuo et al., 
2001, Kalback et al., 2002).  
 Some of the above mentioned differences could be explained with different degrees of cross-linking of 
Aβ fibrils (Kuo et al., 2001). Interchain cross-linking between Gln-15 and Lys-16 could account for the observed 
decrease in detectable Aβ 17-28, since Lys-16, when engaged in a ε-side chain amide bond, is no longer a 
substrate for endoproteinase Lys-C. Additionally, cross-linking may have a substantial influence on the solubility 
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of Aβ fibrils. However, these cross-linked Aβ fragments most probably would escape detection in our mass 
spectrometry procedure. Attempts using other restriction proteases to prove the existence of such cross-links 
were not yet successful.  
Aβ deposits can also be found in brains of PA individuals without clinical symptoms like cognitive 
deficits (Price et al., 1991, Arriagada et al., 1992, Thal et al., 2004). These depositions are almost exclusively of 
diffuse nature. Comparison of Aβ composition in diffuse plaques isolated from PA cases with AD cases did not 
show clear differences. In both cases they contain predominantly Aβ 1-42 and show low levels of N-terminal 
truncation. It was shown by neuropathological analysis that differences are found in the anatomical distribution 
(Thal et al., 2006). This suggests that the PA phenotype constitutes the onset of AD although in the absence of 
clinical symptoms. 
Soluble brain Aβ was found to contain less N3pE-42 in PA compared to AD brains (Piccini et al., 
2005). This makes sense, when the amyloid plaque load of PA brains is taken into consideration, where we 
demonstrated low levels of N-terminal truncated Aβ variants in plaques. However, the diffuse deposits found in 
PA brains are predominantly not neuritic and only an evanescent number of NFT’s and neuropil threads could be 
detected. Since morphologically and biochemically comparable diffuse plaques can be found in AD patients as 
well as in PA individuals, our data are supportive for a view that diffuse deposits represent early and pre-
symptomatic features of AD. Considering the generally low concentration of amyloid fibrils in diffuse plaques, it 
is likely that no substantial neurodegeneration occurred and the human brain can deal with this amount and type 
of Aβ. This is supported by the findings that many diffuse plaques in AD and almost all in PA are not neuritic. In 
addition, our ultrastructural findings might indicate a specific interaction with extracellular matrix components, 
also observed in wound healing. Single amyloid fibrils found in diffuse plaques are surrounded by amorphous 
extracellular matrix, thereby protecting the surrounding tissue from contact with the putative toxic amyloid 
aggregates. Continuous aggregation of additional Aβ might overstrain the compensatory mechanism and might 
finally induce onset of neurodegeneration. 
It has been described before, that accumulation of Aβ leads to stimulation of the innate immune 
response, including activation of microglia and astrocytes, release of cytokines such as TNF-α and IL-β, 
complement activation and free-radical formation (Weiner and Selkoe, 2002). This innate immune activation 
may contribute to neurotoxicity. Brains of PA individuals do not display an extensive gliosis nor tau pathology 
and therefore precede a later stage in the events described in the amyloid hypotheses with extensive 
neurodegeneration. 
 The approach has future potential to measure subtle differences of Aβ composition, investigate the 
process of plaque formation in more detail and study the effect of specific Aβ species in relation to 
neurodegeneration in AD and models of AD. Aβ oligomers are first detected intraneuronally (Gouras et al., 
2005) and may represent an intermediate step in plaque formation and neurodegeneration. As the methodology 
provides a high analytical sensitivity, the isolation and subsequent analysis of neurons containing intracellular 
Aβ will be possible and may be an important step to the understanding of Aβ deposition in brains of AD 
patients. As mentioned, glial activation in response to neuritic plaques induce proinflammatory stimuli and 
subsequent neurodegeneration. The specific analysis of neuritic plaques with this approach is likely to reveal 
important insight in pathophysiological processes occurring in the brain of AD patients. Currently, LC-MS/MS 
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studies are pursued for further investigation of plaque associated proteins apart from Aβ. The methodology of 
these ongoing studies holds promise to identify new disease-related proteins. 
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Tab. 1. Comparison of the sensitivities of the Western blot assay and different MS protocols. 
The values given in the table represent the amount of Aβ present in a collection of excised plaques to obtain a 
signal with the indicated method. WB, Western blotting; MS, mass spectrometry 
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Tab. 2. Relative ratios of N-terminal truncated Aβ variants isolated from human plaques. 
The peak height magnitude of the peaks corresponding to Aβ 1-16, 2-16, 3-16, N3pE-16, 4-16 and 5-16 were 
added and the relative portion of the respective peaks determined. The relative ionization properties of Aβ 2-16, 
3-16, 4-16 and 5-16 are not known, but because Aβ N3pE-16 has almost identical ionization properties to Aβ 1-
16, they were assumed to be comparable. n.e., not evaluable, represents MS-profiles of the type given in Fig. 4B, 
(bottom: elution 90% ACN); PA, pathological aging 
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 Fig. 1. Histology of human and PS2APP transgenic mouse brain sections. 
Brain sections from PS2APP mice (A, E) and from human AD (B-D, F-H) specimen were doublestained with 
thioflavine S and an antibody specific for the amino terminal amino acids 2-8 (BAP-2) in order to differentiate 
between the three plaque types and to guide the dissection procedure. Arrowheads indicate diffuse plaques 
(thioflavine S negative and BAP-2 positive), arrows indicate compact plaques (thioflavine S positive and BAP-2 
positive). A typical example of a cored plaque is given in C and G (core: thioflavine S positive and BAP-2 
positive; corona: thioflavine S negative and BAP-2 positive). Diffuse plaques were found occasionally in 
transgenic mice and more frequently in human brain. Compact plaques were rare in humans, but predominate in 
PS2APP mice. Human vessels with CAA were visualized by both methods (D, H). 
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 Fig. 2. Ultrastructural differences between diffuse plaques in PS2APP mice and human Alzheimer’s 
disease brains. 
Sections of PS2APP (A) and human AD (B) brain were labeled using BAP-2 antibody. Visualization was 
achieved using a goat anti-mouse secondary antibody conjugated to 10 nm colloidal gold spheres, each seen as a 
black dot. Diffuse plaques from PS2APP mice show single or few Aβ fibrils deposited in the extracellular space, 
which can directly contact the cell membrane of neurites. In contrast, Aβ fibrils of human diffuse plaques are 
colocalized within confined clusters of extracellular matrix proteins. 
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 Fig. 3. Detection of the amino-termini of Aβ by mass spectrometry. 
Mass spectrometric profile derived from 30 human cored plaques from the occipital association cortex of a 
patient with severe AD (Braak VI). Typically, N-terminal Aβ peaks corresponding to Aβ 1-16 (1954.9), 2-16 
(1839.9), 3-16 (1768.8), N3pE-16 (1750.8), 4-16 (1639.8) and 5-16 (1492.7) can be observed. None of the 
carboxy-terminal peptides were detected due to poor ionization properties. i.s., internal standard. 
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 Fig. 4. Detection of the carboxy-termini of Aβ by mass spectrometry. 
(A) In order to improve the ionization, the peptides were modified by derivatization with 6-guanidohexanoic 
acid - N-hydroxysuccinimide (6-GuHe). (B) Mass spectrometric profiles derived from 50 human cored plaques 
from the occipital association cortex of a patient with severe AD (Braak VI). The sample was spiked with 0.6 
pmol 15N-Aβ 1-42 ox for quantification. Desalting prior to MS was performed with ZipTip using step gradients 
of 30%, 60% and 90% acetonitrile. This additional procedure results in a better signal to noise ratios in the 60% 
eluate. (C) Peak pattern at higher resolution. The method allows to discriminate between oxidized and reduced 
Met-35. m/z values are: Aβ 29-42 ox: 1441.1, Aβ 29-42 red: 1425.1, Aβ 17-28: 1481.1, 15N-Aβ 29-42 ox: 
1455.2 and 15N-Aβ 17-28: 1495.1.  
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Fig. 5. Peak proportions after 6-GuHe modification. 
Determination of the proportion of Aβ 1-16, Aβ 17-28 and Aβ 29-40/42 was performed as described in the 
method section. (A) The proportion of Aβ 17-28 to Aβ 29-40/42 is in favor of Aβ 17-28 when synthetic Aβ or 
plaques from PS2APP mice were analyzed. In human plaques we found the inverse proportion (example given in 
Fig. 4C). 6-GuHe modification leads to an almost complete quenching of Aβ x-16. (B) Comparison of C-
terminal proportions Aβ 29-40 and Aβ 29-42. Human cored and diffuse plaques both contain high amounts of 
Aβ 42.  
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Fig. 6. Western blot analysis of amyloid deposits. 
(A) Analysis of thioflavine S positive amyloid deposits from human and PS2APP transgenic mice. Note that 
Aβ 1-42 ox and Aβ 1-38 red migrate to almost identical positions. (B) Analysis of diffuse plaques from human 
and from transgenic mice. They contain predominantly Aβ 1-42, in the present example the plaques from the 
human AD specimen contain reduced, from the human PA case oxidized and the plaques from mouse a mixture 
of reduced and oxidized Aβ 1−42. (C) Western blot analysis of human cored plaques with an N3pE-specific 
antibody. Pyroglutamate 3-42 could be detected as suggested by MALDI-TOF MS analysis. Two blots with an 
N3pE-specific antibody (left) and WO-2 antibody (right) are shown. 
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 Fig. 7. Hypothetical model of stages in the plaque deposition process. 
Diffuse plaques are found in human AD brain and in PS2APP mice and are considered to be the initial plaque 
type. Although in both cases diffuse plaques contain mainly Aβ 1-42, electron microscopy revealed 
ultrastructural differences already in this early state of plaque formation. The maturation into cored plaques 
cannot proceed over compact plaques, due to their Aβ 40 to Aβ 42 contents. Therefore, we postulate disparate 
deposition of amyloid in plaques in human AD and in PS2APP mice, respectively.  
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Supplementary data, Fig. 1. Ultrastructure of PS2APP compact plaques and cored plaques from human 
Alzheimer’s disease brain. 
Sections of PS2APP (A) and human AD (B) brain were labeled using an anti-Aβ monoclonal antibody (BAP-2). 
Visualization was achieved using a goat anti-mouse secondary antibody conjugated to 10 nm colloidal gold 
spheres. Aβ fibrils in compact mouse plaques are very densely packed with dystrophic neurites and reactive 
microglia at the periphery. Cored human plaques consist of numerous clusters of densely packed large bundles of 
Aβ fibrils. The fibrillar bundles are often in contact with the surrounding neuropil. 
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Supplementary data, Fig. 2. Ultrastructure of vascular amyloid from human Alzheimer’s disease brain. 
Sections of human AD brain were labeled using an anti-Aβ monoclonal antibody (BAP-2). Visualization was 
achieved using a goat anti-mouse secondary antibody conjugated to 10 nm colloidal gold spheres. Characteristic 
for human vascular amyloid is the dense packing of Aβ fibrils at the basement membrane.   
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Supplementary data, Fig. 3 Ionization properties of the N-terminal fragment of Aβ 1-42 and N3pE-42. 
Different ratios (3/7, 1/1 and 7/3) of synthetic Aβ N3pE-42 and Aβ 1-42 were mixed with 15N labelled Aβ 1-42 
to compare ionization and Lys-C digestion properties in the MALDI-TOF MS. As can be seen, the calculated 
14N / 15N ratios correlate linearly with the experimentally measured peak ratios. This clearly indicates 
comparable ionization and Lys-C digestion properties for Aβ 1-16 and Aβ N3pE-16. Three measured points 
were obtained per sample, since three dilutions (1:1, 1:4 and 1:12) were performed for each preparation. 
Numbers in brackets of the indicated standards indicate the first and second of two independent experiments. 
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We have investigated the N-terminal modification of amyloid-β (Aβ) protein in Alzheimer’s disease (AD) 
brains. Laser dissection microscopy of human cored plaques from AD brains with Braak stage IV, V and VI and 
subsequent mass spectrometric analysis revealed an increase of N-terminally truncated Aβ variants, especially 
pyroglutamate 3-40 / 42, of ~20% correlating with disease progression. Pyroglutamate 3-40 / 42 was consistently 
detected as the major N-terminal truncated Aβ species in human cored plaques. We aimed to determine, whether 
pyroglutamate was artificially induced by the sample preparation procedure or indeed is an in vivo generated 
major component of amyloid plaques in human and may be responsible for the high level of neurodegeneration 
observed AD brains. We used immunohistochemistry, Western blot analysis of laser dissected cored plaques, 
mass spectrometric analysis of synthetic oligopeptides starting with either glutamine or glutamate and in vitro 
aggregation and toxicity studies with synthetic pyroglutamate 3-42 (N3pE-42) to get more insight into the role of 
pyroglutamate in AD. Our findings show that pyroglutamate is a major constituent of all amyloid plaques in AD 
and PS2APP transgenic mice. Synthetic N3pE-42 seems to be less toxic and exhibits a significantly lower rate of 
aggregation than Aβ 1-42. It must therefore be considered much more as an abundant metabolite and not as a 
particular harmful seed for Aβ oligomerization. However, due to its abundance it is worth to follow 
pyroglutamate 3-40 / 42 in CSF or blood and test its usefulness as suitable biomarker for AD. 
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INTRODUCTION 
 
 Alzheimer’s disease is a progressive dementing disorder characterized by the occurrence of two 
pathological hallmarks: intraneuronal neurofibrillary tangles consisting of hyperphosphorylated protein tau and 
senile plaques, which form upon extracellular deposition of Aβ. The cognitive decline that characterizes AD is 
well correlated to the cortical spreading of tau pathology (Delacourte et al., 1999). However, a strong correlation 
of the amyloid pathology and the dynamic progression of tau pathology was shown, suggesting an inductive role 
for amyloid deposition in the spreading of tau pathology (Delacourte et al., 2002, Oddo et al., 2004). 
 Aβ peptides are the main protein component of plaques (Glenner et al., 1984). They are deposited as 
full length Aβ 1-40 and 1-42 as determined by the use of C-terminal specific antibodies several years ago (Jarrett 
et al., 1993, Iwatsubo et al., 1994). Upon deposition, Aβ peptides undergo extensive N-terminal truncation and 
several groups characterized the occurrence of various N-terminal truncated Aβ species by 
immunohistochemistry (Iwatsubo et al., 1996, Saido et al., 1996), the analysis of brain homogenates (Mori et al., 
1992, Miller et al., 1993, Hosoda et al., 1998, Sergeant et al., 2003) or the laser dissection of thousands of 
plaques (Miravalle et al., 2005). A quantification and determination of the extent of N-terminal truncated Aβ 
forms from small numbers of laser dissected plaques of PS2APP transgenic mice  and human AD brains was 
performed by our group (Rufenacht et al., 2005). Furthermore, we were able to correlate disease progression 
with an increase of N-terminally truncated Aβ variants in laser dissected cored human plaques (Güntert et al., 
2006, submitted to Neuroscience). We detected pyroglutamate 3-40 / 42 as the major N-terminal truncated Aβ 
variant, with an incidence of 15-25% depending on the Braak stage of the investigated brains. Consistently, 
N3pE-40 / 42 was described previously to be a major component of amyloid plaques in AD brains (Mori et al., 
1992, Saido et al., 1995, Harigaya et al., 2000). 
 N3pE-40 / 42 is an Aβ species beginning with glutamic acid 3, but blocked by conversion to 
pyroglutamate through intramolecular dehydration. This modification is of particular interest because it may 
contribute to the deposition of Aβ by inhibiting the proteolytic degradation of Aβ by aminopeptidases (Hosoda 
et al., 1998, Harigaya et al., 2000). In addition, it was proposed that  
N3pE-40 / 42 Aβ variants could be more prone to aggregation and deposition through its enhanced 
hydrophobicity due to the loss of one positive and two negative charges (Saido et al., 1995, Saido, 2000). Other 
reports showed a general increase in aggregation properties for N-terminal truncated Aβ peptides (Pike et al., 
1995) or a similar toxicity in cell based assays (Tekirian et al., 1999). 
 To prove that Aβ N3pE-40 / 42 is not artificially induced by the sample preparation procedure, we 
incubated several synthetic oligopeptides starting with either a glutamine or a glutamate with hexa-fluoro-
isopropanol (HFIP, 1,1,1,3,3,3-hexafluoro-2-propanol), 70% formic acid (FA) or trifluoroacetic acid (TFA) and 
determined the amount of pyroglutamine / pyroglutamate formed. Furthermore, we identified N3pE-40 / 42 as a 
constituent of amyloid plaques in human by immunohistochemistry and Western blotting and performed in vitro 
aggregation and toxicity experiments with synthetic N3pE-42. 
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MATERIALS AND METHODS 
 
Human tissues and transgenic mice 
 
 Human brains from AD patients were obtained from the Sun Health Research Institute through Dr. 
Thomas G. Beach (Sun City, AZ, USA). The brain tissue was collected approximately two hours after death and 
was immediately frozen at -80°C. Brains were neuropathologically staged according to Braak (Braak and Braak, 
1991). Laser dissection and immunohistochemistry were performed on a superior parietal gyrus from an 84-year-
old patient with Braak stage V, showing heavy plaque load. 16 month old PS2APP mice were used for 
immunostaining (Richards et al., 2003). 
 
Synthetic oligopeptides 
 
 Synthetic oligopeptides starting either with glutamine or glutamate were purchased from Bachem 
(Bachem Holding AG, Bubendorf, Switzerland). We used peptide 810 (H-2586-0001), Apelin-13 (H4566.0001) 
and anxiety peptide (H-1770.0001) starting with glutamine and neuropeptide el (H-2396.0001) and fibrinogen β-
chain (H-3034.0001) with a glutamate at position 1. The sequence and molecular weight of the oligopeptides can 
be seen in Tab. 1. 
 
Laser dissection microscopy and mass spectrometry of plaques 
 
 Laser dissection microscopy and mass spectrometry of laser dissected plaques was performed as 
previously described (Rufenacht et al., 2005) with minor modifications. For dissolution, the cap containing the 
plaques was rinsed twice with 58.5 μl of HFIP instead of 70% FA, to omit sample preparation artifacts that may 
result from FA treatment. 
 
Sample preparation and mass spectrometry of oligopeptides 
 
 The oligopeptides were dissolved in 1 ml of HFP to obtain a concentration of 1 mg / ml. 
50 nmoles of the respective peptides were incubated with 100 μl of either HFIP, 70% FA or concentrated TFA. 
After an incubation period of 6h, 18 h, 48h and 96h, the samples were sonicated (3 x 3 min in a water-bath at 
room temperature with intermediate vortex mixing) and were dried in an evacuated centrifuge for further 
processing of the peptides. The pellet was dissolved in 10 μl of 10 mM NaHCO3 solution. One μl thereof was 
mixed with an equal volume of a α-cyano-4-hydroxycinnamic acid solution (Sigma-Aldrich Chemie GmbH, 
C2020; 5 mg/ml in 50% (v/v) acetonitrile-water) and spotted onto a standard stainless-steel Bruker MALDI 384-
target plate (Bruker Daltonics GmbH, Bremen, Germany). The measurements were performed on a Bruker 
UltraFlex time of flight mass spectrometer in reflector mode using standard operating parameters. Spectra were 
acquired manually at 4 different shot locations and a total of 400 shots were added per spectrum. 
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Immunohistochemistry 
 
 Immunohistochemistry was performed as previously described (Güntert et al., 2006, submitted to 
Neuroscience). As primary antibody, anti-N3pE (Assay designs, Ann Arbor, MI, USA), specific for 
pyroglutaminated Aβ forms, was used at a concentration of 1 μg / ml. 
 
Urea- based Western blot assay and dot blots 
 
 Western blotting was performed as previously described (Güntert et al., 2006, submitted to 
Neuroscience). As primary antibody, anti-N3pE (Assay designs) was used at a dilution of 1:1000 in  
PBS-T. 
 For dot blots, synthetic Aβ 1-40 / 42 and N3pE-42 was diluted and applied at 5μl drops to PVDF 
membranes (50 ng – 0.005 ng), which were previously activated for 10 sec in methanol and rinsed in H2O. The 
membranes were air-dried and unspecific binding sites were blocked using 5% skim milk in PBS-T for 1 hr at 
room temperature. Following primary antibodies were compared: 8E1 (anti-N3pE, Assay designs), WO-2 (The 
Genetics Company, Zürich, Switzerland) and 6E10 (Sigma-Aldrich Chemie GmbH). Primary antibodies were 
used at 0.1, 0.5 and 1μg/ml concentrations and applied for 2 hrs at room temperature. After the incubation 
period, washing steps with PBS-T were performed for 30 min, 15 min and 2 x 10 min. The membranes were then 
incubated with a horseradish peroxidase linked anti-mouse secondary antibody for 1 hr at room temperature, 
before three more washing steps with PBS-T for 3 x 10 min were performed. Detection was achieved with 
conventional X-ray films (Amersham Biosciences, Piscataway, NJ, USA) after a 5 min development period with 
ECLPlusTM (Amersham Biosciences) according to the manufacturer’s protocol. 
 
Aggregation studies 
 
 Synthetic Aβ 1-42 and N3pE-42 peptides were solubilized according to a previously described method 
(Stine et al., 2003). Aβ was solubilized in HFIP to 0.22 mM, sonicated for 10 min and incubated overnight at 
room temperature. The solutions were aliquoted in Eppendorf tubes, evaporated at room temperature under a 
fume hood, dried completely in an evacuated centrifuge and stored at -80°C. Aliquots were analyzed for amino 
acid composition to determine the precise amount of peptide in each vial and the purity was checked by MALDI-
TOF mass spectrometry analysis. The amyloid fibril formation was analyzed by the thioflavin-T fluorometric 
assay. Thioflavin-T, by specifically binding to amyloid fibrils, induces a shift in its emission spectrum and a 
allows to measure a fluorescent signal proportional to the amount of amyloid fibrils formed (LeVine, 1993, 
Golabek et al., 1996). HFIP pretreated Aβ 1-42 and N3pE-42 were solubilized to a final concentration of 10 μM 
and 50 μΜ in PBS. The solutions were submitted to gentle swirling (450 rpm) for 2.5 days at 0 and 37°C in an 
Eppendorf-Thermomixer. Incubated samples were transferred to a black 96-well plate (Costar, Basel, 
Switzerland) and assay buffer [50 mM glycine, pH 9, 60 μM Thioflavin-T (Sigma, Switzerland)] was added. 
Fluorescence was measured at an excitation of 435 nm and an emission of 480 nm in a spectrophotometer 
(Polarstar Galaxy, BMG Labtechnologies, Offenburg, Germany) and the signal was compared between Aβ 1-42 
and N3pE-42 at 0°C and 37°C respectively. 
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Toxicity assay on PC-12 cells 
 
 Aβ was incubated as described above (thioflavine T assay). Aβ 1-42 and N3pE-42 were added to PC12 
cells cultured in 96-well flat-bottom plates, in Ham’s F12 medium with 10% horse serum and 5% fetal calf 
serum. Final concentrations of Aβ N3pE-42 in 96-well format were 0.1, 0.5, 1, 2 and 5 μM per well, whereas 
concentrations for Aβ 1-42 were 1 μm at 0°C and 0.25 μm at 37°C. After 20 hrs of incubation the cellular 
viability was compared between Aβ N3pE-42 and 1-42 using the MTT assay [3-(4.5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrasodium] according to the protocol of the manufacturer (F. Hoffmann-La Roche Ltd., Basel, 
Switzerland). Values of cell viability were calculated by dividing the absorbance of the sample by the 
absorbance of the vehicle multiplied by one hundred. 
 
 
RESULTS AND DISCUSSION 
 
Dot blots 
 
 To determine whether the pyroglutamate antibody cross-reacts with full length Aβ 1-40 and 1-42, we 
performed dot blot assays. The pyroglutamate antibody detects N3pE-42 at least 100 times more specifically 
than full length Aβ 1-40 / 42. On the other hand, an N-terminal Aβ antibody specific for full length Aβ, is about 
a factor of 100 more sensitive for Aβ 1-40 / 42. 
 
Immunohistochemistry 
 
 Staining of human AD brain sections with N3pE-antibody showed that most amyloid plaques are 
labeled with the pyroglutamate specific antibody (Fig. 1A). This suggests that N3pE-40 / 42 is a constituent of 
these plaques. Cored as well as diffuse plaques were stained and detected, although with a different fluorescent 
signal intensity. Interestingly, vascular amyloid was also labeled and seems to contain considerable amounts of 
pyroglutaminated Aβ. 
 Plaques from PS2APP mice were also stained with the N3pE-specific antibody (Fig. 1B), this confirms 
the occurrence of pyroglutamate in PS2APP mouse plaques as detected with MADLI-TOF MS and described in 
an earlier report of our group (Rufenacht et al., 2005). As the staining protocol differs completely from the 
MALDI-TOF MS sample preparation protocol, pyroglutamate is very unlikely to be induced artificially. Taken 
together, immunohistochemistry supports the view that pyroglutamate Aβ Ν3pE-40 / 42 is present in large 
quantities in human and PS2APP amyloid plaques and is present in vascular amyloid.  
 
Solvent effects on oligopeptides and plaque-derived Aβ 
 
 Five different peptides starting with either glutamine or glutamate (Tab. 1) were incubated for 96 hrs at 
room temperature with HFIP, 70% FA and concentrated TFA. The amount of artificially induced pyroglutamate 
was then determined in the respective incubation assays. Pyroglutamate formation can be detected in MALDI-
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TOF MS with the loss of a H2O molecule (-17 m/z). Furthermore, formylation events (+28 m/z) in the 70% FA 
assay and sodium adducts (+22 m/z) in general were observed (Fig. 2). 
 For evaluation, peak heights related to pyroglutamate were measured, added and put in relation to the 
sum of peak heights for all peaks related to the respective peptide. Like this, mean values for pyroglutamate 
induction could be calculated. For HFIP incubation, we determined a pyroglutamate ratio of 7 ± 2% for 
glutamate starting peptides (like Aβ) and of 25 ± 20% for glutamine starting peptides. For 70% FA, these values 
were 6 ± 2% and 80 ± 2% respectively, whereas for TFA incubation we found pyroglutamate of 10 ± 7% and 60 
± 5%. Our results indicate that glutamine is far more susceptible to artificial induction of pyroglutamate than is 
glutamate with either of the solvents. They also show that HFIP incubation induces artificial pyroglutamate 
formation only to a small extent. Consequently, to further exclude sample preparation artifacts by FA, the 
dissolution of plaque amyloid with HFIP was performed. Even though the dissolution of plaque amyloid with 
HFIP was not as efficient as with FA, we were able to detect pyroglutamate in 50 cored plaques by mass 
spectrometry (Fig. 3). HFIP instead of 70% FA revealed three peaks corresponding to Aβ fragments: 1955.7 (Aβ 
1-16), 1326.0 (Aβ 17-28) and 1751.5 (Aβ N3pE-16).This supports the idea that the detected N3pE-40 / 42 is not 
induced artificially through FA treatment, but indeed resembles an in vivo constituent of human and also 
PS2APP mouse plaques. 
 
Western blotting 
 
 Laser dissection of 100 human cored plaques and subsequent analysis by urea-based Western blotting 
revealed the occurrence of pyroglutamate (Fig. 4). By comparing migration distances of synthetic N3pE-42 with 
Aβ isolated from cored plaques, we were able to detect a considerable amount of pyroglutamate 3-42 and could 
thereby confirm the data obtained by mass spectrometry.  
 
Aggregation and Toxicity 
 
 To determine the in vitro rate of aggregation and toxicity properties we compared synthetic Aβ N3pE-
42 with Aβ 1-42. Oligomers stable at 0°C were used as reference and compared to Aβ peptides incubated at 
37°C. When incubated for 2.5 days at 37°C, the fluorescent signal of thioflavine T is four times higher for Aβ 1-
42 than for Aβ N3pE-42. This suggests that Aβ N3pE-42 has a significantly lower rate of fibril association than 
Aβ 1-42 (Fig. 5A). The toxicity properties of Aβ are likely dependent on the aggregation state. Consistently, a 
markedly reduced cellular toxicity of N3pE-42 was observed when compared to Aβ 1-42 in vitro (Fig. 5B). To 
obtain a comparable cellular toxicity to 0.25 μM Aβ 1-42, a concentration of 5 μM N3pE-42 was necessary, 
which corresponds to a 20 fold increase. Our observations are supported by experiments performed on murine 
hippocampal neurons. These experiments, showed a decreased cellular toxicity of synthetic Aβ N3pE-42 after 
five days compared to full length Aβ (personal communications Prof. Y.-A. Barde, Biocenter, University Basel, 
Switzerland). 
Taking our in vitro data into account, it can be suggested that pyroglutamate 3-40 / 42 alone is an unlikely seed 
for plaque deposition in brains of Alzheimer’s patients. However, it is possible that pyroglutamate together with 
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Aβ 1-40 / 42 as present in vivo may speed up the aggregation process of full length Aβ peptides. Further 
experiments will be necessary to determine the rate of aggregation of N3pE-42 in combination with full length 
Aβ 1-40 / 42. 
 Other groups reported a higher rate of oligomerization (Harigaya et al., 2000, Saido, 2000) and 
suggested an early involvement of pyroglutamate in the plaque development process (Saido et al., 1995). 
Furthermore, it was described that pyroglutamate and N-terminally truncated Aβ forms in general, show 
comparable or even enhanced toxicity compared to Aβ 1-42 (Pike et al., 1995, Tekirian et al., 1999, Russo et al., 
2002). A likely explanation for this discrepancy comes from the used sample preparations. A detailed 
physicochemical characterization of the assembly state of the starting material is necessary to directly compare 
the results. 
 
Concluding Remarks 
 
 This investigation aimed to prove that pyroglutamate is an in vivo constituent of amyloid plaques. We 
detected 15 – 25% N3pE-40 / 42 in human plaques by mass spectrometry in an earlier report (Rufenacht et al. 
2005, Güntert et al., 2006, submitted to Neuroscience) and confirmed the presence of this posttranslationally 
modified Aβ peptide by Western blotting and immunohistochemistry in this study. Further, we show that 
pyroglutamate is not artificially induced by the sample preparation procedure, but is present in all types of 
plaques and vascular amyloid in human and PS2APP transgenic mice. Our in vitro results with synthetic Aβ 
peptides suggest, that Aβ N3pE-40 / 42 alone is an unlikely starting point for plaque deposition, due to its 
aggregation properties. Also, toxic effects of Aβ N3pE-42 are less pronounced compared to full length Aβ 1-42. 
However, pyroglutamate may contribute to the amyloid plaque load in the brain through its enhanced resistance 
to most aminopeptidases. Therefore, the abundance of N3pE-40 / 42 reflects decreased clearance and its amount 
in the brain mirrors the progress of the pathologic process in AD. This is supported by the detection of increasing 
amounts of pyroglutamate from Braak stage IV – VI in a MALDI-TOF analysis by our group (Güntert et al., 
2006, submitted to Neuroscience). 
 Considering the abundance of pyroglutamate in AD brains and its solubility, it would be of great 
interest if N3pE-40 / 42 can also be detected in CSF or even in blood samples and might finally serve as a 
biomarker for diagnosis and progression of the disease. 
 
 
REFERENCES 
 
Braak, H. and Braak, E., 1991. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 
(Berl). 82, 239-259. 
Delacourte, A., David, J. P., Sergeant, N., Buee, L., Wattez, A., Vermersch, P., Ghozali, F., Fallet-Bianco, C., 
Pasquier, F., Lebert, F., Petit, H. and Di Menza, C., 1999. The biochemical pathway of neurofibrillary 
degeneration in aging and Alzheimer's disease. Neurology. 52, 1158-1165. 
Manuscript [III], 
prepared for Submission 
Delacourte, A., Sergeant, N., Champain, D., Wattez, A., Maurage, C. A., Lebert, F., Pasquier, F. and David, J. 
P., 2002. Nonoverlapping but synergetic tau and APP pathologies in sporadic Alzheimer's disease. 
Neurology. 59, 398-407. 
Glenner, G. G., Wong, C. W., Quaranta, V. and Eanes, E. D., 1984. The amyloid deposits in Alzheimer's 
disease: their nature and pathogenesis. Appl Pathol. 2, 357-369. 
Golabek, A. A., Soto, C., Vogel, T. and Wisniewski, T., 1996. The interaction between apolipoprotein E and 
Alzheimer's amyloid beta-peptide is dependent on beta-peptide conformation. J Biol Chem. 271, 10602-
10606. 
Harigaya, Y., Saido, T. C., Eckman, C. B., Prada, C. M., Shoji, M. and Younkin, S. G., 2000. Amyloid beta 
protein starting pyroglutamate at position 3 is a major component of the amyloid deposits in the 
Alzheimer's disease brain. Biochem Biophys Res Commun. 276, 422-427. 
Hosoda, R., Saido, T. C., Otvos, L., Jr., Arai, T., Mann, D. M., Lee, V. M., Trojanowski, J. Q. and Iwatsubo, T., 
1998. Quantification of modified amyloid beta peptides in Alzheimer disease and Down syndrome 
brains. J Neuropathol Exp Neurol. 57, 1089-1095. 
Iwatsubo, T., Odaka, A., Suzuki, N., Mizusawa, H., Nukina, N. and Ihara, Y., 1994. Visualization of A beta 
42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially 
deposited species is A beta 42(43). Neuron. 13, 45-53. 
Iwatsubo, T., Saido, T. C., Mann, D. M., Lee, V. M. and Trojanowski, J. Q., 1996. Full-length amyloid-beta (1-
42(43)) and amino-terminally modified and truncated amyloid-beta 42(43) deposit in diffuse plaques. 
Am J Pathol. 149, 1823-1830. 
Jarrett, J. T., Berger, E. P. and Lansbury, P. T., Jr., 1993. The carboxy terminus of the beta amyloid protein is 
critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. 
Biochemistry. 32, 4693-4697. 
LeVine, H., 3rd, 1993. Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: 
detection of amyloid aggregation in solution. Protein Sci. 2, 404-410. 
Miller, D. L., Papayannopoulos, I. A., Styles, J., Bobin, S. A., Lin, Y. Y., Biemann, K. and Iqbal, K., 1993. 
Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer's 
disease. Arch Biochem Biophys. 301, 41-52. 
Miravalle, L., Calero, M., Takao, M., Roher, A. E., Ghetti, B. and Vidal, R., 2005. Amino-terminally truncated 
Abeta peptide species are the main component of cotton wool plaques. Biochemistry. 44, 10810-10821. 
Mori, H., Takio, K., Ogawara, M. and Selkoe, D. J., 1992. Mass spectrometry of purified amyloid beta protein in 
Alzheimer's disease. J Biol Chem. 267, 17082-17086. 
Oddo, S., Billings, L., Kesslak, J. P., Cribbs, D. H. and LaFerla, F. M., 2004. Abeta immunotherapy leads to 
clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron. 43, 
321-332. 
Pike, C. J., Overman, M. J. and Cotman, C. W., 1995. Amino-terminal deletions enhance aggregation of beta-
amyloid peptides in vitro. J Biol Chem. 270, 23895-23898. 
Richards, J. G., Higgins, G. A., Ouagazzal, A. M., Ozmen, L., Kew, J. N., Bohrmann, B., Malherbe, P., 
Brockhaus, M., Loetscher, H., Czech, C., Huber, G., Bluethmann, H., Jacobsen, H. and Kemp, J. A., 
Manuscript [III], 
prepared for Submission 
2003. PS2APP transgenic mice, coexpressing hPS2mut and hAPPswe, show age-related cognitive 
deficits associated with discrete brain amyloid deposition and inflammation. J Neurosci. 23, 8989-9003. 
Rufenacht, P., Guntert, A., Bohrmann, B., Ducret, A. and Dobeli, H., 2005. Quantification of the A beta peptide 
in Alzheimer's plaques by laser dissection microscopy combined with mass spectrometry. J Mass 
Spectrom. 40, 193-201. 
Russo, C., Violani, E., Salis, S., Venezia, V., Dolcini, V., Damonte, G., Benatti, U., D'Arrigo, C., Patrone, E., 
Carlo, P. and Schettini, G., 2002. Pyroglutamate-modified amyloid beta-peptides--AbetaN3(pE)--
strongly affect cultured neuron and astrocyte survival. J Neurochem. 82, 1480-1489. 
Saido, T. C., 2000. Involvement of polyglutamine endolysis followed by pyroglutamate formation in the 
pathogenesis of triplet repeat/polyglutamine-expansion diseases. Med Hypotheses. 54, 427-429. 
Saido, T. C., Iwatsubo, T., Mann, D. M., Shimada, H., Ihara, Y. and Kawashima, S., 1995. Dominant and 
differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile plaques. 
Neuron. 14, 457-466. 
Saido, T. C., Yamao-Harigaya, W., Iwatsubo, T. and Kawashima, S., 1996. Amino- and carboxyl-terminal 
heterogeneity of beta-amyloid peptides deposited in human brain. Neurosci Lett. 215, 173-176. 
Sergeant, N., Bombois, S., Ghestem, A., Drobecq, H., Kostanjevecki, V., Missiaen, C., Wattez, A., David, J. P., 
Vanmechelen, E., Sergheraert, C. and Delacourte, A., 2003. Truncated beta-amyloid peptide species in 
pre-clinical Alzheimer's disease as new targets for the vaccination approach. J Neurochem. 85, 1581-
1591. 
Stine, W. B., Jr., Dahlgren, K. N., Krafft, G. A. and LaDu, M. J., 2003. In vitro characterization of conditions for 
amyloid-beta peptide oligomerization and fibrillogenesis. J Biol Chem. 278, 11612-11622. 
Tekirian, T. L., Yang, A. Y., Glabe, C. and Geddes, J. W., 1999. Toxicity of pyroglutaminated amyloid beta-
peptides 3(pE)-40 and -42 is similar to that of A beta1-40 and -42. J Neurochem. 73, 1584-1589. 
 
 
ACKNOWLEDGEMENTS 
 
We thank Francoise Gerber and Anita Amhof for the help with the immunohistochemistry, Viviane Anquez for 
sample preparation in the toxicity and aggregation studies. Furthermore, we thank Prof. Yves-Alain Barde and 
Rita Andraus for performing toxicity studies with synthetic N3pE-42 on murine hippocampal cell cultures. 
 
Manuscript [III], 
prepared for Submission 
 Peptide Sequence Molecular weight  
Peptide 810 H-Gln-Asp-Leu-Thr-Met-Lys-Tyr-Gln-Ile-Phe-OH 1286.52 
Neuropeptide 
El H-Glu-Ile-Gly-Asp-Glu-Glu-Asn-Ser-Ala-Lys-Phe-Pro-Ile-NH2 1447.57 
Apelin-13 H-Gln-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Met-Pro-Phe-OH 1550.85 
Anxiety 
Peptide 
H-Gln-Ala-Thr-Val-Gly-Asp-Val-Asn-Thr-Asp-Arg-Pro-Gly-Leu-Leu-
Asp-Leu-Lys-OH 1912.13 
Fibrinogen 
β-Chain 
H-Glu-Glu-Ala-Pro-Ser-Leu-Arg-Pro-Ala-Pro-Pro-Pro-Ile-Ser-Gly-
Gly-Gly-Tyr-Arg-OH 1951.17 
 
Tab. 1. Amino acid sequence of synthetic oligopeptides. 
Three peptides, namely peptide 810, anxiety peptide and apelin-13, start with a glutamine, whereas neuropeptide 
el and fibrinogen β-chain contain a glutamate as first amino acid. Amyloid-β peptide contains a glutamate at 
position three, followed by a phenylalanine. Accordingly, artificial pyroglutamate formation in neuropeptide el, 
which contains a glutamate followed by an isoleucine, can best be compared to the situation in Aβ. 
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Fig. 1. Immunohistochemistry with a pyroglutamate specific antibody. 
Substantial amounts of pyroglutamate 3-40 / 42 were detected in human and PS2APP mouse plaques, as well as 
in human vascular amyloid. Virtually all and all types of plaques were labeled and suggest that N3pE-40 /42 is a 
constituent of these plaques. Arrowhead indicates vascular amyloid. 
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Fig. 2. Mass spectrometric analysis of synthetic oligopeptides. 
Synthetic oligopeptides were incubated with either HFIP, 70% FA or concentrated TFA for 96 hrs and the 
proportion of induced pyroglutamate was determined. The specific masses are listed in Tab.1. According to these 
data, glutamine is far more susceptible to pyroglutamate formation than glutamate, where less than 10% of the 
original peptides were converted to pyroglutamate. HFIP, 1,1,1,3,3,3-hexafluoro-2-propanol; FA, formic acid; 
TFA, trifluoroacetic acid 
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Fig. 3. Mass spectrometric analysis of human cored plaques after HFIP dissolution. 
Fifty laser dissected cored plaques were incubated with HFIP and subsequently analyzed by mass spectrometry. 
By omitting the formic acid treatment in the sample preparation procedure, the exclusion of artificial 
pyroglutamate induction was aimed. The dissolution of plaque amyloid was not as efficient as with 70% formic 
acid and a considerable background was obtained. However, three peaks related to Aβ were still detected. Beside 
Aβ 1-16 (m/z 1954.9) and Aβ 17-28 (m/z 1325.7), also pyroglutamate 3-16 (1750.8) could be identified after 
HFIP treatment. 
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Fig. 4. Western blot analysis of human cored plaques. 
Laser dissection of 100 cored plaques and subsequent analysis by Western blotting using an N3pE-specific 
antibody revealed the existence of pyroglutamate 3-42. pl, plaques; MW marker, molecular weight marker 
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Fig. 5. In vitro aggregation and cytotoxicity assay with synthetic Aβ N3pE-42. 
(A) 10mM and 50mM were incubated at either 0°C or 37°C and the fibril formation was evaluated with 
thioflavin T assay. The rate of fibril formation was markedly decreased for synthetic Aβ N3pE-42 compared to 
Aβ 1-42. (B) Different amounts of Aβ N3pE-42 and Aβ 1-42 were added to PC12 cells cultured in 96-well 
plates. After 20 h of incubation,the  viability of cells was measured using an MTT assay. The toxicity of Aβ 
N3pE-42 was markedly reduced compared to Aβ 1-42. To obtain a comparable cellular toxicity at 37°C, a 20 
fold higher amount of Aβ N3pE-42 than Aβ 1-42 was necessary. 
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Alzheimer’s disease (AD) is the most common form of dementia in the elderly, but the molecular mechanisms 
leading to neurodegenerative and cognitive changes are not fully elucidated. We analyzed the soluble proteome 
from grey matter in the occipital cortex by liquid chromatography coupled with tandem mass spectrometry to 
compare protein levels in human AD and control tissue. In addition to proteins generally accepted to be related 
to AD like Aβ, tau, GFAP and apolipoprotein E, we found 18 new proteins from different functional classes, e.g. 
cell adhesion and synaptic molecules, with significantly altered levels in AD not described previously. Selected 
proteins were further investigated by immunohistochemistry and Western blotting. Specifically, we detected 
increased levels of synaptogyrin-1 and decreased reticulon-1 and syntaxin-1A levels in severe AD. Overall, this 
study provides new information that might be useful for the development of biomarkers in AD. 
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INTRODUCTION 
 
 Alzheimer’s disease (AD) is a complex neurodegenerative dementing illness. It is histopathologically 
characterized by the deposition of extracellular amyloid plaques mainly consisting of amyloid-β peptide (Aβ) 
and the intracellular accumulation of hyperphosphorylated tau into neurofibrillary tangles. At present, the 
amyloid cascade hypothesis (Selkoe, 2001, Hardy, 2006) and neurodegenerative tauopathies (Lee et al., 2005) 
provide a framework for studying AD pathogenesis. According to the former hypothesis, neurodegeneration in 
AD begins with the abnormal processing of the amyloid precursor protein (APP) and results in the production, 
aggregation and deposition of the Aβ peptide. However, current research indicates that soluble Aβ oligomers are 
the toxic amyloid species and not necessarily amyloid deposited in plaques (Watson et al., 2005). Many 
additional factors and pathways are described to be involved in neurodegeneration, like cytoskeletal alterations 
(Goldstein, 2003) leading to neurofibrillary tangles (NFTs) that impair intracellular transport processes to name 
only one. However, the molecular mechanisms leading from Aβ deposition to tau accumulation and 
neurodegeneration with cognitive deficits are still not entirely established. 
 In clinical practice, the diagnosis of AD is presently based on cognitive tests. The current diagnostic 
biomarkers in AD are derived from the cerebrospinal fluid (CSF) which is in direct contact with the extracellular 
space of the central nervous system allowing the measurement of solutes related to AD. A number of biological 
markers for AD are used, like tau (Andreasen et al., 1998) and phospho-tau levels (Parnetti et al., 2001), Aβ 1-42 
levels (Ida et al., 1996, Andreasen and Blennow, 2002) or a combination of all three (Andreasen et al., 2003). 
Yet, a definitive diagnosis of AD relies on a postmortem assessment of brain neuropathology and there is clearly 
a need for a reliable, highly specific and sensitive biomarker for AD, preferentially, in peripheral fluids, i.e. 
plasma or serum. 
 A first step towards biomarker discovery for improved diagnostic assessment would be the detailed 
knowledge of which proteins and processes in brains of AD patients may be affected by the disease. Several 
proteins have been reported by immunohistochemistry to be colocalized with amyloid plaques or to have altered 
protein levels in AD, but biochemical verification of these candidates has been sparse. Previously, proteomic 
analysis was performed by comparing samples between AD cases and controls using 2D-gel electrophoresis and 
subsequent identification of the proteins by mass spectrometry (Schonberger et al., 2001, Tsuji et al., 2002). A 
complete proteomic approach is yet not straight forward with 2D-gel electrophoresis. A substantial technical 
advancement came up with mass spectrometry (MS) instrumentation over the last few years, in particular with 
the development of liquid chromatography combined with tandem mass spectrometry (LC/MS/MS). This allows 
the analysis of thousands of proteins from a complex protein mixture even with concentrations in the femto- or 
sub-femtomolar range. LC/MS/MS technique was demonstrated to be suitable for proteomic characterization in 
various fields, like cancer research (Baker et al., 2005, Gagne et al., 2005) or glycoproteomic analysis (Hashii et 
al., 2005, Wuhrer et al., 2005). The analysis of amyloid plaque associated proteins by use of laser capture 
microdissection and LC/MS/MS (Liao et al., 2004) revealed various proteins with increased levels in amyloid 
plaques compared to non-plaque control samples. Laser dissection microscopy was also used in our group to 
establish a high sensitivity analysis of Aβ peptides in different plaque types by MALDI-TOF MS (Rufenacht et 
al., 2005). 
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 Here we investigated the entire grey matter tissue of postmortem occipital association cortex of two 
severe AD patients, which were compared to age-matched control samples by the use of LC/MS/MS. The 
occipital lobe is known to be the visual processing center in human and to exhibit an extensive amyloidosis in 
AD. Analysis of grey matter enabled the investigation of changes in protein levels in a region, where synaptic 
changes and other disease-related processes occur. The used methodology confirmed known AD related proteins, 
like Aβ, tau, GFAP, apolipoprotein E, Ubiquitin, Hsp90 and others, which are known to be more abundant in 
AD. More importantly, we report significantly altered levels of various other proteins in AD brain samples 
which have not been described previously. We confirmed the findings obtained by LC/MS/MS for selected 
proteins by immunohistochemistry and Western blotting. 
 Altogether, this proteomic study provides important new information in the elucidation of biochemical 
pathways involved in AD and presents potential new biomarker candidates required for an improved diagnosis of 
the disease. 
 
 
MATERIALS AND METHODS 
 
Human tissues 
 
 Human brains from AD patients were obtained from the Sun Health Research Institute through Dr. 
Thomas G. Beach (Sun City, Arizona, USA). The brain tissue was collected approximately two hours after death 
and was immediately frozen at -80°C. Brains were neuropathologically staged according to Braak and Braak 
(Braak and Braak, 1991). Brain tissue was isolated from the occipital association gyrus of 2 different AD 
patients (80 and 78 years old) with Braak stage VI and one control case (88 years old) with Braak stage II. For 
Western blotting, an additional control patient (85 years) with Braak stage II was employed. The individuals 
with Braak stage II showed no plaque pathology, while the patients with Braak stage VI showed heavy plaque 
load. 
 
Preparation of brain slices 
 
 Frozen brain tissue was used and sections of 30 μm thickness were cut with a cryostat microtome 
(Leica Microsystems, CM3050 S). The slices were directly mounted onto glass cover slip coated with a 1.35 μm 
thin polyethylene foil (PALM Robot Microbeam, LPC-MOMeNT-Object slides, 8150) and stored at -20°C. 
Brain tissue sections for immunohistochemistry were cut at a thickness of 10 μm and mounted onto glass cover 
slips (SuperFrost Plus, Menzel GmbH & Co KG, Braunschweig, Germany). 
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Immunohistochemistry 
 
 Brain tissue slices were rehydrated for 5 min with phosphate buffered saline (PBS, Gibco, 14200-067) 
and fixed onto the glass slide by applying 70% acetone (0°C) for approximately 1 min. Sections were washed 
twice for 2 min with 1 ml PBS and incubated with 500 μl PBS containing 1% bovine serum albumin (BSA, 
fraction V, Roche Applied Science) and 1% Ovalbumin (Sigma-Aldrich Chemie GmbH, 05440) for 20 min to 
block unspecific binding sites. The slices were then incubated for 1 hr at room temperature with 200 μl of 
primary antibody.  
 The following primary antibodies were applied: anti-synaptogyrin-1 (clone 80.1, 10 μg / ml, Synaptic 
Systems GmbH, Goettingen, Germany), anti-reticulon-1 (clone Mon-160, 10 μg / ml, Santa Cruz 
Biotechnologies, Santa Cruz, CA, USA), anti-syntaxin-1A (clone MAB336, 10 μg / ml, Chemicon International, 
Temecula, CA, USA), anti-Aβ (clone BAP-2a, 5 μg / ml, kindly provided by Dr. M. Brockhaus), anti-SAP 
(clone5.4A, 10 μg / ml, Monosan, Uden, Netherlands), anti-apolipoprotein E (clone M212166, 10μg / ml, 
Fitzgerald Industries International, Inc, Concord, MA, USA) and anti-GFAP (clone EA-53, 1:400, BioMakor, 
Israel). 
 The samples were then washed three times for 5 min with 500 μl of PBS containing 1% BSA. Detection 
was performed using either an Alexa Fluor 488- or 555-conjugated secondary antibody (1:200 in PBS containing 
1% BSA; Invitrogen AG, Molecular Probes, Basel, Switzerland) applied for 1 hr at room temperature. The 
preparations were then washed once for 5 min with 1 ml PBS and once for 2 min with distilled H2O before being 
air-dried and stored until submitted to confocal laser scanning microscopy. 
 
SDS-PAGE / Western blot 
 
 Frozen grey matter tissue from the corresponding brain areas were isolated after preparing 200 μm thick 
slices with a cryostat microtome using a surgical blade. The tissue was balanced and 4 μl of 2% SDS-buffer was 
added per mg brain. The brain tissue was homogenized using ceramic bead-containing tubes (MagNa Lyser 
Green Beads, 3 358 941, Roche Diagnostics GmbH, Mannheim, Germany) using a shaker (Precellys 24, Bertin 
Technologies, Montigny-le-Bretonneux, France) for 20 seconds. The supernatant was isolated and frozen at -
20°C until analysis by Western blot. One μl of brain homogenate was separated on a 4–12% SDS gel (1 mm 
thick) using 2-(N-Morpholino)ethanesulfonic Acid (MES) running buffer for 1 hr 15 min at 150 Volt. Western 
blotting and immunostaining was performed as described by Wiltfang and colleagues (Wiltfang et al., 1997). 
Proteins were transferred for 60 min at 1 mA/cm2 and room temperature under semi-dry conditions onto Hybond 
membranes (GE Healthcare, Piscataway, NJ, USA). For immunostaining, membranes were air-dried for 15 min 
and boiled for 5 min in PBS at 500 W using a microwave oven (Ida et al., 1996, Wiltfang et al., 1997). Blocking 
was performed for 1 hr at room temperature in the presence of 5% nonfat dry milk in PBS-T (PBS + 0.5% 
Tween-20) or Tris-Buffered Saline Tween-20 (TBS-T), respectively. Incubation with the primary antibodies was 
done overnight at 4°C.  
 The following primary antibodies were applied: anti-Aβ (clone WO-2, 2 μg / ml, The Genetics 
Company, Zuerich, Switzerland), anti-phosphotau pSer422 (1:1000, kindly provided by Dr. F. Grüninger), anti-
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tau (clone HT7, 1:5000, Perbio Science, Lausanne, Switzerland) and anti-syntaxin-1A (clone MAB336, 1:1000, 
Chemicon International, Temecula, CA, USA).  
 Membranes were then washed for 2 x 15 min, in PBS-T (or TBS-T). After the washing steps, the 
membranes were incubated with horseradish peroxidase linked secondary antibodies (GE Healthcare) for 1 hr at 
room temperature. After 2 x 15 min washing in PBS-T (or TBS-T), the membranes were developed for 2 min at 
room temperature with ECLTM (GE Healthcare) solution according to the protocol of the manufacturer. 
Visualization was done with conventional X-Ray films (GE Healthcare) and band intensities were compared. For 
the image analysis, GeneTools software (Syngene, Cambridge, United Kingdom) was used. 
 
Confocal microscopy 
 
 The immunofluorescence images were recorded on Leica TCS SP2 AOBS confocal laser scanning 
microscope (Leica Microsystems, Glattbrugg, Switzerland). For quantification of intensity difference in AD and 
control samples, the 10 μm sections were immunostained with either reticulon-1 or syntaxin-1A antibody at 10 
μg / ml as described above. Three and five images from grey matter regions were taken from reticulon-1 and 
syntaxin-1A stained sections, respectively. Optical sections at an interval of 0.4 μm were recorded using a HCX-
PL APO CS 40x 1.25 oil objective. Instrument settings for laser intensity, scan speed and averaging were 
adjusted to enable recording of the fluorescence signal in the effective dynamic range of the photomultiplier tube 
(PMT) and kept constant for a given staining to allow intensity comparison. Images were processed and analyzed 
using Imaris Software (Bitplane AG, Zuerich, Switzerland). The sum of intensities of the fluorescence emission 
signal was quantified from the layer with the highest intensity within a tissue section. The background from 
secondary antibodies was regarded as negligible by visual inspection. 
 High resolution confocal immunofluorescence images of double stained specimen for co-localization 
analysis were acquired by sequential scanning and with a resolution accordingly to satisfy the Nyquist criteria 
using a HCX PL APO CS 63x 1.3 glycerol immersion objective. The xy-projections were superimposed using 
Imaris Software (Bitplane). Images were sharpened with ImageAccess software (Imagic Bildverarbeitung AG, 
Glattbrugg, Switzerland).  
 
Sample preparation for LC/MS/MS 
 
 The brain tissue was isolated using a sterile surgical blade and areas of 30 and 35 mm2 (AD) and 32 and 
36 mm2 (control) were collected, which corresponds to less than one mg of brain tissue. Exclusively grey matter 
areas from the first apical layer to white matter were gathered. Brain tissue was solubilized by addition of 2 x 50 
μl of 2 % SDS-buffer (2 % SDS, 66 mM Na2CO3, 2 % β-mercapto-ethanol, 10 % sucrose) with intermediate 
heating for 10 min at 70°C. Supernatants were combined and protein was precipitated according to Wessel and 
Flugge (Wessel and Flugge, 1984). Briefly, 400 μl methanol were added to the supernatant and mixed 
thoroughly. 200 μl of chloroform were added and after another mixing step and addition of 300 μl H2O, the 
sample was incubated on ice for 5 min and centrifuged at 10000 rpm for 2 min until a clear phase separation was 
achieved. The denatured proteins resided in the interphase and were concentrated by carefully removing the 
hydrophilic phase. After addition of 300 μl methanol, mixing and a second incubation on ice for 5 min, the 
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proteins were sedimented by centrifugation for 5 min at 10000 rpm. The supernatant was removed and the 
protein pellet was dried at room temperature. 
 Proteins in each sample were separated on a 4–12% SDS gel (1 mm thick) using 3-(N-morpholino) 
propanesulphonic acid (MOPS) running buffer for 1.5 hrs at 120 volts. Subsequently, the gels were stained with 
Coomassie Blue G-250 overnight and destained for  
6 hrs in H2O. 
 The entire lane was cut into 14 pieces followed by in-gel trypsin digestion. Several washing steps with 
2 x 1 ml H2O, H2O / acetonitrile (ACN) (50% / 50%) and destainer solution (0.1M NH4HCO3 / ACN, 50% / 30% 
v/v) for 5 min each and incubation with 1 ml ACN preceded a reduction step with 0.1M NH4HCO3 / 10mM 
dithioerythritol for 45 min at 56°C. After two incubation steps with 1 ml ACN, the samples were alkylated with 
0.1M NH4HCO3 / 55 mM iodoacetamide in the dark at room temperature for 30 min. The gel pieces were 
digested after two additional washing steps with NH4HCO3 and ACN by incubation with 30 μl trypsin (0.02 μg / 
ml, Seq. Grade modified trypsin, Promega, Madison, WI, USA) overnight at room temperature. The peptides 
were eluted by addition of 250 μl 25mM NH4HCO3 and 5% formic acid for 15 min at 37°C. The eluates were 
combined and evaporated to dryness. 
 
Analysis by LC/MS/MS 
 
 The resulting peptides from each gel piece were analyzed by liquid chromatography (LC) coupled to a 
LTQ ion trap mass spectrometer (Thermo Electronics, San Jose, CA USA) equipped with a nano-LC 
electrospray ionization source. Peptides were dissolved in buffer A (1% formic acid, 0.5% Acetic acid, 0.012% 
Heptafluorobutyric acid) and concentrated and desalted online on a C18 PepMap 100 micro precolumn (5 µm 
particle size, 300 µm x 1 mm; Dionex Corporation, Sunnyvale, CA, USA) that was coupled to a self packed (7 
cm, 3µm; ProntoSil C18-ACE-EPS, Bischoff Chromatography, Atlanta, GA, USA) and pulled (P-2000 laser 
puller, Sutter Instrument, Novato, CA, USA) fused silica capillary (100 μm i.d. × 365 μm o.d.). The 
chromatographic separation was then performed by a 100 minute nonlinear gradient from 5 to 55% buffer B 
(80% ACN / 0.5% Acetic Acid / 0.012% HFBA) with a constant flow rate of 0.20 µl / min. The mass 
spectrometric data acquisition was performed with a survey scan followed by 7 data dependent MS / MS scans 
with a repeat count of 2. The collision energy was set to 35%. 
 
Database searching for protein identification 
 
 SEQUEST (Bioworks, Thermo Electron Corporation, Waltham, MA, USA) was used to search the 
HumanGP database for peptide sequence and protein identification. HumanGP is a protein sequence database 
that is derived by assembling in sequences the results of Blast searches against the human chromosomes of a 
non-redundant protein set from Swissprot and Trembl (from human, mouse and other major organisms). Search 
parameters included differential mass modification to methionine due to possible oxidation and static mass 
modification to cysteine due to alkylation by iodoacetamide. Furthermore one missed cleavage of trypsin was 
accepted.  
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Protein quantification and normalization 
 
 Protein quantification was based on the comparison of peptide counts in samples derived from AD 
patients with samples from control tissue. Peptide counts reflect the number of peptides identified for a given 
protein. This number is indicative for the relative abundance of a protein in a sample. The comparison was 
performed with an in-house developed software (MSPresso). 
 As the brain tissue was isolated from tissue sections using a surgical blade, it was not possible to isolate 
exactly the same amount of brain tissue. To overcome this limitation, we normalized the peptide counts of the 
AD patients. Therefore, we used the averaged ratios of several abundant proteins that were assumed to be 
unchanged both in AD and control tissue, namely alpha-actinin 1, tubulin alpha-1 chain, tubulin alpha-8 chain, 
tubulin beta-2 chain, tubulin beta-4 chain and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) for 
normalization of AD samples. Obtained normalization factors were 0.93 and 1.44 for AD cases 1 and 2, 
respectively. 
 
Criteria for peptide and protein identification 
 
 For the comparisons of peptide counts, the single datasets from the analysis of the respective samples 
were combined to final sets. Peptides identified by SEQUEST may have three different charge states (+1, +2, or 
+3), each of which results in a unique spectrum for the same peptide. Except in rare instances, an accepted 
SEQUEST result had to have a delta cross-correlation (ΔCn) score of at least 0.1 (regardless of charge state). 
Peptides with a +1 charge state were accepted if they were fully tryptic or represented C-terminal fragments of a 
protein and had a cross correlation (Xcorr) of at least 1.8. Peptides with a +2 charge state were accepted if they 
were fully or partially tryptic with Xcorr ranges of at least 2.3 and higher. Finally, peptides with charge state +3 
were accepted if they were fully or partially tryptic and had an Xcorr larger than 2.8. Only proteins identified 
with at least 2 different peptides with a peptide count (number of MS/MS events that lead to the identification of 
a certain peptide) larger than 7 were taken into account. In addition, only proteins identified in both of the two 
independent datasets of AD versus control were accepted. 
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RESULTS 
 
Comparison of protein levels in AD brain and control 
 
 To compare protein levels from AD brains with control tissue, two comparable sized brain areas of grey 
matter of the occipital cortex of AD patients with Braak stage VI were isolated, the protein samples resolved on 
an SDS gel (Fig. 1 A), trypsin digested and finally submitted to LC/MS/MS. An overview of the preparative 
stages is illustrated in a flowchart (Fig. 1 B). The sample preparation procedure included a protein precipitation 
step where interfering lipids were removed, but which is suitable to isolate many of the membrane proteins. It is 
therefore assumed, that most of the soluble brain proteins, as well as part of the membrane proteins could be 
analyzed. 
 For acceptance of proteins, several filter criteria were applied. Only proteins, for which the measured 
peptide ratio in the respective pair of samples was in a range of ± 0.3 were accepted. For example, if a protein X 
was found in the first measurement with a ratio of 0.6 between AD and control and in the second series with a 
ratio of 0.8, the average of 0.7 was taken and the protein was accepted for the analysis and evaluation.  
 To evaluate the proteins with significantly altered protein levels in AD brain samples, we classified 
them into functional groups. As the number of proteins from less than 1 mg of brain tissue detected by this 
method reached more than 2000, we accepted only proteins with a peptide count of larger than 7. The peptide 
count is indicative for protein amount present in the brain. The approach is semi-quantitative, but the obtained 
results demonstrate applicability to reveal alterations in protein amount. A protein with an averaged ratio of x > 
1.3 was considered to be increased. A protein with an averaged ratio of 0.7 ≤ x ≤ 1.3 was regarded as 
comparable, whereas a ratio being x < 0.7 was accepted as being decreased. Ubiquitous proteins with 
comparable protein levels were not considered as important and are therefore not listed. 
 To overcome limitations concerning the amount of isolated brain tissue, we normalized the detected 
protein levels. The used cytoskeletal proteins and GAPDH levels were assumed not to be affected in the 
pathogenesis of AD. This approach appears to be adequate, since most proteins were comparable after the 
normalization. Substantial alterations of identified protein levels are more significant when the abundance of 
most of the observed proteins remains unchanged. Therefore, the proteins of the AD patients and control tissue 
were ordered by their observed abundance. The comparison of respective proteins in AD and control was 
assessed and a correspondence of over 90% was determined. This enabled us to extract a set of proteins with 
significantly altered protein levels revealed by LC/MS/MS. 
 A large number of previously identified proteins related to AD could be confirmed and demonstrate the 
feasibility of the approach. Among these proteins were few proteins like Aβ and complement C3 and C4 that are 
only detectable in AD tissue. Also, highly increased levels of tau, apolipoprotein E, ubiquitin, several heat shock 
proteins (e.g. Hsp 90) and the astroglial protein GFAP were revealed in grey matter tissue of the investigated AD 
cases. Other proteins known to be associated with AD (e.g. antichymotrypsin (ACT), serum amyloid P 
component (SAP) or C-reactive protein) were detected, but only with low peptide counts. This might result from 
their low abundance, restricted accessibility for solubilization or unfavorable ionization properties in the 
LC/MS/MS approach. Proteins most abundant are listed in Table 1. In the functional groups mentioned below, 
we describe the findings for elevated, decreased or comparable proteins after applying the filter criteria 
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described, what is known about their function, especially in relation to AD pathogenesis and also putative new 
AD related biomarkers. 
 
Cell adhesion and neurite outgrowth 
 
 Molecules involved in cell adhesion are usually localized at the cell surface. They are predominantly 
glycoproteins that mediate cell-to-cell adhesion and their functions include the assembly and interconnection of 
cells, as well as maintenance of tissue integration, morphogenic movement and cellular migration. We detected 
various neural specific cell adhesion molecules, as well as ubiquitously expressed ones. Among these, Collagen 
α3 (VI), which acts as a cell-binding protein, was present only in AD, whereas various proteins previously 
reported to also play a role in neurite extension were either at comparable or decreased levels. For example, 
neural cell adhesion molecules (NCAMs) have been shown to be effective neurite outgrowth promoters. We 
detected tendentially decreased levels of NCAM 1. Previously, unchanged levels in AD and control in occipital 
association cortex were reported (Yew et al., 1999). In contrast, connexin-43 was found by LC/MS/MS to be 
tendentially increased in AD, consistent with elevated immunoreactivity at sites of amyloid plaques in AD (Nagy 
et al., 1996).  
 The oligodendrocyte specific protein claudin-11 plays an important role in minimizing the intercellular 
space through calcium-dependent cell adhesion activity. We detected decreased levels of claudin-11 in AD 
compared to control tissue. An implication of claudin-11 in AD was not reported previously. 
 The contactins mediate cell surface interactions during nervous system development. Contactin 1 
participates in oligodendrocytes generation by acting as a ligand of notch 1, whereas contactin 2 may play a role 
in the initial growth and guidance of axons. We found slightly decreased levels of contactin 1 and more 
significantly decreased levels of contactin 2 and contactin associated protein 1 (Neurexin IV). 
 A different protein involved in axonal guidance and which we found decreased is dihydropyrimidinase 
related protein-5 (DRP-5). Another member of this family, DRP-2, was previously described to be disregulated 
in AD (Lubec et al., 1999).  
 We detected low Thy-1 membrane glycoprotein levels in AD. Thy-1 was implicated to promote neurite 
outgrowth and decreased levels in AD were reported earlier (Leifer and Kowall, 1992). 
 Notably, two other proteins which were not reported before in relation to AD and which show 
significantly decreased levels with our approach are the myelin oligodendrocyte glycoprotein (MOG) and the 
myelin-associated glycoprotein (MAG). These proteins are adhesion molecules important for maintaining the 
myelin sheet and for cell-cell communication. This is indicative for deteriorations of axonal integrity (Kalback et 
al., 2004). 
 Overall, most of the identified proteins involved in cell adhesion and important for the development and 
maintenance of the neuritic functions show consistently lower protein levels in AD than in the control samples, 
which is indicative for disease related deficits in the neuritic network.  
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Chaperones 
 
 In biology, chaperones are proteins whose function is to assist other proteins in achieving proper protein 
folding. Many chaperones are heat shock proteins expressed in response to elevated temperatures or other 
cellular stresses. Chaperones can also play an important role in signal transduction, in the maintenance of the 
proper organization of the cytoplasm and other intracellular compartments, in intracellular trafficking and other 
vital functions of the cells. 
 We found increased levels of heat shock protein 90 (Hsp 90) and Hsp 27. An upregulation and 
colocalization of Hsp 90 with Aβ plaques or reactive astrocytes in AD brain was previously reported (Renkawek 
et al., 1993, Kakimura et al., 2002, Liao et al., 2004). By using Hsp 90 inhibitors, a reduced ERK 
phosphorylation was detected, implicating a role for Hsp 90 in tau phosphorylation (Dou et al., 2005). 
 Interestingly, a significant increase of Hsp 75 was also observed, which was not described previously. 
Other heat shock proteins like Hsp 70.1 and glucose-regulated protein 78 (GRP 78) were found at comparable 
and Hsp 60 at decreased levels, which was previously shown by Yoo and colleagues (Yoo et al., 2001). 
 
Cytoskeleton 
 
 The cytoskeleton is a dynamic structure that maintains cell shape, enables cell motion and plays 
important roles in both intracellular transport and cellular division. We identified the major cytoskeletal proteins, 
including actin and tubulin, with high peptide counts. As mentioned above, we normalized the peptide count of 
AD brain proteins against an average of the peptide counts of tubulin, actinin and GAPDH in the controls, 
because they were assumed as proteins at basically unchanged levels both in AD and age-matched controls.  
 As expected, we identified the microtubule-associated protein tau, the major constituent of NFTs, 
beeing substantially increased in AD brains. 
 Plectin 1 interlinks intermediate filaments with microtubules and microfilaments and anchors 
intermediate filaments to desmosomes or hemidesmosomes. Plectin 1 may be involved not only in the cross-
linking and stabilization of cytoskeletal intermediate filaments network, but also in the regulation of their 
dynamics. Plectin 1 was found abundantly and detected at a tendentially elevated level in AD. No implications of 
plectin 1 in AD were described previously. Other cytoskeletal proteins like neurofilament or spectrin were 
identified at comparable levels.  Interestingly, gelsolin was found to be decreased. Gelsolin plays a role in a 
familial form of AD and it was suggested, that gelsolin may inhibit Aβ-induced cytotoxicity (Qiao et al., 2005). 
A decrease in gelsolin during the progression of AD might therefore have serious effects on neuronal survival 
and apoptotis of nerve cells. 
 Another abundant structural protein is α-internexin which belongs to the intermediate filament family 
of cytoskeletal proteins. We found lower levels of α-internexin in AD samples than in control tissue. A role of 
α-internexin in AD was demonstrated recently by Dickson and colleagues (Dickson et al., 2005). 
 A decrease in other cytoskeletal proteins, like α-adducin or ankyrin 2, is likely to reflect also 
cytoskeletal impairment of neuronal cells in AD, which may result in a deficit in axonal transporting and neuritic 
dystrophy. 
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 The most pronounced reduction was observed in the microtubule-associated proteins (MAP) 1B and 
MAP RP / EB, which show markedly decreased peptide counts in AD brain, indicative for a deficit and 
impairment of axonal transport. 
 
Inflammation 
 
 Triggered by the deposition of amyloid plaques, an inflammatory response is known to occur in AD. 
Glial fibrillary acidic protein (GFAP) and vimentin, two members of the intermediate filament group, are 
expressed in reactive astrocytes and were both found at significantly increased levels in AD. This is consistent 
with the literature (Porchet et al., 2003). Remarkably, complement C3 and C4, both activators of the complement 
system, were only found in AD brains. The complement system stimulates inflammation, facilitates antigen 
phagocytosis, and lyses some cells directly upon activation by a pathogen. Significant changed levels of 
complement isoforms were recently detected and suggested as potential biomarkers in AD (Finehout et al., 2005, 
Selle et al., 2005).  
 
Kinases, enzymes and metabolism 
 
 Different enzymes involved in diverse biochemical pathways were previously reported to play a role in 
AD. One of these enzymes is the Protein-arginine deiminase type II and Ishigami and co-workers showed the 
abnormal accumulation of citrullinated proteins catalyzed by peptidylarginine deiminase in hippocampal extracts 
from patients with Alzheimer's disease (Ishigami et al., 2005). Consistent with this data, we detected 
significantly increased levels of peptidylarginine deiminase in AD samples. 
 The hyperphosphorylation of tau is crucial for its assembly into NFTs and the control of 
phosphorylation versus dephosphorylation events is likely to be important in the progression of the disease. 
Accordingly, mitogen-activated protein kinase 3 (ERK 1) was found only in AD brains, while mitogen-activated 
protein kinase 1 (ERK 2) was found at comparable levels between AD and control. They were described 
previously to phosphorylate tau on serine / threonine residues (Goedert et al., 1992, Ledesma et al., 1992, Hyman 
et al., 1994, Pei et al., 2002). Further, we identified a significant decrease in the protein level of the serine / 
threonine phosphatase 2A, which dephosphorylates tau and it was reported earlier that a decrease in the activity 
promotes the abnormal hyperphosphorylation of tau (Drewes et al., 1993, Gong et al., 1994). Overall, a decrease 
in the phosphatase activity and increased phosphorylation of tau in AD is likely to result in the abnormal 
hyperphosphorylation and to an enhanced deposition of tau in NFTs.  
 Oxidative stress refers to a state in which oxidant production surpasses the endogenous antioxidant 
capability leading to oxidative molecular damage of the tissue. Such a state can result from increased production 
of oxidants and/or decreased concentration of antioxidants. Stepwise reduction of oxygen during normal 
metabolism produces reactive oxygen species (ROS), such as superoxide anion, hydrogen peroxide, and 
hydroxyl radicals. Oxidative stress-associated cell damage has also been described in Alzheimer’s disease 
(Multhaup et al., 1997, Aksenova et al., 1999) and accordingly we could identify several enzymes involved in 
the disposing of ROS. Peroxiredoxin 1 level was unchanged in AD and control as previously described 
(Krapfenbauer et al., 2003), whereas Peroxiredoxin 5, Superoxide dismutase (SOD2) and microsomal 
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glutathione-S transferase 3 (MGST-3) levels were decreased, likely to indicate reduced elimination of ROS and 
enhanced susceptibility to oxidative damage. 
 It is well documented, that a decreased brain glucose turnover can have serious effects on the onset 
and/or progression of AD (Hoyer, 1991, Hoyer, 1996, Meier-Ruge and Bertoni-Freddari, 1997, Schubert, 2005). 
Several glycolytic key proteins, such as phosphofructokinase 1 (PFK), were described to have decreased 
activities in AD brains (Meier-Ruge et al., 1984), which might finally contribute to a disturbance of the glucose 
turnover and an insufficient amount of ATP to maintain the neuronal function and survival. The consequence is 
nerve cell atrophy. Numerous enzymes and proteins involved in various metabolic pathways were detected with 
our approach, among them we found a decrease in several enzymes involved in glucose turnover, like PFK-B, 
Isocitrate dehydrogenase, Malate dehydrogenase, Succinyl-CoA ligase and Succinate dehydrogenase, thereby 
indicating the aberrant energy metabolism in brains of AD patients. 
 
Membrane trafficking and synaptic proteins 
 
 Membrane traffic occurs by vesicular transport between successive compartments of the secretory 
pathway. Dynein plays an important role in protein sorting and occurred at tendentially decreased levels in AD 
compared to control in our measurements. It was shown previously, that dynein is increased at sites of amyloid 
plaques (Liao et al., 2004). 
 Clathrin is the major protein of the polyhedral coat in coated pits, which form during endocytosis. We 
found, with high peptide counts, unchanged levels of clathrin in AD compared to control samples, whereas the 
clathrin coat assembly protein AP180, which is central for clathrin alignment, showed reduced levels in AD 
brains as suggested previously by immunohistochemistry (Yao et al., 1999). 
 Other synaptic proteins like presynaptic density protein 95 (PSD-95), syntaxin-1A and synaptotagmin-1 
and -12 were also found to be significantly decreased. The loss of synaptic proteins in AD is expected and 
reflects the synapse loss that occurs in the disease. Contrary to that was the finding of marked elevated levels of 
synaptogyrin-1 and synaptogyrin-3, implications of synaptogyrins in AD are discussed below. 
 Synaptophysin was found at only slightly decreased levels in one AD patient and at comparable levels 
in the second patient, which is not subsidiary to earlier reports, which reported a decrease of synaptophysin up to 
25% in AD brains (Zhan et al., 1993, Masliah et al., 1994). An explanation may be the enlargement of synaptic 
boutons surrounding the plaques and the accumulation of synaptophysin in dystrophic axons (Lassmann et al., 
1993). 
 Interestingly, we found three members of the reticulon (rtn) family with altered protein levels in AD. 
Rtn-3 was tendentially decreased, whereas rtn-1 and rtn-4, the neurite outgrowth inhibitor protein Nogo, showed 
significantly lower levels in AD. This was not described previously. 
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Proteolysis 
 
 The ubiquitin proteasome system (UPS) is the major protein quality control system in eukaryotic cells. 
The last few years have seen increasing evidence for the involvement of the UPS in neurodegenerative disorders, 
including AD. The involvement of ubiquitin in AD has been extensively reviewed (Forloni et al., 2002, de Vrij 
et al., 2004, Song and Jung, 2004) and the colocalization of ubiquitin with senile plaques was reported almost 20 
years ago (Perry et al., 1987). It was therefore not surprising to find ubiquitin with high peptide counts at 
markedly increased levels in AD brains compared to control tissue. Other proteins involved in proteolysis, like 
cystatin B and C, antitrypsin or cathepsin D, were detected, but due to their low abundance not listed. It was 
recently reported that these proteins colocalize with amyloid plaques (Liao et al., 2004). However, our analysis 
of entire grey matter areas did not show significant changes in protolytic enzymes, except for ubiquitin. The high 
abundance of ubiquitin in AD grey matter tissue supports a role in activation of protein degradation mechanisms 
and / or stress-induced processes. 
 
Others 
 
 We detected the Aβ peptide only in AD and enhanced levels of apolipoprotein E. Also, ACT was 
detected only in the AD samples but with low peptide counts, whereas α-synuclein, a non-Aβ component of 
senile plaques, was identified at comparable levels in AD and control. SAP was detected in only one AD patient, 
whereas C-reactive protein appears to be increased. However, both pentraxins were detected only with very low 
peptide counts and are therefore not listed. 
 We detected decreased levels of the neuroprotective major prion protein in AD, which is consistent with 
a report showing decreased levels in AD brain in occipital association cortices (Rezaie et al., 2005). 
Contradictory to the literature, we found decreased levels of NDRG2 in AD, even though it was described to be 
associated with senile plaques and elevated in hippocampal pyramidal neurons (Mitchelmore et al., 2004). 
Moreover, we detected some proteins not described previously to be related to AD, like decreased neuronal 
protein 25 (NP 25, transgelin-3) and Matrin-3 whose functions are not known. Furthermore, we determined low 
levels of programmed cell death protein 8, which is a caspase-independent mitochondrial effector of apoptotic 
cell death. This finding might also present a compensatory mechanism to prevent redundant nerve cell death.  
 
Correlation of LC/MS/MS with immunohistochemistry and Western blotting 
 
 To validate selected candidates identified at altered levels in AD by LC/MS/MS, immunohistochemistry 
and Western blots were performed. 
 Analysis of known AD related proteins with Western blotting of homogenates from the same brain 
regions analyzed by LC/MS/MS showed the expected increase in Aβ, tau and phospho-tau in AD compared to 
control samples (Fig. 2 A – C). Furthermore, syntaxin-1A antibody was used to compare with MS and 
immunostaining (Fig. 2 D). Densitometric analysis revealed a decrease for syntaxin-1A of ~ 15% (data not 
shown). Although the lower abundance of syntaxin-1A in AD brains could also be demonstrated by Western blot 
analysis, the decrease was more sensitively revealed by LC/MS/MC and immunohistochemistry as seen below.  
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 For immunohistochemistry of brain tissue, we tested antibodies against Aβ, GFAP, SAP, apolipoprotein 
E, reticulon-1, synaptogyrin-1, and syntaxin-1A.  
 A double staining of Aβ with SAP (Fig. 3 A – C) and apolipoprotein E (Fig. 3 D – F) showed a clear 
co-localization of these proteins with amyloid plaques. As amyloid plaques are pathological hallmarks in AD 
patients, an increase of these proteins was expected and was shown for apolipoprotein E with the LC/MS/MS 
assay. SAP was detected in only very low amounts in one AD patient in the LC/MS/MS; an explanation for this 
can be the low rate of solubilization of SAP from the Aβ fibrils. The immunohistochemistry clearly shows the 
presence of SAP in plaques, which is consistent with a described association of SAP with amyloid deposits 
(Pepys et al., 1994).  
 Immunostaining analysis with synaptogyrin-1 antibody revealed a higher immunoreactivity in AD, 
thereby supporting the data obtained by mass spectrometry, where increased levels of synaptogyrin-1 in AD 
were detected. Confocal analysis of immunolabeled brain slices showed a co-localization of synaptogyrin-1 with 
GFAP positive cells (Fig. 3 G - I), suggesting that synaptogyrin-1 is expressed in reactive astrocytes. Since 
amyloid plaques in AD brains trigger an inflammatory response, which is absent or greatly reduced in control 
brains, a considerably higher number of reactive astrocytes can be found in diseased brains. This may explain the 
observed increase in synaptogyrin-1. However, the expression of synaptogyrin-1 in astrocytes is indicative for a 
local compensatory response to nerve cell atrophy, as synaptogyrin-1 was reported to play a role in synaptic 
plasticity (Janz et al., 1999). 
 Reticulon-1 and syntaxin-1A were found at decreased levels in AD patients by LC/MS/MS. 
Immunostaining for these proteins and quantification by confocal laser scanning microscopy revealed an 
intensity decrease in AD patients, demonstrating a clear correlation with the data from the mass spectrometry 
approach  
(Fig. 4).  
 
 
DISCUSSION 
 
Methodological approach 
 
 We used a high sensitivity proteomic approach to analyze low amounts of brain tissue from two severe 
Alzheimer’s patients and control tissue. The study provides insight into altered molecular components of various 
processes involved in the pathogenesis of AD. By semi-quantitative mass spectrometry, we were able to detect 
numerous proteins previously described in relation with AD and in addition to this, we identified 18 new 
proteins with significantly altered levels in AD, which were not described yet. The overall good consistency with 
available data demonstrates the validity of the methodological approach and confirmed altered protein levels 
reported in AD as obtained by different approaches from earlier studies. In addition, we employed 
immunohistochemistry and Western blotting as independent approaches to get a first validation of selected 
proteins detected with LC/MS/MS. 
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Proteins implicated in AD 
 AD related proteins like Aβ, apolipoprotein E and microtubule associated protein tau were found most 
prominently at increased levels in AD. Furthermore, the approach enabled the study of multiple pathogenic 
processes affected in the disease progression of AD and, consistent with the literature, we detected the activation 
of an inflammatory cascade indicated by increased levels of GFAP, vimentin and complement factors, the 
activation of the ubiquitin proteasome system, synaptic nerve cell loss reflected by a decrease of PSD-95, 
syntaxin-1A, synaptotagmin and AP-180, as well as an impaired glucose turnover, indicated by a decrease of 
enzymes involved in the citrate cycle.  
 One protein previously reported to occur at altered protein levels in AD is syntaxin-1A. This protein is a 
plasma membrane protein at presynaptic sites and was described to be decreased in AD (Minger et al., 2001). It 
was also shown, that dystrophic neurites of senile plaques are defective in proteins involved in exocytosis and 
neurotransmission, like syntaxin-1A or synapsin (Ferrer et al., 1998). The markedly reduced levels of syntaxin-
1A in AD brains detected with our method support these findings and indicate impaired synaptic function. 
Relevant to these findings is the described binding of syntaxin-1A to the presenilin 1 complex (Smith et al., 
2000). It is possible that presenilin 1 is involved in the control of calcium entering the cell (LaFerla, 2002), 
required for initiation of synaptic vesicle exocytosis. Mutations in presenilin 1 may interfere with this process by 
altering syntaxin-1A function, thus interfering with the docking and fusing of vesicles with the presynaptic 
membrane. Taken together, syntaxin-1A seems to play an important role in the maintenance of exocytosis and a 
significant decrease might therefore be detrimental for neurotransmission and contribute to cognitive impairment 
in AD. 
 Another protein family proposed to be involved in the pathogenesis of AD is the reticulon family 
(Selkoe et al., 1996, Lynch and Mobley, 2000). However, the protein level of rtns in AD was not reported earlier 
and we are the first group to show tendentially lower levels of rtn-3 and considerably decreased rtn-1 and -4 
(Nogo) levels in AD. Rtns are a group of integral membrane proteins, consisting of four members, rtn-1 to rtn-4. 
Their precise cellular function remains to be established, although rtns have already been shown to regulate 
many different cellular processes such as neuroendocrine secretion or membrane trafficking and to interact with 
diverse cellular proteins such as BACE 1 (He et al., 2004) or SNARE proteins (Steiner et al., 2004). Rtn-4 has 
been intensively investigated and was shown to be a critical inhibitory molecule controlling axonal growth and 
regeneration (Strittmatter, 2002). Rtns are localized in the ER, Golgi and plasma membranes, which suggests an 
involvement of rtns in endo- and exocytosis along the secretory compartments. A disregulation of rtns in AD 
indicates abnormalities in endo- or exocytosis. Furthermore, BACE 1 was shown to interact with all four rtn 
proteins by co-immunoprecipitation and an increased expression of a single rtn member in HEK-293 cells 
expressing Swedish mutant APP was shown to reduce the levels of Aβ (He et al., 2004) . Lowered rtn levels may 
cause a dysfunction of the endoplasmic reticulum that could lead to altered processing of membrane proteins 
such as APP (Katayama et al., 2004). Reduced rtn levels in AD are also indicative for an accelerated Aβ 
production, which may further contribute to amyloid plaque formation typical for AD. On the other hand, Nogo 
was reported to inhibit neurite outgrowth (Prinjha et al., 2000) and a down regulation of Nogo might indicate a 
compensatory mechanism in response to nerve cell atrophy in AD (Strittmatter, 2002). 
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New potential AD related proteins 
 
 In addition to numerous proteins described to be implicated in AD, we determined altered levels of 18 
proteins previously unknown in relation to AD. These are the synaptic proteins synaptogyrin-1 and -3, MAG, 
MOG, contactin-1, contactin-2, contactin associated protein 1 and claudin-11 involved in cell adhesion, the 
chaperone protein Hsp 75, plectin 1, ankyrin, α-adducin and microtubule-associated protein RP/EB family 
member 3 as structural cytoskeletal proteins, peroxiredxin 5 and microsomal glutathione S-transferase 3 for the 
protection against oxidative stress and programmed cell death protein 8, matrin-3 and transgelin-3 (NP 25), 
whose functions are not known.  
 We detected significantly increased levels of synaptogyrin-1 and -3 in AD. The synaptogyrin family 
consists of three members, two neuronal isoforms and a ubiquitous isoform (cellugyrin) and is distantly related 
to the synaptophysin family. It is known that synaptogyrins are associated with presynaptic vesicles in neuronal 
cells; the functions of synaptogyrins however have remained obscure despite considerable efforts (Stenius et al., 
1995, Kedra et al., 1998, Zhao and Nonet, 2001, Belizaire et al., 2004, Verma et al., 2004). In studies using 
transgenic mice with a double knockout for synaptogyrin and synaptophysin, the mice were still viable and 
fertile, suggesting that these proteins can be substituted (Janz et al., 1999). However, major changes in synaptic 
plasticity were detected and an essential role in the regulation of neurotransmitter release was proposed. 
Conversely, another study reported that all synaptogyrins and the distantly related synaptophysin-1 severely 
inhibit exocytosis in transfected PC12 cells, suggesting a direct involvement in the exocytotic process (Sugita et 
al., 1999). We revealed by immunohistochemistry a localization of synaptogyrin-1 in reactive astrocytes, which 
likely explains the measured increase in synaptogyrin-1 levels in AD tissue. This increase may resemble a 
compensatory response of astrocytes in AD in response to the nerve cell loss and impaired synaptic activity. 
 
Concluding remarks 
 
 Another aspect of the findings relate to the identification of potential new biomarkers. AD is a common 
disease, but a definite diagnosis can still only be made by a postmortem assessment of the brain and to follow 
progression of the disease is difficult. A specific biomarker, preferentially measurable in the periphery, is 
urgently needed for improved diagnosis and also for monitoring drug response in AD treatment. Identified 
biomarker candidates found at altered levels in AD brain tissue, like synaptogyrin and reticulons, are possibly 
reflected in the CSF and eventually in the periphery through increased or decreased levels of their metabolized 
protein fragments. The determination and confirmation of peripheral fragment levels in blood presents therefore 
a promising approach for biomarker development. 
 Taken together, the understanding of the molecular pathogenesis underlying AD is necessary for the 
establishment of surrogate markers. Newly identified proteins described in this report are candidates for such 
markers, but need further investigation and validation. It will require independent replication in a larger number 
of samples before biomarkers for clinical diagnosis of AD can be firmly established. However, the results 
obtained clearly indicate the potential of the approach in the development of biomarkers in AD and other 
diseases. 
 
Manuscript [IV], 
submitted to Neurobiology of Disease 
REFERENCES 
 
Aksenova, M. V., Aksenov, M. Y., Payne, R. M., Trojanowski, J. Q., Schmidt, M. L., Carney, J. M., Butterfield, 
D. A. and Markesbery, W. R., 1999. Oxidation of cytosolic proteins and expression of creatine kinase 
BB in frontal lobe in different neurodegenerative disorders. Dement Geriatr Cogn Disord. 10, 158-165. 
Andreasen, N. and Blennow, K., 2002. Beta-amyloid (Abeta) protein in cerebrospinal fluid as a biomarker for 
Alzheimer's disease. Peptides. 23, 1205-1214. 
Andreasen, N., Sjogren, M. and Blennow, K., 2003. CSF markers for Alzheimer's disease: total tau, phospho-tau 
and Abeta42. World J Biol Psychiatry. 4, 147-155. 
Andreasen, N., Vanmechelen, E., Van de Voorde, A., Davidsson, P., Hesse, C., Tarvonen, S., Raiha, I., 
Sourander, L., Winblad, B. and Blennow, K., 1998. Cerebrospinal fluid tau protein as a biochemical 
marker for Alzheimer's disease: a community based follow up study. J Neurol Neurosurg Psychiatry. 
64, 298-305. 
Baker, H., Patel, V., Molinolo, A. A., Shillitoe, E. J., Ensley, J. F., Yoo, G. H., Meneses-Garcia, A., Myers, J. 
N., El-Naggar, A. K., Gutkind, J. S. and Hancock, W. S., 2005. Proteome-wide analysis of head and 
neck squamous cell carcinomas using laser-capture microdissection and tandem mass spectrometry. 
Oral Oncol. 41, 183-199. 
Belizaire, R., Komanduri, C., Wooten, K., Chen, M., Thaller, C. and Janz, R., 2004. Characterization of 
synaptogyrin 3 as a new synaptic vesicle protein. J Comp Neurol. 470, 266-281. 
Braak, H. and Braak, E., 1991. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 
(Berl). 82, 239-259. 
de Vrij, F. M., Fischer, D. F., van Leeuwen, F. W. and Hol, E. M., 2004. Protein quality control in Alzheimer's 
disease by the ubiquitin proteasome system. Prog Neurobiol. 74, 249-270. 
Dickson, T. C., Chuckowree, J. A., Chuah, M. I., West, A. K. and Vickers, J. C., 2005. alpha-Internexin 
immunoreactivity reflects variable neuronal vulnerability in Alzheimer's disease and supports the role 
of the beta-amyloid plaques in inducing neuronal injury. Neurobiol Dis. 18, 286-295. 
Dou, F., Yuan, L. D. and Zhu, J. J., 2005. Heat shock protein 90 indirectly regulates ERK activity by affecting 
Raf protein metabolism. Acta Biochim Biophys Sin (Shanghai). 37, 501-505. 
Drewes, G., Mandelkow, E. M., Baumann, K., Goris, J., Merlevede, W. and Mandelkow, E., 1993. 
Dephosphorylation of tau protein and Alzheimer paired helical filaments by calcineurin and 
phosphatase-2A. FEBS Lett. 336, 425-432. 
Ferrer, I., Marti, E., Tortosa, A. and Blasi, J., 1998. Dystrophic neurites of senile plaques are defective in 
proteins involved in exocytosis and neurotransmission. J Neuropathol Exp Neurol. 57, 218-225. 
Finehout, E. J., Franck, Z. and Lee, K. H., 2005. Complement protein isoforms in CSF as possible biomarkers 
for neurodegenerative disease. Dis Markers. 21, 93-101. 
Forloni, G., Terreni, L., Bertani, I., Fogliarino, S., Invernizzi, R., Assini, A., Ribizzi, G., Negro, A., Calabrese, 
E., Volonte, M. A., Mariani, C., Franceschi, M., Tabaton, M. and Bertoli, A., 2002. Protein misfolding 
in Alzheimer's and Parkinson's disease: genetics and molecular mechanisms. Neurobiol Aging. 23, 957-
976. 
Manuscript [IV], 
submitted to Neurobiology of Disease 
Gagne, J. P., Gagne, P., Hunter, J. M., Bonicalzi, M. E., Lemay, J. F., Kelly, I., Le Page, C., Provencher, D., 
Mes-Masson, A. M., Droit, A., Bourgais, D. and Poirier, G. G., 2005. Proteome profiling of human 
epithelial ovarian cancer cell line TOV-112D. Mol Cell Biochem. 275, 25-55. 
Goedert, M., Cohen, E. S., Jakes, R. and Cohen, P., 1992. p42 MAP kinase phosphorylation sites in microtubule-
associated protein tau are dephosphorylated by protein phosphatase 2A1. Implications for Alzheimer's 
disease [corrected]. FEBS Lett. 312, 95-99. 
Goldstein, L. S., 2003. Do disorders of movement cause movement disorders and dementia? Neuron. 40, 415-
425. 
Gong, C. X., Grundke-Iqbal, I. and Iqbal, K., 1994. Dephosphorylation of Alzheimer's disease abnormally 
phosphorylated tau by protein phosphatase-2A. Neuroscience. 61, 765-772. 
Hardy, J., 2006. Has the amyloid cascade hypothesis for Alzheimer's disease been proved? Curr Alzheimer Res. 
3, 71-73. 
Hashii, N., Kawasaki, N., Itoh, S., Hyuga, M., Kawanishi, T. and Hayakawa, T., 2005. 
Glycomic/glycoproteomic analysis by liquid chromatography/mass spectrometry: analysis of glycan 
structural alteration in cells. Proteomics. 5, 4665-4672. 
He, W., Lu, Y., Qahwash, I., Hu, X. Y., Chang, A. and Yan, R., 2004. Reticulon family members modulate 
BACE1 activity and amyloid-beta peptide generation. Nat Med. 10, 959-965. 
Hoyer, S., 1991. Abnormalities of glucose metabolism in Alzheimer's disease. Ann N Y Acad Sci. 640, 53-58. 
Hoyer, S., 1996. Oxidative metabolism deficiencies in brains of patients with Alzheimer's disease. Acta Neurol 
Scand Suppl. 165, 18-24. 
Hyman, B. T., Elvhage, T. E. and Reiter, J., 1994. Extracellular signal regulated kinases. Localization of protein 
and mRNA in the human hippocampal formation in Alzheimer's disease. Am J Pathol. 144, 565-572. 
Ida, N., Hartmann, T., Pantel, J., Schroder, J., Zerfass, R., Forstl, H., Sandbrink, R., Masters, C. L. and 
Beyreuther, K., 1996. Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood 
by a newly developed sensitive Western blot assay. J Biol Chem. 271, 22908-22914. 
Ishigami, A., Ohsawa, T., Hiratsuka, M., Taguchi, H., Kobayashi, S., Saito, Y., Murayama, S., Asaga, H., Toda, 
T., Kimura, N. and Maruyama, N., 2005. Abnormal accumulation of citrullinated proteins catalyzed by 
peptidylarginine deiminase in hippocampal extracts from patients with Alzheimer's disease. J Neurosci 
Res. 80, 120-128. 
Janz, R., Sudhof, T. C., Hammer, R. E., Unni, V., Siegelbaum, S. A. and Bolshakov, V. Y., 1999. Essential roles 
in synaptic plasticity for synaptogyrin I and synaptophysin I. Neuron. 24, 687-700. 
Kakimura, J., Kitamura, Y., Takata, K., Umeki, M., Suzuki, S., Shibagaki, K., Taniguchi, T., Nomura, Y., 
Gebicke-Haerter, P. J., Smith, M. A., Perry, G. and Shimohama, S., 2002. Microglial activation and 
amyloid-beta clearance induced by exogenous heat-shock proteins. Faseb J. 16, 601-603. 
Kalback, W., Esh, C., Castano, E. M., Rahman, A., Kokjohn, T., Luehrs, D. C., Sue, L., Cisneros, R., Gerber, F., 
Richardson, C., Bohrmann, B., Walker, D. G., Beach, T. G. and Roher, A. E., 2004. Atherosclerosis, 
vascular amyloidosis and brain hypoperfusion in the pathogenesis of sporadic Alzheimer's disease. 
Neurol Res. 26, 525-539. 
Katayama, T., Imaizumi, K., Manabe, T., Hitomi, J., Kudo, T. and Tohyama, M., 2004. Induction of neuronal 
death by ER stress in Alzheimer's disease. J Chem Neuroanat. 28, 67-78. 
Manuscript [IV], 
submitted to Neurobiology of Disease 
Kedra, D., Pan, H. Q., Seroussi, E., Fransson, I., Guilbaud, C., Collins, J. E., Dunham, I., Blennow, E., Roe, B. 
A., Piehl, F. and Dumanski, J. P., 1998. Characterization of the human synaptogyrin gene family. Hum 
Genet. 103, 131-141. 
Krapfenbauer, K., Engidawork, E., Cairns, N., Fountoulakis, M. and Lubec, G., 2003. Aberrant expression of 
peroxiredoxin subtypes in neurodegenerative disorders. Brain Res. 967, 152-160. 
LaFerla, F. M., 2002. Calcium dyshomeostasis and intracellular signalling in Alzheimer's disease. Nat Rev 
Neurosci. 3, 862-872. 
Lassmann, H., Fischer, P. and Jellinger, K., 1993. Synaptic pathology of Alzheimer's disease. Ann N Y Acad 
Sci. 695, 59-64. 
Ledesma, M. D., Correas, I., Avila, J. and Diaz-Nido, J., 1992. Implication of brain cdc2 and MAP2 kinases in 
the phosphorylation of tau protein in Alzheimer's disease. FEBS Lett. 308, 218-224. 
Lee, V. M., Kenyon, T. K. and Trojanowski, J. Q., 2005. Transgenic animal models of tauopathies. Biochim 
Biophys Acta. 1739, 251-259. 
Leifer, D. and Kowall, N. W., 1992. Thy-1 in hippocampus: normal anatomy and neuritic growth in Alzheimer's 
disease. J Neuropathol Exp Neurol. 51, 133-141. 
Liao, L., Cheng, D., Wang, J., Duong, D. M., Losik, T. G., Gearing, M., Rees, H. D., Lah, J. J., Levey, A. I. and 
Peng, J., 2004. Proteomic characterization of postmortem amyloid plaques isolated by laser capture 
microdissection. J Biol Chem. 279, 37061-37068. 
Lubec, G., Nonaka, M., Krapfenbauer, K., Gratzer, M., Cairns, N. and Fountoulakis, M., 1999. Expression of the 
dihydropyrimidinase related protein 2 (DRP-2) in Down syndrome and Alzheimer's disease brain is 
downregulated at the mRNA and dysregulated at the protein level. J Neural Transm Suppl. 57, 161-177. 
Lynch, C. and Mobley, W., 2000. Comprehensive theory of Alzheimer's disease. The effects of cholesterol on 
membrane receptor trafficking. Ann N Y Acad Sci. 924, 104-111. 
Masliah, E., Mallory, M., Hansen, L., DeTeresa, R., Alford, M. and Terry, R., 1994. Synaptic and neuritic 
alterations during the progression of Alzheimer's disease. Neurosci Lett. 174, 67-72. 
Meier-Ruge, W., Iwangoff, P. and Reichlmeier, K., 1984. Neurochemical enzyme changes in Alzheimer's and 
Pick's disease. Arch Gerontol Geriatr. 3, 161-165. 
Meier-Ruge, W. A. and Bertoni-Freddari, C., 1997. Pathogenesis of decreased glucose turnover and oxidative 
phosphorylation in ischemic and trauma-induced dementia of the Alzheimer type. Ann N Y Acad Sci. 
826, 229-241. 
Minger, S. L., Honer, W. G., Esiri, M. M., McDonald, B., Keene, J., Nicoll, J. A., Carter, J., Hope, T. and 
Francis, P. T., 2001. Synaptic pathology in prefrontal cortex is present only with severe dementia in 
Alzheimer disease. J Neuropathol Exp Neurol. 60, 929-936. 
Mitchelmore, C., Buchmann-Moller, S., Rask, L., West, M. J., Troncoso, J. C. and Jensen, N. A., 2004. NDRG2: 
a novel Alzheimer's disease associated protein. Neurobiol Dis. 16, 48-58. 
Multhaup, G., Ruppert, T., Schlicksupp, A., Hesse, L., Beher, D., Masters, C. L. and Beyreuther, K., 1997. 
Reactive oxygen species and Alzheimer's disease. Biochem Pharmacol. 54, 533-539. 
Nagy, J. I., Li, W., Hertzberg, E. L. and Marotta, C. A., 1996. Elevated connexin43 immunoreactivity at sites of 
amyloid plaques in Alzheimer's disease. Brain Res. 717, 173-178. 
Manuscript [IV], 
submitted to Neurobiology of Disease 
Parnetti, L., Lanari, A., Amici, S., Gallai, V., Vanmechelen, E. and Hulstaert, F., 2001. CSF phosphorylated tau 
is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies. Phospho-
Tau International Study Group. Neurol Sci. 22, 77-78. 
Pei, J. J., Braak, H., An, W. L., Winblad, B., Cowburn, R. F., Iqbal, K. and Grundke-Iqbal, I., 2002. Up-
regulation of mitogen-activated protein kinases ERK1/2 and MEK1/2 is associated with the progression 
of neurofibrillary degeneration in Alzheimer's disease. Brain Res Mol Brain Res. 109, 45-55. 
Pepys, M. B., Rademacher, T. W., Amatayakul-Chantler, S., Williams, P., Noble, G. E., Hutchinson, W. L., 
Hawkins, P. N., Nelson, S. R., Gallimore, J. R., Herbert, J. and et al., 1994. Human serum amyloid P 
component is an invariant constituent of amyloid deposits and has a uniquely homogeneous 
glycostructure. Proc Natl Acad Sci U S A. 91, 5602-5606. 
Perry, G., Friedman, R., Shaw, G. and Chau, V., 1987. Ubiquitin is detected in neurofibrillary tangles and senile 
plaque neurites of Alzheimer disease brains. Proc Natl Acad Sci U S A. 84, 3033-3036. 
Porchet, R., Probst, A., Bouras, C., Draberova, E., Draber, P. and Riederer, B. M., 2003. Analysis of glial acidic 
fibrillary protein in the human entorhinal cortex during aging and in Alzheimer's disease. Proteomics. 3, 
1476-1485. 
Prinjha, R., Moore, S. E., Vinson, M., Blake, S., Morrow, R., Christie, G., Michalovich, D., Simmons, D. L. and 
Walsh, F. S., 2000. Inhibitor of neurite outgrowth in humans. Nature. 403, 383-384. 
Qiao, H., Koya, R. C., Nakagawa, K., Tanaka, H., Fujita, H., Takimoto, M. and Kuzumaki, N., 2005. Inhibition 
of Alzheimer's amyloid-beta peptide-induced reduction of mitochondrial membrane potential and 
neurotoxicity by gelsolin. Neurobiol Aging. 26, 849-855. 
Renkawek, K., Bosman, G. J. and Gaestel, M., 1993. Increased expression of heat-shock protein 27 kDa in 
Alzheimer disease: a preliminary study. Neuroreport. 5, 14-16. 
Rezaie, P., Pontikis, C. C., Hudson, L., Cairns, N. J. and Lantos, P. L., 2005. Expression of cellular prion protein 
in the frontal and occipital lobe in Alzheimer's disease, diffuse Lewy body disease, and in normal brain: 
an immunohistochemical study. J Histochem Cytochem. 53, 929-940. 
Rufenacht, P., Guntert, A., Bohrmann, B., Ducret, A. and Dobeli, H., 2005. Quantification of the A beta peptide 
in Alzheimer's plaques by laser dissection microscopy combined with mass spectrometry. J Mass 
Spectrom. 40, 193-201. 
Schonberger, S. J., Edgar, P. F., Kydd, R., Faull, R. L. and Cooper, G. J., 2001. Proteomic analysis of the brain 
in Alzheimer's disease: molecular phenotype of a complex disease process. Proteomics. 1, 1519-1528. 
Schubert, D., 2005. Glucose metabolism and Alzheimer's disease. Ageing Res Rev. 4, 240-257. 
Selkoe, D. J., 2001. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev. 81, 741-766. 
Selkoe, D. J., Yamazaki, T., Citron, M., Podlisny, M. B., Koo, E. H., Teplow, D. B. and Haass, C., 1996. The 
role of APP processing and trafficking pathways in the formation of amyloid beta-protein. Ann N Y 
Acad Sci. 777, 57-64. 
Selle, H., Lamerz, J., Buerger, K., Dessauer, A., Hager, K., Hampel, H., Karl, J., Kellmann, M., Lannfelt, L., 
Louhija, J., Riepe, M., Rollinger, W., Tumani, H., Schrader, M. and Zucht, H. D., 2005. Identification 
of novel biomarker candidates by differential peptidomics analysis of cerebrospinal fluid in Alzheimer's 
disease. Comb Chem High Throughput Screen. 8, 801-806. 
Manuscript [IV], 
submitted to Neurobiology of Disease 
Smith, S. K., Anderson, H. A., Yu, G., Robertson, A. G., Allen, S. J., Tyler, S. J., Naylor, R. L., Mason, G., 
Wilcock, G. W., Roche, P. A., Fraser, P. E. and Dawbarn, D., 2000. Identification of syntaxin 1A as a 
novel binding protein for presenilin-1. Brain Res Mol Brain Res. 78, 100-107. 
Song, S. and Jung, Y. K., 2004. Alzheimer's disease meets the ubiquitin-proteasome system. Trends Mol Med. 
10, 565-570. 
Steiner, P., Kulangara, K., Sarria, J. C., Glauser, L., Regazzi, R. and Hirling, H., 2004. Reticulon 1-
C/neuroendocrine-specific protein-C interacts with SNARE proteins. J Neurochem. 89, 569-580. 
Stenius, K., Janz, R., Sudhof, T. C. and Jahn, R., 1995. Structure of synaptogyrin (p29) defines novel synaptic 
vesicle protein. J Cell Biol. 131, 1801-1809. 
Strittmatter, S. M., 2002. Modulation of axonal regeneration in neurodegenerative disease: focus on Nogo. J Mol 
Neurosci. 19, 117-121. 
Sugita, S., Janz, R. and Sudhof, T. C., 1999. Synaptogyrins regulate Ca2+-dependent exocytosis in PC12 cells. J 
Biol Chem. 274, 18893-18901. 
Tsuji, T., Shiozaki, A., Kohno, R., Yoshizato, K. and Shimohama, S., 2002. Proteomic profiling and 
neurodegeneration in Alzheimer's disease. Neurochem Res. 27, 1245-1253. 
Verma, R., Chauhan, C., Saleem, Q., Gandhi, C., Jain, S. and Brahmachari, S. K., 2004. A nonsense mutation in 
the synaptogyrin 1 gene in a family with schizophrenia. Biol Psychiatry. 55, 196-199. 
Watson, D., Castano, E., Kokjohn, T. A., Kuo, Y. M., Lyubchenko, Y., Pinsky, D., Connolly, E. S., Jr., Esh, C., 
Luehrs, D. C., Stine, W. B., Rowse, L. M., Emmerling, M. R. and Roher, A. E., 2005. Physicochemical 
characteristics of soluble oligomeric Abeta and their pathologic role in Alzheimer's disease. Neurol Res. 
27, 869-881. 
Wessel, D. and Flugge, U. I., 1984. A method for the quantitative recovery of protein in dilute solution in the 
presence of detergents and lipids. Anal Biochem. 138, 141-143. 
Wiltfang, J., Smirnov, A., Schnierstein, B., Kelemen, G., Matthies, U., Klafki, H. W., Staufenbiel, M., Huther, 
G., Ruther, E. and Kornhuber, J., 1997. Improved electrophoretic separation and immunoblotting of 
beta-amyloid (A beta) peptides 1-40, 1-42, and 1-43. Electrophoresis. 18, 527-532. 
Wuhrer, M., Deelder, A. M. and Hokke, C. H., 2005. Protein glycosylation analysis by liquid chromatography-
mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 825, 124-133. 
Yao, P. J., Morsch, R., Callahan, L. M. and Coleman, P. D., 1999. Changes in synaptic expression of clathrin 
assembly protein AP180 in Alzheimer's disease analysed by immunohistochemistry. Neuroscience. 94, 
389-394. 
Yew, D. T., Li, W. P., Webb, S. E., Lai, H. W. and Zhang, L., 1999. Neurotransmitters, peptides, and neural cell 
adhesion molecules in the cortices of normal elderly humans and Alzheimer patients: a comparison. 
Exp Gerontol. 34, 117-133. 
Yoo, B. C., Kim, S. H., Cairns, N., Fountoulakis, M. and Lubec, G., 2001. Deranged expression of molecular 
chaperones in brains of patients with Alzheimer's disease. Biochem Biophys Res Commun. 280, 249-
258. 
Zhan, S. S., Beyreuther, K. and Schmitt, H. P., 1993. Quantitative assessment of the synaptophysin immuno-
reactivity of the cortical neuropil in various neurodegenerative disorders with dementia. Dementia. 4, 
66-74. 
Manuscript [IV], 
submitted to Neurobiology of Disease 
Zhao, H. and Nonet, M. L., 2001. A conserved mechanism of synaptogyrin localization. Mol Biol Cell. 12, 2275-
2289. 
 
 
ACKNOWLEDGEMENTS 
 
We thank Fabienne Goepfert for assistance with Western blot analysis, Dr. Christian Czech and Dr. Fiona 
Grüninger for providing antibodies and copious discussions. Furthermore, we thank Claudia Richardson for 
general assistance and support. Finally, we thank Professor Theodor Güntert and Dr. Grayson Richards for 
critical review of the manuscript. 
 
Manuscript [IV], 
submitted to Neurobiology of Disease 
 Manuscript [IV], 
submitted to Neurobiology of Disease 
 Manuscript [IV], 
submitted to Neurobiology of Disease 
 
 
Fig. 1. Sample preparation for LC/MS/MS analysis of brain tissue. 
(A) Solubilized protein sample of an AD case was run on an SDS gel followed by Coomassie Blue staining. The 
sample lane was cut into 14 pieces that were subjected to trypsin digestion and LC/MS/MS analysis. The left 
lane shows the molecular weight marker, the gel excision pattern is shown on the right. (B) Overview of the 
sample preparation procedure. 
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Fig. 2. Western blot analysis of brain homogenates.  
Grey matter tissue from occipital association cortices was analyzed by Western blot analysis with tau (A), 
phospho-tau (p-tau) (B) and Αβ (C) antibodies. A substantial increase of the respective proteins in AD could be 
demonstrated. Densitometric analysis of syntaxin-1A revealed a decrease in both AD cases of ~ 15%. 
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Fig. 3. Confocal microscopy of human AD grey matter sections of occipital association cortex. 
Indirect immunofluorescence images were acquired by sequential scanning. The co-localization of Aβ present in 
cored senile plaques with SAP (A – C) and with apolipoprotein E (D – F) is clearly visible. Co-localization of 
synaptogyrin-1 with GFAP (G – I) was detected in the cytoplasm of astrocytes. The cell nucleus of astrocytes is 
revealed by nuclear counterstaining with DAPI. Scale bar in A – I: 10 μm 
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Fig. 4. Quantification of immunofluorescence signal by confocal laser scanning microscopy shown for 
reticulon-1 and syntaxin-1A. 
Grey matter sections from AD occipital association cortex and control tissue were stained with reticulon-1 and 
syntaxin-1A antibodies. Fluorescence intensity is decreased for reticulon-1 and syntaxin-1A in AD brain 
compared to control tissue, consistent with the findings from the LC/MS/MS analysis. 
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